iKang Healthcare (KANG) 20-F 10 Aug 18 2018 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Mar. 31, 2018shares
Entity Registrant Name	iKang Healthcare Group, Inc.
Entity Central Index Key	1,524,190
Document Type	20-F
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Class A common shares
Entity Common Stock, Shares Outstanding	33,916,439
Class C common shares
Entity Common Stock, Shares Outstanding	805,100

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Current assets
Cash and cash equivalents	$ 62,901	$ 64,898
Restricted cash		392
Term deposits		4,359
Accounts receivable, net of allowance for doubtful accounts of $14,261 and $23,142 as of March 31, 2017 and 2018, respectively	149,259	79,576
Inventories	9,261	6,781
Deferred tax assets-current		9,635
Amount due from related parties	7,019	4,538
Prepaid expenses and other current assets	66,939	49,736
Total current assets	295,379	219,915
Property and equipment, net	173,283	163,081
Acquired intangible assets, net	21,993	25,852
Goodwill	117,995	107,237
Long-term investments	196,816	180,758
Deferred tax assets-non-current	39,380	16,698
Rental deposit and other non-current assets	20,309	14,950
TOTAL ASSETS	865,155	728,491
Current liabilities
Accounts payable (including accounts payable of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $34,637 and $43,840 as of March 31, 2017 and 2018, respectively)	52,800	39,892
Accrued expenses and other current liabilities (including accrued expenses and other current liabilities of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $48,910 and $60,281 as of March 31, 2017 and 2018, respectively)	76,586	59,278
Income tax payable (including income tax payable of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $6,414 and $13,523 as of March 31, 2017 and 2018, respectively)	15,579	11,951
Deferred revenues (including deferred revenues of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $57,361 and $87,388 as of March 31, 2017 and 2018, respectively)	95,422	64,740
Amounts due to related parties (including amounts due to related parties of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of nil and $3,480 as of March 31, 2017 and 2018, respectively)	3,692
Short term borrowings (including short term borrowings of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $111,299 and $196,450 as of March 31, 2017 and 2018, respectively)	196,450	111,299
Total current liabilities	440,529	287,160
Long-term borrowings (including long term borrowings of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of 101,697 and $38,884 as of March 31, 2017 and 2018, respectively)	38,884	101,697
Deferred tax liabilities-non-current (including deferred tax liabilities-non-current of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $7,009 and $4,944 as of March 31, 2017 and 2018, respectively)	5,917	7,229
TOTAL LIABILITIES	485,330	396,086
Commitments and contingencies (Note 22)
iKang Healthcare Group, Inc. shareholders' equity
Additional paid-in capital	472,677	436,649
Statutory reserve	18,396	14,761
Accumulated deficit	(133,642)	(112,698)
Accumulated other comprehensive loss	(2,071)	(26,622)
Total iKang Healthcare Group, Inc. shareholders' equity	355,707	312,437
Non-controlling interests	24,118	19,968
TOTAL EQUITY	379,825	332,405
TOTAL LIABILITIES AND EQUITY	865,155	728,491
Class A common shares
iKang Healthcare Group, Inc. shareholders' equity
Common shares	339	339
Class C common shares
iKang Healthcare Group, Inc. shareholders' equity
Common shares	$ 8	$ 8

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Allowance for doubtful accounts	$ 23,142	$ 14,261
Accounts payable	52,800	39,892
Accrued expenses and other current liabilities	76,586	59,278
Income tax payable	15,579	11,951
Deferred revenues	95,422	64,740
Amount due to related parties	3,692
Short term borrowings	196,450	111,299
Long-term borrowings	38,884	101,697
Deferred tax liabilities-non-current	$ 5,917	$ 7,229
Common shares, authorized	39,648,485	39,648,485
Common shares, issued	34,721,539	34,721,539
Common shares, outstanding	34,721,539	34,721,539
Consolidated VIEs without recourse to iKang Healthcare Group, Inc.
Accounts payable	$ 43,840	$ 34,637
Accrued expenses and other current liabilities	60,281	48,910
Income tax payable	13,523	6,414
Deferred revenues	87,388	57,361
Amount due to related parties	3,480	0
Short term borrowings	196,450	111,299
Long-term borrowings	38,884	101,697
Deferred tax liabilities-non-current	$ 4,944	$ 7,009
Class A common shares
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	37,648,485	37,648,485
Common shares, issued	33,916,439	33,916,439
Common shares, outstanding	33,916,439	33,916,439
Class C common shares
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	2,000,000	2,000,000
Common shares, issued	805,100	805,100
Common shares, outstanding	805,100	805,100

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
CONSOLIDATED STATEMENTS OF OPERATIONS
Net revenues	$ 563,932	$ 435,713	$ 370,812
Cost of revenues	325,656	262,134	210,909
Gross profit	238,276	173,579	159,903
Operating expenses:
Selling and marketing expenses	96,594	74,304	64,763
General and administrative expenses (including share-based compensation expenses of $1,949, $1,941 and $34,822 in 2016, 2017 and 2018, respectively)	126,255	82,783	65,422
Research and development expenses	3,055	3,194	3,716
Total operating expenses	225,904	160,281	133,901
Income from operations	12,372	13,298	26,002
Interest expense	(20,191)	(13,880)	(4,603)
Interest income	382	939	785
Other income			1,874
Income/(loss)before provision for income taxes and gain/(loss) from equity method investments	(7,437)	357	24,058
Income tax expenses	6,791	3,354	5,838
Income/(loss) before loss from equity method investments	(14,228)	(2,997)	18,220
Loss from equity method investments	(2,448)	(9,547)	(1,732)
Net income/(loss)	(16,676)	(12,544)	16,488
Less: Net income/(loss) attributable to non-controlling interest	633	(1,293)	(1,837)
Net income/(loss) attributable to iKang Healthcare Group, Inc.	(17,309)	(11,251)	18,325
Net income/(loss) attributable to common shareholders of iKang Healthcare Group, Inc.	$ (17,309)	$ (11,251)	$ 18,325
Net income/(loss) per share attributable to common shareholders of iKang Healthcare Group, Inc.
Basic (in dollars per share)	$ (0.50)	$ (0.33)	$ 0.55
Diluted (in dollars per share)	$ (0.50)	$ (0.33)	$ 0.54
Weighted average shares used in calculating net (loss) income per common share
Basic (in shares)	34,295,160	34,060,579	33,583,005
Diluted (in shares)	34,295,160	34,060,579	34,235,542

CONSOLIDATED STATEMENTS OF OPE5

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS
Share-based compensation	$ 34,822	$ 1,941	$ 1,949	$ 1,949

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net income/(loss)	$ (16,676)	$ (12,544)	$ 16,488
Other comprehensive income/(loss):
Foreign currency translation adjustment	25,604	(20,252)	(12,187)
Unrealized gain/(loss) of available-for-sale investments, net of taxes of $47, $40 and $221 for the years ended March 31, 2016, 2017 and 2018, respectively	885	(161)	186
Comprehensive income/(loss)	9,813	(32,957)	4,487
Less: comprehensive income/(loss)attributable to non-controlling interest	2,571	(2,661)	(2,321)
Comprehensive income/(loss) attributable iKang Healthcare Group, Inc.	$ 7,242	$ (30,296)	$ 6,808

CONSOLIDATED STATEMENTS OF COM7

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Unrealized gain (loss) available-for-sale investments, tax	$ 221	$ 40	$ 47

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY - USD ($) $ in Thousands		iKang's shareholder's equityiKang Shanghai Gubei	iKang's shareholder's equityShenzhen Hospital Management	iKang's shareholder's equityFujian iKang	iKang's shareholder's equityIMHealthcare	iKang's shareholder's equityWeihai iKang Guobin Ciming Medical Examination Management Co., Ltd. Clinic & Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd	iKang's shareholder's equity	Common	Additional paid-in capitaliKang Shanghai Gubei	Additional paid-in capitalShenzhen Hospital Management	Additional paid-in capitalFujian iKang	Additional paid-in capitalIMHealthcare	Additional paid-in capitalWeihai iKang Guobin Ciming Medical Examination Management Co., Ltd. Clinic & Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd	Additional paid-in capital	Statutory reserve	Accumulated deficit	Accumulated other comprehensive income/(loss)	Non-controlling InterestiKang Shanghai Gubei	Non-controlling InterestBeijing Tianzhikangjian	Non-controlling InterestiKang Yinchuan Ciming	Non-controlling InterestWeihai Ciming	Non-controlling InterestXi'an iKang Guobin Medical Examination Management Co., Ltd.	Non-controlling InterestGuizhou Wishstar	Non-controlling InterestChina Physician Alliance	Non-controlling InterestWuhu iKang	Non-controlling InterestWuxi iKang Guobin	Non-controlling InterestMediFast	Non-controlling InterestShenzhen Hospital Management	Non-controlling InterestZhenjiang Clinic	Non-controlling InterestiKang Ningbo Haishu	Non-controlling InterestFujian iKang	Non-controlling InterestIMHealthcare	Non-controlling InterestYinchuan iKang Guobin Ciming Clinic (Co., Ltd.) & Yinchuan iKang Guobin Clinic (Co., Ltd.)	Non-controlling Interest	iKang Shanghai Gubei	Beijing Tianzhikangjian	iKang Yinchuan Ciming	Weihai Ciming	Xi'an iKang Guobin Medical Examination Management Co., Ltd.	Guizhou Wishstar	China Physician Alliance	Wuhu iKang	Wuxi iKang Guobin	MediFast	Shenzhen Hospital Management	Zhenjiang Clinic	iKang Ningbo Haishu	Fujian iKang	IMHealthcare	Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd. Clinic & Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd	Yinchuan iKang Guobin Ciming Clinic (Co., Ltd.) & Yinchuan iKang Guobin Clinic (Co., Ltd.)	Total
Balance at Mar. 31, 2015							$ 319,130	$ 343						$ 419,862	$ 8,399	$ (113,410)	$ 3,936																	$ 9,218																		$ 328,348
Balance (in shares) at Mar. 31, 2015								34,361,539
Increase (Decrease) in Stockholders' Equity
Provision for statutory reserve															3,130	(3,130)																																				3,130
Share-based compensation expenses							1,949							1,949																																						1,949
Exercise of employee share options	[1]						8,035							8,035																																						8,035
Settlement of acquisition payable of Shanghai Huajian Health Examination Management Co., Ltd.							7,206							7,202			4																																			7,206
Addition of non-controlling interest in connection with capital injection																																																				$ 457
Issuance of common shares in connection with exercise of options (in shares)																																																				995,255
Purchase of non-controlling interest		$ (302)							$ (302)									$ (486)	$ (1,178)																$ (788)	$ (1,178)																$ (1,664)
Addition of non-controlling interest in connection with acquisition																			$ 5,050	$ 1,613	$ 2,416	$ 3,242	$ 4,446													$ 5,050	$ 1,613	$ 2,416	$ 3,242	$ 4,446												16,767
Addition of non-controlling interest in connection with capital injection																						$ 457																	$ 457
Addition of non-controlling interest in connection with establishment																								$ 551	$ 182																$ 551	$ 182
Dividend distribution to non-controlling interest holder																		$ (557)									$ (57)								$ (557)									$ (57)								(614)
Net income/(loss)							18,325									18,325																		(1,837)																		16,488
Foreign currency translation adjustments							(11,703)										(11,703)																	(484)																		(12,187)
Unrealized gain (loss) on available-for-sale investments							186										186																																			186
Balance at Mar. 31, 2016							342,826	$ 343						436,746	11,529	(98,215)	(7,577)																	22,576																		365,402
Balance (in shares) at Mar. 31, 2016								34,361,539
Increase (Decrease) in Stockholders' Equity
Provision for statutory reserve															3,232	(3,232)																																				3,232
Share-based compensation expenses							1,941							1,941																																						1,941
Exercise of employee share options	[1]						1,324							1,324																																						1,324
Issuance of common shares, to option pool, in connection with share-based compensation arrangements							4	$ 4																																												$ 4
Issuance of common shares, to option pool, in connection with share-based compensation arrangements (in shares)								350,000
Issuance of common shares in connection with exercise of options (in shares)								10,000																																												274,565
Purchase of non-controlling interest			$ (3,362)							$ (3,362)																		$ 906																	$ (2,456)							$ 906
Capital contribution from non-controlling interest																										$ 130																	$ 130
Dividend distribution to non-controlling interest holder																											$ (983)																	$ (983)								(983)
Net income/(loss)							(11,251)									(11,251)																		(1,293)																		(12,544)
Foreign currency translation adjustments							(18,884)										(18,884)																	(1,368)																		(20,252)
Unrealized gain (loss) on available-for-sale investments							(161)										(161)																																			(161)
Balance at Mar. 31, 2017							312,437	$ 347						436,649	14,761	(112,698)	(26,622)																	19,968																		$ 332,405
Balance (in shares) at Mar. 31, 2017								34,721,539																																												34,721,539
Increase (Decrease) in Stockholders' Equity
Provision for statutory reserve															3,635	(3,635)																																				$ 3,635
Share-based compensation expenses							34,822							34,822																																						34,822
Exercise of employee share options							1,324							1,324																																						$ 1,324
Issuance of common shares in connection with exercise of options (in shares)																																																				242,834
Purchase of non-controlling interest				$ (1,872)							$ (1,872)																				$ (630)																	$ (2,502)				$ (630)
Addition of non-controlling interest in connection with acquisition					$ 2,326							$ 2,326																				$ 1,444																	$ 3,770
Capital contribution from non-controlling interest																													$ 909	$ 461																$ 909	$ 461
Return of capital						$ (572)							$ (572)																																					$ (572)
Dividend distribution to non-controlling interest holder																																	$ (605)																		$ (605)
Net income/(loss)							(17,309)									(17,309)																		633																		(16,676)
Foreign currency translation adjustments							23,666										23,666																	1,938																		25,604
Unrealized gain (loss) on available-for-sale investments							885										885																																			885
Balance at Mar. 31, 2018							$ 355,707	$ 347						$ 472,677	$ 18,396	$ (133,642)	$ (2,071)																	$ 24,118																		$ 379,825
Balance (in shares) at Mar. 31, 2018								34,721,539																																												34,721,539
[1]	Shares were previously issued to the option pool.

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net income/(loss)	$ (16,676)	$ (12,544)	$ 16,488
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	42,182	37,413	30,394
Share-based compensation expenses	34,822	1,941	1,949
Impairment of property and equipment	708	276	281
Loss on liquidation of a subsidiary			106
Gain from disposal of cost method investment			(1,772)
Allowance for doubtful accounts	7,317	6,136	8,509
Loss from equity method investments	2,448	9,547	1,732
Changes in assets and liabilities
Accounts receivable	(65,799)	(16,271)	(22,632)
Inventories	(1,654)	(3,103)	(1,279)
Prepaid expenses and other current assets	(6,344)	3,165	(10,069)
Deferred tax assets	(9,925)	(11,476)	(8,296)
Rental deposit and other long-term assets	(3,916)	(2,150)	(2,781)
Accounts payable	8,629	9,337	4,766
Accrued expenses and other current liabilities	7,453	18,741	3,979
Deferred revenues	23,165	6,846	23,914
Income tax payable	2,327	4,368	702
Deferred government subsidy			(61)
Deferred tax liabilities	(1,732)	(2,183)	(2,328)
Net cash provided by generated from operating activities	23,005	50,043	43,602
CASH FLOWS FROM INVESTING ACTIVITIES:
Restricted cash	408	30,124	20,772
Term deposits	4,528	7,679	2,361
Purchase of property and equipment	(34,912)	(63,389)	(37,024)
Purchase of intangible assets			(157)
Payments for business acquisitions (net of cash acquired of $10,165 and $6 and $516 for years ended March 31, 2016, 2017 and 2018, respectively)	(1,307)	(2,371)	(37,249)
Prepayment for business acquisitions	(879)
Payment for long-term investments	(3,149)	(5,473)	(204,414)
Return of prepayment for long-term investments		4,000
Proceeds from sale of cost method investment			1,897
Loan provided to related parties		(2,508)	(4,719)
Repayment of loan by related parties	140	2,324
Proceeds from disposal of the subsidiaries	2,231
Payment of loan receivables			(1,000)
Net cash used in investing activities	(34,783)	(32,011)	(261,533)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from exercise of share options	1,324	1,324	8,035
Capital contribution from non-controlling interest shareholders	909	134	567
Return of capital to non-controlling interest shareholders	(572)
Dividend distribution to non-controlling interest shareholders	(884)	(704)	(795)
Payments for business acquisitions			(1,853)
Proceeds from financing agreement in relation with New China Life Insurance Health Investment Management Co., Ltd	31,886
Proceeds from long-term borrowings	9,565		232,744
Proceeds from short-term borrowings	65,679	37,176	54,126
Repayments of short-term borrowings	(103,403)	(60,610)	(55,359)
Repayments of long-term borrowings		(29,741)
Net cash provided by (used in) financing activities	4,504	(52,421)	237,465
Effect of exchange rate on cash and cash equivalents	5,277	(8,824)	(8,759)
Net increase (decrease) in cash and cash equivalents	(1,997)	(43,213)	10,775
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	64,898	108,111	97,336
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	62,901	64,898	108,111
Supplemental cash flow information
Income tax paid	17,894	11,649	13,327
Interest paid	24,673	3,600	1,957
Supplemental non-cash financing and investing activities
Payable for business acquisitions	(10,127)	(6,436)	(9,350)
Payable for purchase of long term investments			3,743
Payable for purchase of property and equipment	12,456	11,830	7,109
Prepayment for business acquisitions	4,524	3,322	10,570
Prepayment for long term investments			4,000
Prepayment for purchase of property and equipment	17,699	12,677	11,318
Capital contribution, through other assets, relating to non-controlling interest	461
Shenzhen Hospital Management
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of non-controlling interest		$ (2,397)
iKang Shanghai Gubei
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of non-controlling interest			(788)
Fujian iKang
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of non-controlling interest	$ (1,843)
Beijing Tianzhikangjian
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of non-controlling interest			$ (1,212)

CONSOLIDATED STATEMENTS OF CA10

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
CONSOLIDATED STATEMENTS OF CASH FLOWS
Cash acquired	$ 516	$ 6	$ 10,165

ORGANIZATION AND PRINCIPAL ACTI

ORGANIZATION AND PRINCIPAL ACTIVITIES	12 Months Ended
	Mar. 31, 2018
ORGANIZATION AND PRINCIPAL ACTIVITIES
ORGANIZATION AND PRINCIPAL ACTIVITIES	1. ORGANIZATION AND PRINCIPAL ACTIVITIES iKang Healthcare Group, Inc. (the “Company”), was incorporated on May 25, 2011 as a limited liability company in the Cayman Islands. On March 1, 2014, the Company entered into a share swap agreement and became the ultimate holding company of iKang Guobin Healthcare Group, Inc. with the completion of the one to one share exchange to the existing shareholders of iKang Guobin Healthcare Group, Inc. for all shares of equivalent classes. The Company, its subsidiaries, its variable interest entities (“VIEs”) and its VIEs’ subsidiaries (collectively, the “Group”) are primarily engaged in providing medical examination services, disease screening services, dental services and other healthcare related services in the People’s Republic of China (the “PRC”). List of the Group’s subsidiaries, VIEs and the VIEs’ major subsidiaries as of March 31, 2018 were as follows: Percentage of beneficial interest by iKang Names Place of Healthcare Principal activities Subsidiaries: iKang Guobin Healthcare Group, Inc.(“iKang Guobin”) BVI 100% Holding company ShanghaiMed iKang, Inc. (“Beijing iKang”) PRC 100% On-demand healthcare services Shanghai iKang Co., Ltd. (“Shanghai iKang”) PRC 100% On-demand healthcare services iKang Zhejiang, Inc. (“iKang Zhejiang BVI”) BVI 73% Holding company iKang Health Management (Zhejiang) Co., Ltd. (“Zhejiang iKang”) PRC 73% On-demand healthcare services Bayley & Jackson (China) Medical Services Limited (“Bayley & Jackson (Hong Kong)”) Hong Kong 100% Holding company Beijing Bayley & Jackson Clinic Co., Ltd. (“iKang Beijing Ritan”) PRC 100% Medical examinations & clinical services Yuanhua Healthcare Limited (“Yuanhua HK”) Hong Kong 100% Holding company Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. (“Yuanhua WFOE”) PRC 100% On-demand healthcare services MediFast (Hong Kong) Limited (“MediFast”) Hong Kong 80% Medical examinations & clinical services WA Centers HK Limited (“WA Health Care”) Hong Kong 70% Holding company iKang(Shanghai) Financing Lease Co., Ltd. (“iKang(Shanghai) Financing Lease”) PRC 100% Lease services iKang MRI Center, Inc. BVI 70% Medical service iKang MRI Center, Limited Hong Kong 100% Medical service iKang mHealth, Inc. BVI 70% Medical service iKang Health Cloud Technology Limited Hong Kong 100% Medical service iKang Health Cloud (Beijing) Software Co., Ltd. (“iKang Health Cloud”) PRC 100% Research & development VIEs: iKang Healthcare Technology Group Co., Ltd.(formerly named as “Shanghai iKang Guobin Holding Co., Ltd.”)(“iKang Holding”) PRC 100% Holding company Hangzhou iKang Guobin Clinic Co., Ltd. (“iKang Hangzhou Xixi”) PRC 73% Medical examinations Shanghai Yuanhua Information Technology Co., Ltd. (“Yuanhua Information”) PRC 100% Holding company Jiandatong Health Technology (Beijing) Co., Ltd. (“Beijing Jiandatong”) PRC 80% On-demand healthcare services Percentage of Names Place of Principal activities VIEs’ major subsidiaries (Note): iKang Guobin Healthcare Group Co., Ltd.(formerly named as “Beijing iKang Online Technology PRC 100% On-demand healthcare services Guangzhou iKang Guobin Health Examination Co., Ltd. (“iKang Guangzhou Huanshi”) PRC 100% Medical examinations Shanghai Guobin Medical Center Co., Ltd. (“iKang Shanghai Xikang Road”) PRC 100% Medical examinations & clinical services Shanghai iKang Guobin Mingmen Clinic Co., Ltd. (“iKang Shanghai Pudong Avenue”) PRC 100% Medical examinations Shanghai iKang Jianwei Healthcare Management Co., Ltd. (“Jianwei Healthcare Management”) PRC 54.4% On-demand healthcare services Shanghai Yalong Daoyi Services Co., Ltd. (“Yalong Daoyi”) PRC 70% On-demand healthcare services Beijing iKang Jun’an Clinic Co., Ltd. (“iKang Beijing Jun’an”) PRC 100% Medical examinations & clinical services Beijing iKang Guobin Yayun Clinic Co., Ltd. (“iKang Beijing Yayun”) PRC 100% Medical examinations Beijing iKang Guobin Wanzhishou Clinic Co., Ltd. (“iKang Beijing Wanzhishou”) PRC 100% Medical examinations Beiijng iKang Medical Examination Application Technology Co., Ltd. (“Medical Examination Application”) PRC 70% On-demand healthcare services Beijing Daoyitong Health Management Co., Ltd. (“Beijing Daoyitong”) PRC 70% On-demand healthcare services Shanghai Jinxiu Huajian Clinic Co., Ltd. (“Shanghai Jinxiu Huajian”) PRC 100% Medical examinations Chengdu Gaoxin iKang Dental Clinic Co., Ltd. (“iKang Chengdu Gaoxin”) PRC 100% Dental services Shenzhen iKang Guobin Clinic Co., Ltd. PRC 100% Medical examinations Beijing iKang Guobin Zhongguan Clinic Co., Ltd. (“iKang Beijing Zhongguancun”) PRC 100% Medical examinations Shanghai iKang Guobin Renren Clinic Co., Ltd. (“iKang Shanghai Yangpu”) PRC 100% Medical examinations Shanghai iKang Guobin Blue Cross Clinic Co., Ltd. (“iKang Shanghai Lujiazui”) PRC 100% Medical examinations Beijing iKang Guobin Clinic Co., Ltd. (“iKang Beijing Xuanwumen”) PRC 100% Medical examinations Nanjing iKang Guobin Clinic Co., Ltd. (“iKang Nanjing Gulou”) PRC 100% Medical examinations Beijing iKang Guobin Xinei Clinic Co., Ltd. (“iKang Beijing Xinei”) PRC 100% Medical examinations Shanghai iKang Guobin Fukang Clinic Co., Ltd. (“Yan’an West Road”) PRC 100% Medical examinations Hangzhou iKang Guobin Wenhui Clinic Co., Ltd. (“iKang Hangzhou Wenhui”) PRC 100% Medical examinations Chengdu Jinjiang iKang Guobin Hongzhaobi Health Examination General Clinic Co., Ltd. (“iKang Chengdu Hongzhaobi”) PRC 100% Medical examinations iKang Dental Hospital Management Co., Ltd. (“iKang Dental Hospital Management”) PRC 100% Management of dental services Beijing iKang Guobin Lidu Clinic Co., Ltd. (“iKang Beijing Lidu”) PRC 100% Medical examinations Beijing iKang Guobin Jianwai Clinic Co., Ltd. (“iKang Beijing Jianguomen”) PRC 100% Medical examinations Fuzhou iKang Guobin Clinic Co., Ltd. (“iKang Fuzhou Gulou”) PRC 100% Medical examinations Shanghai iKang Guobin Zhonghuan Yipin Clinic Co., Ltd. (formerly named as “Shanghai Zhonghuan Yipin Clinic Co., Ltd.”) (“iKang Shanghai Zhonghuan”) PRC 100% Medical examinations Shanghai iKang Guobin Yipin Clinic Co., Ltd. PRC 100% Medical examinations Shanghai iKang Guobin Waizhitan Clinic Co., Ltd. PRC 100% Medical examinations Shanghai iKang Guobin Jianzhiwei Clinic Co., Ltd. PRC 100% Medical examinations Tianjin Heping Aibin Clinic Co., Ltd. (“iKang Tianjin Heping”) PRC 100% Medical examinations Suzhou iKang Guobin Clinic Co., Ltd. PRC 100% Medical examinations Suzhou Zhuoyue Clinic Co., Ltd. (“Suzhou Zhuoyue”) PRC 100% Medical examinations Guangzhou iKang Guobin Huacheng Clinic (LLP) (“iKang Guangzhou Wokang”) PRC 100% Medical examinations Shanghai Yuanhua Clinic Co., Ltd. (“Yuanhua Clinic”) PRC 100% Medical examinations Shanghai Wangzu Guobin Medical Center Co., Ltd. (“iKang Shanghai Gubei”) PRC 100% Medical examinations Changzhou iKang Guobin Clinic Co., Ltd. (“iKang Changzhou”) PRC 62.5% Medical examinations Chengdu Gaoxin iKang Guobin Chengnan Clinic Co., Ltd. (“Chengdu Gaoxin iKang West City”) PRC 100% Medical examinations Shanghai Huajian Clinic Co., Ltd. (“Shanghai Huajian”) PRC 100% Medical examinations Shanghai Huajian Health Examination Management Co., Ltd. (“Shanghai Huajian Management”) PRC 100% On-demand healthcare services Shanghai Zhenjing Clinic Co., Ltd. (“Shanghai Zhenjing”) PRC 70% Medical examinations Beijing iKang Guobin Shunping Clinic Co., Ltd. (“iKang Beijing Shunping”) PRC 100% Medical examinations Chongqing iKang Zhuoyue Clinic Co., Ltd. (“iKang Chongqing Zhuoyue”) PRC 100% Medical examinations Xi’an Lianhu iKang Guobin Zhuoyue Hospital Co., Ltd. (“Xi’an Lianhu Yinglun”) PRC 70% Medical examinations Guizhou Wishstar Health Examination Clinic Co., Ltd. (“Guizhou Wishstar”) PRC 60% Medical examinations Beijing iKang Guobin Sunny Jingchao Clinic Co., Ltd. (“iKang Beijing Jingchao”) PRC 83% Medical examinations Yantai iKang Guobin Ciming Medical Examination Management Co., Ltd. (“Yantai Ciming”) PRC 70% On-demand healthcare services Beijing Bohui Clinic Co., Ltd. (“Beijing Bohui”) PRC 100% Medical examinations Wuhan iKang Zhuoyue Clinic Co., Ltd. (“Wuhan Zhuoyue”) PRC 100% Medical examinations Shanghai iKang Jun’an Clinic Co., Ltd. (“Shanghai Jun’an”) PRC 100% Medical examinations Yinchuan iKang Guobin Clinic Co., Ltd. (“Yinchuan Clinic”) PRC 100% Medical examinations Note: Net revenues generated from these VIEs’ major subsidiaries accounted for approximately 80% of the Group’s net revenues as of March 31, 2018. The VIE arrangements Before January 31, 2012, PRC regulations limited business entities with direct foreign ownership of more than 70% to provide certain healthcare services in the PRC. To comply with related PRC regulations, the Company conducted the majority of its businesses through Beijing iKang and Zhejiang iKang, subsidiaries of the Group, and iKang Holding, iKang Holding’s subsidiaries and iKang Hangzhou Xixi, which are VIEs and VIEs’ subsidiaries (“VIE entities”) of the Company. Beijing iKang and Zhejiang iKang entered into a series of contractual arrangements with the VIEs and their shareholders, and through those contractual arrangements, as described below, the Company obtained the control and the right to substantially all of economic benefits of the VIE entities. In July 2013, iKang Guobin acquired 100% of Yuanhua, including Yuanhua HK, Yuanhua WFOE (a variable interest entity), Yuanhua Information and Yuanhua Clinic, which provide medical examination related services in China. Yuanhua WFOE entered into a series of contractual arrangements with Yuanhua Information and Mr. Haiqing Hu and Mr. Lei Zhao through which Yuanhua WFOE gained effective control over the operation of Yuanhua Information and is able to receive substantially all the economic benefits of Yuanhua Information. In March 2017, one of Yuanhua Information’s shareholders, Mr. Lei Zhao, was changed to Ms. Juan Tan; Yuanhua WFOE, Yuanhua Information and Yuanhua Information’s shareholders entered into a new series of contractual arrangements with the same terms and the original contractual arrangements were terminated. In December 2013, Beijing iKang entered into a series of contractual arrangements with Beijing Jiandatong and Mr. Haiqing Hu through which Beijing iKang gained effective control over the operation of Beijing Jiandatong and is able to receive substantially all the economic benefits of Beijing Jiandatong. Starting from January 31, 2012, foreign-invested enterprises incorporated in the PRC are not expressly prohibited from providing healthcare services in the PRC; however, in order to operate under a foreign-invested enterprise, the Group needs to reapply for the licenses or permits required for conducting such business from the National Health Commission of the PRC and Ministry of Commerce of the PRC, because currently most licenses of the Group to conduct healthcare services are held by PRC entities. As of March 31, 2018, the Group has not yet applied for such licenses or permits. Therefore the Group still operates through its VIE entities. Beijing iKang, Zhejiang iKang and Yuanhua WFOE have entered into the following contractual arrangements with iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong, Yuanhua Information and the shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information that enable the Company to (1) have power to direct the activities that most significantly affects the economic performance of the VIE entities, and (2) receive the economic benefits of the VIE entities that could be significant to the VIE entities. Accordingly, the Company is considered the primary beneficiary of the VIE entities and has consolidated the VIE entities’ financial results of operations, assets and liabilities in the Company’s consolidated financial statements. In making the conclusion that the Company is the primary beneficiary of the VIE entities, the Company believes the Company’s rights under the terms of the Exclusive Equity Option Agreement provide it with a substantive kick out right. More specifically, the Company believes the terms of the Exclusive Equity Option Agreement are valid, binding and enforceable under PRC laws and regulations currently in effect. The Company also believes that the minimum amount of consideration permitted by the applicable PRC law to exercise the option does not represent a financial barrier or disincentive for the Company to currently exercise its rights under the Exclusive Equity Option Agreement. The Company’s rights under the Exclusive Equity Option Agreement give the Company the power to control the shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information and thus the power to direct the activities that most significantly impact the VIE entities economic performance. In addition, the Company’s rights under the Power of Attorney also reinforce the Company’s abilities to direct the activities that most significantly impact the VIE entities’ economic performance. The Company also believes that this ability to exercise control ensures that the VIE entities will continue to execute and renew the Exclusive Service Agreement and pay service fees to the Company. By charging service fees in whatever amounts the Company deems fit, and by ensuring that the Exclusive Service Agreements are executed and renewed indefinitely, the Company has the rights to receive substantially all of the economic benefits from the VIE entities. Agreements that provide the Company effective control over the VIE entities (1) Power of Attorney: Each registered shareholder of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information has executed a power of attorney agreement appointing Beijing iKang, Zhejiang iKang or Yuanhua WFOE to be the only and exclusive attorney, and irrevocably authorizing it to vote on each registered shareholders’ behalf on all of the matters concerning the VIE entities, that may require shareholders’ approval. The term of the power of attorney is perpetual and the contract can be terminated at the discretion of the wholly foreign owned enterprises (“WFOEs”). (2) Exclusive Equity Option Agreement: Beijing iKang, Zhejiang iKang and Yuanhua WFOE have the exclusive right to purchase the equity interests of the VIE entities from the registered legal equity owners at the lowest consideration allowed by PRC regulations as far as PRC regulations permit a transfer of legal ownership to foreign ownership. The term of the exclusive purchase right agreement is ten years and will be renewed on the expiration date by WFOEs and can be terminated at the discretion of the WFOEs. (3) Spousal Consent Under the Spousal Consent letters: The spouse of each married registered shareholder of iKang Holding has signed a spousal consent letter, whereby the spouse agrees that (i) the equity interests of iKang Holding owned by such shareholder will be disposed of only in accordance with the applicable Exclusive Equity Option Agreement, Equity Interest Pledge Agreement, and other related agreements executed by the shareholder, (ii) such equity interests do not constitute communal property with such shareholder and (iii) the spouse irrevocably and unconditionally waives all rights and benefits with respect to such equity interests, including the right to sue in any court and under all applicable laws. Agreements that transfer economic benefits to the Company (1) Exclusive Services Agreement: Beijing iKang, Zhejiang iKang, Yuanhua WFOE and registered shareholders irrevocably agree that Beijing iKang, Zhejiang iKang and Yuanhua WFOE shall be the exclusive technology and consulting service provider to the VIE entities in return for a service fee as determined by Beijing iKang, Zhejiang iKang and Yuanhua WFOE up to the entire net profit of the VIE entities. The terms of the services agreement are ten years, respectively, and this agreement will be automatically renewed on applicable expiration dates, and the agreement can be terminated at the discretion of the WFOEs. (2) Equity Interest Pledge Agreement: Shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information have pledged all of their equity interests in VIE entities with Beijing iKang, Zhejiang iKang and Yuanhua WFOE, and Beijing iKang, Zhejiang iKang and Yuanhua WFOE are entitled to the rights to sell the pledged equity interests if the VIE entities or the shareholders default in their obligations. The term of the pledge agreement is as long as the service agreement; and it can be terminated when the service agreement is terminated. Through these contractual agreements, the Company has the ability to effectively control the VIE entities and is also able to receive substantially all the economic benefits of the VIE entities. Risk in relation to the VIE structure The Company believes that WFOE’s contractual arrangements with the VIEs are in compliance with PRC law and are legally enforceable. The shareholders of iKang Holding are also shareholders of the Company and therefore have no current interest in seeking to act contrary to the contractual arrangements. However, uncertainties in the PRC legal system could limit the Company’s ability to enforce these contractual arrangements and if the shareholders of the VIEs were to reduce their interest in the Company, their interests may diverge from that of the Company and that may potentially increase the risk that they would seek to act contrary to the contractual terms, for example by influencing the VIEs not to pay the service fees when required to do so. The Company’s ability to control the VIE entities also depends on the power of attorney Beijing iKang, Zhejiang iKang and Yuanhua WFOE have to vote on all matters requiring shareholder approval in the VIEs. As noted above, the Company believes this power of attorney is legally enforceable but may not be as effective as direct equity ownership. In addition, if the legal structure and contractual arrangements were found to be in violation of any existing PRC laws and regulations, the PRC government could: · revoke the Group’s business and operating licenses; · require the Group to discontinue or restrict operations; · restrict the Group’s right to collect revenues; · block the Group’s websites; · require the Group to restructure the operations in such a way as to compel the Group to establish a new enterprise, · re-apply for the necessary licenses or relocate our businesses, staff and assets; · impose additional conditions or requirements with which the Group may not be able to comply; or · take other regulatory or enforcement actions against the Group that could be harmful to the Group’s business. The imposition of any of these penalties may result in a material and adverse effect on the Group’s ability to conduct the Group’s business. In addition, if the imposition of any of these penalties causes the Group to lose the rights to direct the activities of the VIE entities or the right to receive their economic benefits, the Group would no longer be able to consolidate the VIE entities. The Group does not believe that any penalties imposed or actions taken by the PRC government would result in the liquidation of the Company, Beijing iKang, Zhejiang iKang, Yuanhua WFOE or the VIEs. The shareholders of the VIEs and the Company are as the following: (1) Mr. Lee Ligang Zhang and Mr. Boquan He are shareholders of the Company, who held 34.8% and 9.74% voting interest of the Company as of March 31, 2018, respectively. They own the equity interests in iKang Holding and iKang Hangzhou Xixi. (2) iKang Holding’s shareholders are Mr. Lee Ligang Zhang and Mr. Boquan He, each of whom holds 50% of the equity interest in iKang Holding. (3) iKang Hangzhou Xixi’s shareholders are iKang Holding and Yalong Daoyi, which hold 80% and 20% of the equity interest in iKang Hangzhou Xixi, respectively. Yalong Daoyi is wholly-owned by iKang Holding. Therefore, iKang Holding owns the 100% equity interest in iKang Hangzhou Xixi. (4) Beijing Jiandatong’s shareholders is Mr. Haiqing Hu, who holds 80% of the equity interest in Beijing Jiandatong. (5) Yuanhua Information’s shareholders are Mr. Haiqing Hu and Ms. Juan Tan, who hold 80% and 20% of the equity interest in Yuanhua Information, respectively. The two shareholders of iKang Holding are directors and shareholders of the Company. One of them is the Company’s CEO, and the managing director of the VIEs. Therefore they have no current interest in seeking to act contrary to the contractual arrangements. The interests of the VIEs’ shareholders may differ from the interests of the Company as a whole. The Company cannot assure that when conflicts of interest arise, the shareholders will act in the best interests of the Company or that conflicts of interests will be resolved in the Company’s favor. Currently, the Company does not have existing arrangements to address potential conflicts of interest the shareholders of the VIEs’ may encounter in their capacity as the beneficial owners and director of the VIE entities, on the one hand, and as beneficial owners and directors or officer of the Company, on the other hand. The Company believes the shareholders of the VIEs will not act contrary to any of the contractual arrangements and the Exclusive Equity Option Agreement provides the Company with a mechanism to remove the shareholders as the beneficial shareholders of the VIEs should they act to the detriment of the Company. The Company relies on the VIEs’ shareholders, as directors and officer of the Company, to fulfill their fiduciary duties and abide by laws of the PRC and BVI and act in the best interest of the Company. If the Company cannot resolve any conflicts of interest or disputes between the Company and the VIEs’ shareholders, the Company would have to rely on legal proceedings, which could result in disruption of its business, and there is substantial uncertainty as to the outcome of any such legal proceedings. The following financial statements amounts and balances of the VIE entities were included in the accompanying consolidated financial statements as of and for the years ended March 31 (after inter-company elimination): As of March 31, 2017 2018 Cash and cash equivalents $ $ Accounts receivable and other current assets Amount due from related parties — Total current assets Property and equipment, net Acquired intangible assets, net Other noncurrent assets Total non-current assets Total assets Deferred revenues Accounts payable and other current liabilities Amount due to related parties — Total current liabilities Total non-current liabilities Total liabilities For the years ended March 31, 2016 2017 2018 Net revenues $ $ $ Net income/(loss) $ $ ) $ For the years ended March 31, 2016 2017 2018 Net cash provided by operating activities $ $ $ Net cash used in investing activities $ ) $ ) $ ) Net cash provided by (used in) financing activities $ $ ) $ ) For the years ended March 31, 2016, 2017 and 2018, the amounts charged to the VIEs and their subsidiaries by WOFEs related to the service fees was $3,354, $2,245 and $3,326, respectively and was eliminated upon consolidation. The VIE entities contributed an aggregate of 89.1%, 87.1% and 91.2% of the consolidated net revenues for the years ended March 31, 2016, 2017 and 2018, respectively. The Company’s operations not conducted through contractual arrangements with the VIE entities primarily consist of its high-end health check services. As of the fiscal years ended March 31, 2017 and 2018, the VIE entities accounted for an aggregate of 85.2% and 86.5%, respectively, of the consolidated total assets, and 92.7% and 92.5%, respectively, of the consolidated total liabilities. The assets that were not associated with the VIE entities primarily consist of cash and cash equivalents, accounts receivable and prepaid expenses and other current assets. There are no terms in any arrangements, considering both explicit arrangements and implicit variable interests, that require the Company or its subsidiaries to provide financial support to the VIE entities. However, if the VIE entities ever need financial support, the Company or its subsidiaries may, at its option and subject to statutory limits and restrictions, provide financial support to its VIE entities through loans to the shareholders of the VIEs or entrustment loans to the VIE entities. Relevant PRC laws and regulations restrict the VIE entities from transferring a portion of its net assets, equivalent to the balance of its statutory reserve and its share capital, to the Company in the form of loans and advances or cash dividends. Please refer to Note 24 for disclosure of restricted net assets.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2018
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Group had negative working capital of approximately $145,150 as of March 31, 2018, which was mainly attributable to the current liability balance associated with the convertible loans issued in December 2015, of which $135,510 will become due during fiscal year 2018. Taking into consideration of the expected positive operating cash flows to be generated from operations by the Group, the undrawn available banking facilities and additional capital commitment from certain privatization investors whom have signed the amended and restated interim investors agreement with the Company and will provide such capital injection to the Company upon the completion of privatization proceeding, the Group is expected to obtain sufficient financial resource prior to the due date of the convertible loans. Therefore, management is of the opinion that the Group will be able to satisfy its liabilities as and when they become due, and accordingly, these consolidated financial statements are prepared on a going concern basis. Basis of consolidation The consolidated financial statements of the Group include the financial statements of iKang Guobin Healthcare Group Inc., its subsidiaries, its VIEs and its VIEs’ subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues, costs and expenses in the consolidated financial statements and accompanying notes. Significant accounting estimates reflected in the Group’s consolidated financial statements include allowance for doubtful accounts, the useful lives and impairment of property and equipment, purchase price allocation relating to business acquisitions, the useful lives and impairment of intangible assets, impairment of goodwill, impairment of long-term investments, valuation allowance for deferred tax assets, share-based compensation, interest accrual on long-term borrowings, fair value of long-term available-for-sale investments. Business Acquisitions Business combinations are recorded using the acquisition method of accounting. The purchase price of the acquisition is allocated to the tangible assets, liabilities, identifiable intangible assets acquired and non-controlling interest, if any, based on their estimated fair values as of the acquisition date. The excess of the purchase price over those fair values is recorded as goodwill. Acquisition-related expenses and restructuring costs are expensed as incurred. Where the consideration in an acquisition includes contingent consideration and the payment of which depends on the achievement of certain specified conditions post-acquisition, the contingent consideration is recognized and measured at its fair value at the acquisition date and if recorded as a liability, it is subsequently carried at fair value with changes in fair value reflected in earnings. Cash and cash equivalents Cash and cash equivalents consist of cash on hand and demand deposits, which are unrestricted as to withdrawal and use, and have maturities of three months or less when purchased. Restricted cash Restricted cash mainly consists of the cash deposit denominated in U.S. dollar in overseas accounts used to collateralize the local borrowings in China to meet the Group’s RMB funding needs, which is primarily to purchase property and equipment within China. The balance of the restricted cash was $392 and nil as of March 31, 2017 and 2018, respectively. Term deposits Term deposits consist of deposits placed with financial institutions with original maturity terms of greater than three months but less than one year. Accounts receivable represents those receivables derived in the ordinary course of business. A general allowance for doubtful accounts is provided based on aging analyses of accounts receivable balances, historical bad debt rates, in addition to specific provisions established based on customers’ repayment patterns and customer credit worthiness. The Group decides to write off a receivable and the corresponding provision when events indicate that there is a remote chance that an account receivable can be collected, such as liquidation of a customer or termination of business cooperation. Financial instruments Financial instruments of the Group primarily consist of cash and cash equivalents, restricted cash, term deposits, accounts receivable, available-for-sale investments, amount due from/to related parties, accounts payable, short-term borrowings and long-term borrowings. The carrying values of cash and cash equivalents, restricted cash, term deposits, accounts receivable, accounts payable, amounts due from/to related parties, and short-term borrowings approximate their fair values due to short-term maturities. Effective interest method The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Interest expense is recognized on an effective interest basis relating to financing arrangements included in the long-term borrowings. Fair value measurements Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. Authoritative literature provides a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement as follows: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Group also measures certain assets, including long-term investments and intangible assets, at fair value on a nonrecurring basis when they are deemed to be impaired. The fair values of intangible assets are determined based on valuation techniques using the best information available, and may include management judgments, future performance projections, etc. An impairment charge to the intangible assets is recorded when their carrying amounts may not be recoverable. Fair value of financial instruments is discussed in Note 18. Significant risks and uncertainties The Group operates in an industry with rapid changes in regulations, customer demand and competition and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations, or cash flows: advances and trends in healthcare industry standards, changes in certain strategic relationships or customer relationships, regulatory or other PRC related factors, risks associated with the Group’s ability to keep and increase the customer base, and risks surrounding pending litigations. Foreign currency risk The Renminbi (“RMB”) is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. Cash and cash equivalents of the Group included aggregate amounts of $57,553 and $56,593 as of March 31, 2017 and 2018, respectively, which were denominated in RMB. Concentration of credit risk Financial instruments that potentially expose the Group to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Group places their cash with financial institutions with high-credit ratings and quality. The Group conducts credit evaluations of customers and generally do not require collateral or other security from their customers. No customer accounted for 10% or more of total revenues for the years ended March 31, 2016, 2017 and 2018, respectively. No customer accounted for 10% or more of accounts receivable as of March 31, 2017 and 2018, respectively. Inventories Inventories are medical consumable supplies and are stated at the lower of cost or net realizable value. Inventories are written down for obsolescence to net realizable value based upon estimates of future demand and expiration date of inventories. The Group did not record a write-down of inventories for the years ended March 31, 2016, 2017 and 2018, respectively. Property and equipment, net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated on a straight-line basis over the following estimated useful lives: Computer equipment and application software 5 years Furniture and fixtures 5 years Medical equipment 10 years Motor vehicles 5 years Leasehold improvement Shorter of useful life of the asset or the lease term Construction in progress represents unfinished leasehold improvement and installment of equipment for new clinics. Construction in progress will be transferred to leasehold improvement or property and equipment when it is finished. Depreciation is recorded starting at the time when assets are ready for the intended use. Intangible assets, net Intangible assets, other than goodwill, resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by management based on the fair value of assets acquired. Identifiable intangible assets are carried at cost less accumulated amortization. Amortization of customer relationship is computed using the estimated attrition pattern of the acquired customers, and amortization of other finite- lived intangible assets is computed using the straight-line method over the following estimated average useful lives, which are as follows: Weighted average (years) Range (years) Customer relationship 5.7 2.1~10.0 Non-compete agreements 3.0 2.0~3.0 Contract backlog 0.7 0.4~0.9 Operating licenses 3.0 0.3~5.0 Favorable lease contracts 7.1 1.4~9.8 The weighted average estimated average useful life of the intangible assets with determinable lives is 5.5 years. Intangible assets-indefinite lives If an intangible asset is determined to have an indefinite life, it should not be amortized until its useful life is determined to be no longer indefinite. An intangible asset that is not subject to amortization is tested for impairment at least annually or if events or changes in circumstances indicate that the asset might be impaired. Such impairment test consists of the fair values of assets with their carrying value amounts and an impairment loss is recognized if and when the carrying amounts exceed the fair values. The estimates of fair values of intangible assets not subject to amortization are determined using various discounted cash flow valuation methodologies. Significant assumptions are inherent in this process, including estimates of discount rates. Impairment of long-lived assets and intangible assets with definite life Long-lived assets, such as property and equipment and definite-lived intangible assets are stated at cost less accumulated depreciation or amortization. Depreciation and amortization is computed using the straight-line method. The Group evaluates the recoverability of long-lived assets, with determinable useful lives whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. The Group measures the carrying amount of long-lived assets against the estimated undiscounted future cash flows associated with it. Impairment exists when the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated. Impairment loss is calculated as the amount by which the carrying value of the asset exceeds its fair value. Fair value is estimated based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Group to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. Goodwill Goodwill represents the excess of the fair value of consideration paid over the fair value of identifiable net assets acquired in business combinations. Goodwill and intangible assets deemed to have indefinite useful lives are not amortized, but tested for impairment annually or more frequently if events and circumstances indicate that they might be impaired. Goodwill is tested for impairment at the reporting unit level on an annual basis (March 31 for the Group) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the stock prices, business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. The first step compares the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of each reporting unit exceeds its carrying amount, goodwill is not considered to be impaired and the second step will not be required. If the carrying amount of a reporting unit exceeds its fair value, the second step compares the implied fair value of goodwill to the carrying value of a reporting unit’s goodwill. The implied fair value of goodwill is determined in a manner similar to accounting for a business combination with the allocation of the assessed fair value determined in the first step to the assets and liabilities of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to the assets and liabilities is the implied fair value of goodwill. An impairment loss is recognized for any excess in the carrying value of goodwill over the implied fair value of goodwill. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The estimation of fair value of each reporting unit using a discounted cash flow methodology also requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the Group’s business, estimation of the useful life over which cash flows will occur, and determination of the Group’s weighted average cost of capital. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results and market conditions. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for the reporting unit. The Group did not incur any impairment loss on goodwill for the years ended March 31, 2016, 2017 and 2018, respectively. Long-term investments The Group’s long-term investments consist of cost method investments, equity method investments and available-for-sale investments. Cost method investments For equity investments that are not considered to be equity securities that have readily determinable fair values and over which the Group has neither significant influence nor control through investment in common stock or in-substance common stock, the cost method is used. Under the cost method, the Company carries the investment at cost and recognizes income to the extent of dividends received from the distribution of the equity investee’s post-acquisition profits. Equity method investments The Group applies the equity method to account for an equity investment in common stock or in-substance common stock over which it has significant influence but does not own a majority equity interest or otherwise control. Significant influence is generally considered to exist when the Group has an ownership interest in the voting stock of the investee between 20% and 50%, and other factors, such as representation on the investee’s board of directors, voting rights and the impact of commercial arrangements, are considered in determining whether the equity method of accounting is appropriate. Under the equity method, the Group initially records its investment at cost and subsequently adjusts the carrying amount of the investment to recognize the Group’s proportionate share of each equity investee’s net income or loss into earnings after the date of investment. The Group periodically reviews its investments in equity investees to determine whether a decline in fair value below the carrying value is other than temporary. The primary factors the Group considers in its determination are the length of time that the fair value of the investment is below the Group’s carrying value; the financial condition, operating performance and the prospects of the equity investee; and other Group specific information such as recent financing rounds. If the decline in fair value is deemed to be other than temporary, the carrying value of the equity investee is written down to fair value. The Group estimated the fair value of these investee companies based on discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. Available-for-sale investments Available-for-sale investments are carried at their fair values and the unrealized gains or losses from the changes in fair values are included in accumulated other comprehensive income. Revenue recognition The Group recognizes revenues when persuasive evidence of an arrangement exists, service has been provided, the sales price is fixed or determinable, and collectability is reasonably assured. The Group offers medical examination and disease screening services and renders such services at the request of its customers. The Group recognizes revenues when the examination reports are issued and passed to the local couriers if hard copy reports are required by its customers, or when the examination reports are uploaded on-line and can be viewed by the customers on-line if hard copy reports are not required. The Group notifies its customers when their examination reports are delivered to the local couriers or ready to be viewed and downloaded on line. For individual customers, fees are collected before the performance of the services while corporate customers prepay a portion of service fees upon signing of the master contract, which is recorded as deferred revenue by the Group. All fees for services rendered are first charged against the corporate customer’s deferred revenues until it is entirely exhausted before the Group starts to invoice the corporate customers. The Group records accounts receivables from its corporate customers when the examination reports of the employees of corporate customers have been delivered or uploaded on line but the Group has not received remaining payments from the corporate customers. When needed, the Group engages third-party providers to provide medical examination and disease screening services on behalf of the Group. The Group evaluates the services provided by third parties on behalf of the Group to determine whether to recognize the revenues on a gross or net basis. The determination is based upon an assessment as to whether the Group acts as a principal or agent when providing the services. All of the revenues involving third-party providers providing medical examination or disease screening services on behalf of the Group are currently accounted for on a gross basis since the Group is the primary obligor, has the latitude in establishing prices, discretion in third-party provider selection and the credit risks. The Group also provides packages of bundled services principally comprising combinations of medical examination, disease screening, health consultation and medical concierge services to its corporate customers, which normally expire within one year from the date of purchase and does not include right of return. The Group allocates revenues from the sale of bundled services to each component using the relative selling price of each component based on the Group’s best estimate. Revenue recognition criteria for components included in the bundled services is identical to as if the components are sold on a standalone basis. The Group recognizes revenue from dental services when the service is rendered and the service fee is collectable. Before the enforcement of value-added taxes (“VAT”) policy, revenue was stated net of business tax and related surcharges. The Group recorded $2,692 and $910 business tax and related surcharges for the years ended March 31, 2016 and 2017, respectively, and $932 VAT related surcharges for the year ended March 31, 2018. Value added tax (“VAT”) On March 23, 2016, State Administration of Taxation launched Cai Shui [2016] No.36 (“Circular 36”), which takes effect starting May 1, 2016. In accordance with Circular 36, entities and individuals engaged in sales of services, intangible assets or real property within the territory of the People’s Republic of China are value-added taxpayers, and shall pay VAT rather than business tax (“BT”) according to these Measures. With the effect of Circular 36, Pilot Program is repealed. Pursuant to Circular 36, VAT exemption applies to medical services where all of the following conditions should be satisfied: (1) The medical institutions have obtained the Practice License for Medical Institutions in accordance with the Administrative Regulations on Medical Institutions of the State Council; (2) Medical services include the services which are listed in the Specifications for Pricing Items of National Medical Services; and (3) The price of medical services shall not be higher than the guiding prices for medical services set by competent price departments at or above the prefecture (city) level. Circular 36 becomes effective from May 1, 2016. In accordance with Circular 36, the Group’s medical services is eligible for the aforesaid tax exemption conditions. Non-monetary exchange The Group occasionally exchanges medical examination services with advertising agencies for advertising credits. The amount of deferred revenues and prepaid expenses is based on the fair value of the medical examination services to be rendered which approximates the price the Group offers to the individual customers and is more readily determinable. The amounts of revenues recognized for non-monetary transactions were $1,767, $674, and $1,046 for the years ended March 31, 2016, 2017 and 2018, respectively. Direct costs attributable to the revenues have been immaterial. Cost of revenues Cost of revenues consist of expenditures incurred in the generation of the Group’s revenues, includes but not limited to salaries and welfare paid to physicians, nurses, purchase of medical consumables, depreciation and amortization, rental, and fees paid to third-party service providers. Research and development expenses Research and development expenses primarily consist of (i) salaries and benefits for research and development personnel, and (ii) office rental, general expenses and depreciation and amortization expenses associated with the research and development activities. The Group’s research and development activities primarily consist of the research and development of its information technology platform. Research and development expenses are expensed when incurred. Income taxes Current income taxes are provided for in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Net operating loss carry forwards and credits are applied using enacted statutory tax rates applicable to future years. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that a portion of or all of the deferred tax assets will not be realized. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics up to the period ended March 31, 2017. The Group adopted ASU 2015-17 on April 1, 2017 and classified all deferred tax assets and liabilities as non-current as of March 31, 2018. The Group did not retrospectively apply the changes to prior years. The impact of an uncertain income tax position on the income tax return is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Interest and penalties on income taxes will be classified as a component of the provisions for income taxes. The Group did not recognize any income tax due to uncertain tax position or incur any interest and penalties related to potential underpaid income tax expenses for the years ended March 31, 2016, 2017 or 2018, respectively. Share-based compensation Share-based payment transactions with employees, such as share options are measured based on the grant date fair value of the equity instrument. The Group recognizes the compensation costs net of an estimated forfeiture rate using the graded vesting attribution method over the requisite service period of the award, which is generally the vesting period of the award. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share compensation expense to be recognized in future periods. Share awards issued to non-employees, such as advisors, are measured at fair value at the earlier of the commitment date or the date the service is completed and recognized over the period the service is provided. Earnings (loss) per share Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common share reflect the potential dilution that could occur if securities were exercised or converted into common shares. The Group has stock options, which could potentially dilute basic earnings per share. To calculate the number of shares for diluted income per share, the effect of the stock options is computed using the treasury stock method. Foreign currency translation The functional and reporting currency of the Company is the United States dollar (“U.S. dollar”). The financial records of the Group’s subsidiaries and VIE entities located in the PRC are maintained in their local currencies, the RMB, which are also the functional currencies of these entities. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange ruling at the balance sheet date. Transactions in currencies other than the functional currency during the year are converted into functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the statement of operations. The Group’s entities with functional currency of RMB translate their operating results and financial positions into the U.S. dollar, the Group’s reporting currency. Assets and liabilities are translated using the exchange rates in effect on the balance sheet date. Revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of other comprehensive income (loss). Comprehensive income (loss) Comprehensive income (loss) includes net income (loss), cumulative foreign currency translation adjustments, unrealized gain (loss) in available-for-sale investments (net of tax effect), and is reported in the consolidated statement of changes in equity. Operating leases Leases where the risks and rewards of ownership of assets primarily remain with the lessor are accounted for as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the lease periods. Newly adopted accounting pronouncements In November 2015, the Financial Accounting Standards Board (“FASB”) issued a new pronouncement Accounting Standard Update (“ASU”) 2015-17 which changes how deferred taxes are classified on organizations’ balance sheets. The ASU eliminates the current requirement for organizations to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, organizations will be required to classify all deferred tax assets and liabilities as noncurrent. The amendments apply to all organizations that present a classified balance sheet. For public companies, the amendments are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. This ASU may be applied prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. At April 1, 2017, the Group adopted ASU 2015-17 on a prospective basis and accordingly, presented all deferred tax assets and liabilities as noncurrent in the accompanying consolidated balance sheet as of March 31, 2018. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new guidance simplifies certain aspects related to income taxes, statement of cash flows, and forfeitures when accounting for share-based payment transactions. Certain of the amendments related to timing of the recognition of tax benefits and tax withholding requirements should be applied using a modified retrospective transition method. Amendments related to the presentation of the statemen

ACQUISITIONS

ACQUISITIONS	12 Months Ended
	Mar. 31, 2018
ACQUISITIONS
ACQUISITIONS	3. ACQUISITIONS (1) Acquisition of Beijing Bohui On May 20, 2016, the Group acquired 100% equity interest of Beijing Bohui and Beijing Zhongpu Bohui (collectively, “Beijing Bohui”), which provide medical examination services, with cash consideration of $5,371. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 4.6 years Operating license 2.6 years Goodwill Deferred tax liability ) The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Beijing Bohui have been included in the Group’s consolidated financial statements since the date of acquisition. Beijing Bohui contributed net revenue of $3,795 and $5,448, and net income of $1,382 and $1,810 to the Group’s consolidated statements of operations in the years ended March 31, 2017 and 2018, respectively. (2) Acquisition of IMHealthcare and its subsidiaries On July 31, 2017, Shanghai Jianwei Management acquired 100% equity interest of IMHealthcare (Beijing) Technology Co., Ltd. (“IMHealthcare”) and its subsidiaries, which provides on-demand healthcare services, by exchanging the 35.06% of Shanghai Jianwei Management’s equity interests. The settlement was made on July 31, 2017 and the Group obtained control of the acquiree on July 31, 2017. The transaction was accounted for as a business combination using the acquisition method of accounting. The purchase price of IMHealthcare was approximately $2,930 based on the valuation result. The allocation on the acquisition date was determined by management with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 6.7 years Trademark Indefinite Favorable Lease 1.4 years Operating license 3.6 years Goodwill Deferred tax liability ) The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of IMHeathcare and its subsidiaries have been included in the Group’s consolidated financial statements since the date of acquisition. IMHeathcare and its subsidiaries contributed net revenue of $2,024, and net income of $101 to the Group’s consolidated statements of operations in the year ended March 31, 2018. (3) Pro forma information The following unaudited pro forma information summarizes the results of operations of the Group for the years ended March 31, 2016 and 2017 assuming that the acquisition of Beijing Bohui occurred as of April 1, 2015. The following pro forma financial information is not necessarily indicative of the results that would have occurred had the acquisitions been completed at the beginning of the periods indicated, nor is it indicative of future operating results: Years ended March 31, 2016 2017 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income/(loss) attributable to common shareholders of iKang Healthcare Group, Inc. $ $ ) The following unaudited pro forma information summarizes the results of operations of the Group for the years ended March 31, 2017 and 2018 assuming that the acquisition of IMHealthcare and its subsidiaries occurred as of April 1, 2016. The following pro forma financial information is not necessarily indicative of the results that would have occurred had the acquisitions been completed at the beginning of the periods indicated, nor is it indicative of future operating results: Years ended March 31, 2017 2018 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net loss attributable to common shareholders of iKang Healthcare Group, Inc. $ ) $ )

ACCOUNTS RECEIVABLE, NET

ACCOUNTS RECEIVABLE, NET	12 Months Ended
	Mar. 31, 2018
ACCOUNTS RECEIVABLE, NET
ACCOUNTS RECEIVABLE, NET	4. ACCOUNTS RECEIVABLE, NET Accounts receivable consists of the following: As of March 31, 2017 2018 Accounts receivable $ $ Less: allowance for doubtful accounts Accounts receivable, net $ $ Movement of allowance for doubtful accounts is as follows: As of March 31, 2016 2017 2018 Balance at beginning of year $ $ $ Charge to expenses Write off ) ) — Exchange difference ) ) Balance at end of year $ $ $

INVENTORIES

INVENTORIES	12 Months Ended
	Mar. 31, 2018
INVENTORIES
INVENTORIES	5. INVENTORIES Inventories consist of the following: As of March 31, 2017 2018 Medical consumable supplies $ $

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Mar. 31, 2018
PREPAID EXPENSES AND OTHER CURRENT ASSETS
PREPAID EXPENSES AND OTHER CURRENT ASSETS	6. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consist of the following: As of March 31, 2017 2018 Advance to suppliers $ $ Other receivable (1) Staff advance Prepaid rental expenses Advance payments to acquisitions Prepaid expenses (2) Interest income receivable $ $ (1) Other receivable mainly consist of VAT receivable and amounts receivable from independent third parties. (2) Prepaid expenses mainly consist of amounts paid for professional fees and advertisement fees for which the related services have not been provided.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Mar. 31, 2018
PROPERTY AND EQUIPMENT, NET
PROPERTY AND EQUIPMENT, NET	7. PROPERTY AND EQUIPMENT, NET Property and equipment, net consists of the following: As of March 31, 2017 2018 Medical equipment $ $ Leasehold improvement Computer equipment and application software Furniture and fixtures Motor vehicles Construction in progress Total cost Less: accumulated depreciation and amortization Property and equipment, net $ $ Depreciation expenses charged to the consolidated statement of operations for the years ended March 31, 2016, 2017 and 2018 were $19,625, $27,560 and $34,972, respectively.

ACQUIRED INTANGIBLE ASSETS, NET

ACQUIRED INTANGIBLE ASSETS, NET	12 Months Ended
	Mar. 31, 2018
ACQUIRED INTANGIBLE ASSETS, NET
ACQUIRED INTANGIBLE ASSETS, NET	8. ACQUIRED INTANGIBLE ASSETS, NET The gross carrying amount, accumulated amortization, impairment and net carrying amount of the intangible assets are as follows: As of March 31, 2017 2018 Acquired intangible assets not subject to amortization Trade-name $ $ Acquired intangible assets subject to amortization Customer relationship Operating licenses Favorable lease contracts Contract backlog Non-compete agreements Less: accumulated amortization Customer relationship Operating licenses Favorable lease contracts Contract backlog Non-compete agreements Less: impairment Intangible assets, net $ $ Amortization expenses for the years ended March 31, 2016, 2017 and 2018 were $10,769, $9,853 and $7,210, respectively. Amortization expenses for the years ending March 31, 2019, 2020, 2021, 2022, 2023 and thereafter would be $4,784, $2,785, $1,024, $209, $142 and $839, respectively. No impairment loss was recognized on acquired intangible assets during the years ended March 31, 2016, 2017 and 2018, respectively. The change of impairment is caused by the exchange rate difference.

LONG-TERM INVESTMENTS

LONG-TERM INVESTMENTS	12 Months Ended
	Mar. 31, 2018
LONG-TERM INVESTMENTS
LONG-TERM INVESTMENTS	9. LONG-TERM INVESTMENTS The Group’s long-term investments consist of cost method investments, equity method investments and available-for-sale investments. As of March 31, 2017 2018 Cost method investments (1) $ $ Equity method investments (2) Available-for-sale investments (3) $ $ (1) Cost method investments Pursuant to a co-operation agreement with shareholder of Xi’an Puhui Physical Examination Co., Ltd. (“Xi’an Puhui”) in November 2015, the Group invested 23.1% equity interest of Xi’an Puhui, which operates fifteen medical clinics in Xi’an, Zhengzhou and other six cities, with a cash consideration of approximately $32,090. The transaction was closed in December 2015. The Group has no representative on Xi’an Puhui’s board of directors and does not have the ability to exercise significant influence over the operating and financial policies of Xi’an Puhui. The Group used cost method to account for this investment. In May 2015, the Group invested 1.8% equity interests of American Well Corporation (“AW”), a Delaware company with a cash consideration of approximately $13,500. The Group used cost-method to account for the investment as the Group has no representative on AW’s board of directors and does not have the ability to exercise significant influence over the operating and financial policies of AW. In September 2015, March 2016, and October 2016, the Group acquired minority equity interests in several third-party private companies through investments in their common shares or in-substance common shares with cash consideration of $2,000, $993, $232 respectively. The Group accounts for these investments under the cost method as the Group has no ability to exercise significant influence over the investees. In December 2017, the Group sold and disposed two early-stage subsidiaries to a related party, Ningbo Meishan Bonded Port Area Aiying Xingsheng Investment LLP (“Aiying Xingsheng Fund”). After the transaction, the Group held 1% equity interest of each of these two entities, which was accounted for using cost method and the carrying value was at $66 as of March 31, 2018. (2) Equity method investments In September 2015, the Group invested $10, 372 cash to acquire 21.8% equity interest of Shenzhen Topsky Jianxin Technology Co., Ltd. (“Topsky”). The transaction was closed in October 2015. The Group has two out of five representations on Topsky’s board of directors and has the ability to exercise significant influence over the operating and financial policies of Topsky. The Group accounted for this investment as equity method investment and recognized its share of loss of $931 and $315 for the years ended March 31, 2017 and 2018, respectively. In December 2015, a share purchase agreement was signed by the Group and Worldcare International Inc., a worldwide medical institution providing innovative advisory services for various hospitals and medical organizations, pursuant to which the Group agreed to invest $4,032 cash to acquire 20% equity interest. The transaction was closed in January 2016. The Group accounted for this investment as equity method investment because the Group has one out of five representations on the investee’s board of directors and has the ability to exercise significant influence but does not have control over the investees. The Group accounted for this investment as equity method investment and recognized its share of loss of $246 and $142 for the years ended March 31, 2017 and 2018, respectively. In February 2016, the Group completed a strategic investment in New China Life Insurance Health Investment Management Co., Ltd. (“NCI Health”), which was established by New China Life Insurance Co., Ltd. on December 13, 2012 and operates sixteen medical centers in 16 cities in China, with a total cash consideration of $119,363. After the investment, the Group holds 45% equity interest in NCI Health. The Group has two out of five representations on NCI Health’s board of directors and has the ability to exercise significant influence but does not have control over NCI Health and used the equity method to account for the investment. The Group recognized its share of loss of $7,985 and $1,536 for the years ended March 31, 2017 and 2018, respectively. NCI Health’s audited financial statements for the year ended December 31, 2017 are included in this annual report in accordance with Regulation S-X Rule 3-09. In December 2017, the Group, together with three other parties, entered into partnership agreement to establish AVIC Partnership, a limited partnership, to invest in the healthcare section, with total registered capital amounted to $80,031 (equivalent to RMB502,000,000). Ligang Capital Investment (Shenzhen) Co. Ltd.(“Ligang Capital”), an entity owned by the Group’s founder, also invested in the partnership as one of the general partners. The Group subscribed $11,160 (equivalent to RMB70,000,000) as a junior limited partner, but had not made the capital contribution as of March 31, 2018. The Group signed agreements with AVIC Partnership in December 2017 to sell 25% of its equity interest in NCI Health to AVIC Partnership for a total consideration of $ 65,321 (equivalent to RMB 425,000,000). The Company will purchase back the 25% equity interest in NCI Health in three years at the above purchase price plus interest at an annual rate of 10%. The above transaction did not have any impact over the Company’s voting right on NCI Health, and the Company still had the ability to exercise significant influence of NCI Health. The transaction was a financing arrangement and the Company continued to account for its investment in NCI Health as equity investment with 45% equity interest holdings in NCI Health for the year ended March 31, 2018. (Please refer to Note 13.a). The Group purchased 40% equity interest of Beijing Minzhong Clinic Co., Ltd. (“Beijing MZ”) with a total cash consideration of $12,407. The transaction was closed in March 2016. The Group has one out of three representations on Beijing MZ’s board of directors and has the ability to exercise significant influence but does not have control over Beijing MZ and used the equity method to account for the investment. The Group recognized its share of loss of $385 and $455 for the years ended March 31, 2017 and 2018. In August 2016, the Group invested 49% equity interest of Shanghai Changqingshu Health Management Co., Ltd. (“Changqingshu”) with a total cash consideration of $712. The transaction was closed in November 2016. The Group has two out of five representations on Changqingshu’s board of directors and has the ability to exercise significant influence over the operating and financial policies of Changqingshu but does not have control over Changqingshu and used the equity method to account for the investment. The Group did not recognize its share of income or loss for the years ended March 31, 2017 and 2018 as they were immaterial. In December 2017, the Group invested $768 cash to acquire 9.96% equity interest of Aiying Xingsheng Fund, as a junior limited partner. Ligang Capital, an entity owned by the Group’s founder serves as one of the general partners of Aiying Xingsheng Fund. The other general partner of Aiying Xingsheng Fund is a related party of the preferred limited partner to Aiying Xingsheng Fund whom holds veto power on investment decisions made by the Investment Committee of Aiying Xingsheng Fund. The Group does not have control over Aiying Xingsheng Fund and used equity method to account for the investment. The Group did not recognize its share of loss for the year ended March 31, 2018 as it was immaterial. In part of the investment on Aiying Xingsheng Fund, medical centers owned and operated by Aiying Xingsheng Fund will be transferred to the Group firstly or other third parties at tentative agreed price equals to its original costs plus an annual rate of 15% or the price then agreed by partners of Aiying Xingsheng Fund during the exit period. The Group summarizes the condensed financial information below for the Group’s equity method investments as a group in accordance with Rule 4-08 of Regulation S-X. The summarized financial information of the equity method investments were as follows: As of March 31, 2017 2018 Current assets $ $ Non-current assets Current liabilities Non-current liabilities For the years ended March 31, 2016 2017 2018 Total revenues $ $ $ Gross profit Loss from operations ) ) ) Net loss ) ) ) (3) Available-for-sale investments In June 2015, the Group acquired 20% equity interest in Shanghai Shenmin Medical Technology Company Limited, with a cash consideration of $1,897, which is a medical technology company incorporated under the laws of the PRC. The investment was classified as available-for-sale investments since it can be redeemed at the option of the Group once the redeemable events occurred and measured subsequently at fair value. The change in fair value are recorded in other comprehensive income. There was no unrealized gain or loss recognized for the years ended March 31, 2017 and 2018. In June 2015, the Group invested $5,000 in China Medonline Inc. (“HDF”), a company engaged in providing on-line medical services, for 1% equity ownership interests on an as-converted basis. The investment was classified as available-for-sale investments since it can be redeemed at the option of the Group once the redeemable events occurred, and measured subsequently at fair value. $161 unrealized loss and $885 unrealized gain, net of tax, were recorded in other comprehensive income for the years ended March 31, 2017 and 2018, respectively.

GOODWILL

GOODWILL	12 Months Ended
	Mar. 31, 2018
GOODWILL
GOODWILL	10. GOODWILL The changes in carrying amounts of goodwill for the years ended March 31, 2017 and 2018 were as follows: As of March 31, 2017 2018 Beginning balance $ $ Additions for the year by acquisitions of Beijing Bohui — IMHealthcare and its subsidiaries — Disposal for the year Changchun iKang Guobin Jiachang General Clinic Co., Ltd. (“Changchun Jiachang”) — ) Impairment loss: ) ) Exchange difference ) Goodwill $ $

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	12 Months Ended
	Mar. 31, 2018
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	11. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following: As of March 31, 2017 2018 Accrued payroll and welfare $ $ Acquisitions consideration payable (1) Interest expense payable Other taxes payable Accrued rental expense Accrued social insurance Accrued professional fee Accrued outsourcing cost Dividend payable (2) — Other payables $ $ (1) A acquisitions consideration payable consists of remaining payables to sellers of the acquired business for the years ended March 31, 2017 and 2018, which were as follows: As of March 31, 2017 2018 Beijing Tianzhikangjian Xi’an iKang Guobin Yantai Hongkang Fujian iKang — Others (i) $ $ (i) Others consist of a number of individually insignificant acquisitions made in prior years. (2) As of March 31, 2017, the balance represents the dividend payable for the non-controlling interest shareholder of MediFast which is paid in fiscal year ended March 31, 2018.

SHORT-TERM BORROWINGS

SHORT-TERM BORROWINGS	12 Months Ended
	Mar. 31, 2018
SHORT-TERM BORROWINGS
SHORT-TERM BORROWINGS	12. SHORT-TERM BORROWINGS As of March 31, 2017 2018 Bank borrowings (1) $ $ Long-term loans due within one year (2) $ $ (1) Bank borrowings a. In December 2015, iKang Holding entered into multiple two-year loan framework agreements with China Merchants Bank totaling RMB104,600,000 (equivalent to $15,198) to satisfy its daily operation needs. Each of the loans bear interest at a rate of 4.75% per annum. During fiscal years ended March 31, 2017 and 2018, the Group repaid RMB43,500,000 (equivalent to $6,249) and RMB61,100,000 (equivalent to $9,602). As of March 31, 2017 and 2018, the Group has RMB61,100,000 (equivalent to $8,877) and nil bank borrowings outstanding, respectively. b. In June 2016, iKang Holding entered into multiple two-year loan framework agreements with Industrial and Commercial Bank of China totaling RMB40,000,000 (equivalent to $5,811) to satisfy the daily operation needs. Each of the loan bears interest at a rate of 4.35%. During fiscal year ended March 31, 2018, the Group repaid RMB40,000,000 (equivalent to $6,377). As of March 31, 2017 and 2018, the Group has RMB40,000,000 (equivalent to $5,811) and nil bank borrowings outstanding, respectively. c. In September 2016, iKang Holding entered into a two-year loan framework agreements with China Merchants Bank totaling RMB15,000 ,000 (equivalent to $2,179) to satisfy the daily operation needs. The annual interest rate is 4.75%. During fiscal year ended March 31, 2018, the Group repaid RMB15,000,000 (equivalent to $2,391). The balance of this short-term borrowing were RMB15,000,000 (equivalent to $2,179) and nil as of March 31, 2017 and 2018, respectively. d. In December 2016, iKang Holding entered into a two-year loan framework agreements with Industrial Bank Co., Ltd. totaling RMB100,000,000 (equivalent to $14,528) to satisfy the daily operation needs. The annual interest rate is 4.35%. During fiscal year ended March 31, 2018, the Group repaid RMB100,000,000 (equivalent to $15,942). As of March 31, 2017 and 2018, the Group has RMB100,000,000 (equivalent to $14,528) and nil bank borrowings outstanding, respectively. e. In December 2016, iKang Holding entered into a two-year loan framework agreements with Hongkong and Shanghai Banking Corporation Limited RMB50,000,000 (equivalent to $7,264) to satisfy the daily operation needs. The annual interest rate is 4.35%. During fiscal years ended March 31, 2017 and 2018, the Group repaid RMB20,00,000 (equivalent to $2,906) and RMB30,000,000 (equivalent to $4,783). As of March 31, 2017 and 2018, the Group has RMB30,000,000 (equivalent to $4,358) and nil bank borrowings outstanding, respectively. f. In March 2017, iKang Holding entered into a two-year loan framework agreements with Bank of China RMB20,000,000 (equivalent to $2,906) to satisfy the daily operation needs. The annual interest rate is 4.35%. During fiscal year ended March 31, 2018, the Group repaid RMB20,000,000 (equivalent to $3,188). As of March 31, 2017 and 2018, the Group has RMB20,000,000 (equivalent to $2,906) and nil bank borrowings outstanding, respectively. g. In June 2017, iKang Holding entered into a one-year loan framework agreement to obtain a short-term borrowing facility totaling RMB20,000,000 (equivalent to $3,188) with Industrial and Commercial Bank of China to satisfy the daily operation needs, of which RMB20,000,000 (equivalent to $3,188) was drawn down in June 2017. The loan bears interest at a rate of 4.35% per annum with a maturity date of June 15, 2018. As of March 31, 2018, the outstanding balance of this short-term borrowing was RMB20,000,000 (equivalent to $3,188). h. In April 2017, iKang Holding entered into a one-year loan framework agreement to obtain a short-term borrowing facility totaling RMB100,000,000 (equivalent to $15,942) with China Minsheng Bank to satisfy the daily operation needs, of which RMB47,055,000 (equivalent to $7,502) was drawn down in August 2017. The loan bears interest at a rate of 5.00% per annum with a maturity date on August 7, 2018. As of March 31, 2018, the outstanding balance of this short-term borrowing was RMB47,055,000 (equivalent to $7,502). i. In November 2017, iKang Holding entered into a one-year loan framework agreement of RMB100,000,000 (equivalent to $15,942) with Industrial Bank Co., Ltd. to satisfy the daily operation needs. The loan bears interest at a rate of 4.83% per annum with a maturity date on November 28, 2018. As of March 31, 2018, the balance of this short-term borrowing was RMB100,000,000 (equivalent to $15,942). j. In December 2017, iKang Holding entered into a one-year loan framework agreement to obtain a short-term borrowing facility totaling RMB30,000,000 (equivalent to $4,783) with the Hongkong and Shanghai Banking Corporation Limited to satisfy the daily operation needs, of which RMB29,100,000 (equivalent to $4,639) was drawn down in December 2017. The loan bears interest at a rate of 4.79% per annum with a maturity date on December 6, 2018. As of March 31, 2018, the outstanding balance of this short-term borrowing was RMB29,100,000 (equivalent to $4,639). k. In December 2017, iKang Holding entered into a one-year loan framework agreement to obtain a short-term borrowing facility totaling RMB200,000,000 (equivalent to $31,884) with China Merchants Bank to satisfy the daily operation needs, of which RMB100,000,000 (equivalent to $15,942) and RMB50,000,000 (equivalent to $7,972) were drawn down in December 2017 and January 2018, respectively. Both of the two loans bear interest at a rate of 4.57% per annum with a maturity date on June 5, 2018 and January 8, 2019, respectively. As of March 31, 2018, the outstanding balance of these short-term borrowings were RMB150,000,000 (equivalent to $23,914). l. In March 2018, iKang Holding entered into a one-year loan framework agreement of RMB20,000,000 (equivalent to $3,188) with Industrial Bank Co., Ltd. to satisfy the daily operation needs. The loan bears interest at a rate of 5.00% per annum with a maturity date on March 29, 2019. As of March 31, 2018, the balance of this short-term borrowing was RMB20,000,000 (equivalent to $3,188). The above amount of short-term borrowing remained outstanding, which amounted to $38,659 and $58,373 as of March 31, 2017 and 2018, respectively. Interest expense incurred for the years ended March 31, 2016, 2017 and 2018 was $1,734 and $1,725 and $2,517, respectively. The weighted average effective interest rate for the years ended March 31, 2016, 2017 and 2018 was 3.3%, 4.2% and 4.54%, respectively. (2) Long-term loans due within one year a. In December 2015, iKang Holding entered into a series of agreements to issue long-term loans with principal amount totaling $203,393 (equivalent to RMB1,400,000,000) to four third-party investors (“bond holders”) with terms varying from eighteen months to thirty-six months. The agreement stipulate that if the Group successfully completes the privatization before the maturity date of the long-term loans, and the bond holders decide to convert the loans into the future listing vehicle’s shares, no interest will be charged; however, if the bond holders decide not to convert, the interest rate will be at 5% or 8% (was originally 20%, amended to 8% subsequently in January 2017). Furthermore, if the privatization is not completed before the maturity date of the long-term loans, or the Group fails to put their best effort to facilitate the bond holder conversion of the loan into the future listing vehicle’s shares, the interest rate will be at 8% or 10% (was originally 5%, amended to 10% subsequently in December 2017). Interest rates of 8% and 10% were applied to accrue the interest expenses for above long-term loans for the year ended March 31, 2018, respectively. Interest expense incurred for the years ended March 31, 2016, 2017 and 2018 was $2,869, $11,768 and $17,317, respectively. The effective interest rate for the year ended March 31, 2018 was 11.1%. Loan amount of $29,056 (equivalent to RMB200, 000,000) was repaid in the year ended March 31, 2017, and $52,808 (equivalent to RMB350,000,000) was repaid during the year ended March 31, 2018. As of March 31, 2018, all the remaining outstanding loan amount of $135,510 (equivalent to RMB 850,000,000) was classified to short-term borrowings as the loans become due in three tranches in December 2018, January 2019 and March 2019, respectively. b. In November 2017, two of the Group’s wholly-owned subsidiaries entered into medical equipment sale-leaseback agreements as financial lease arrangement with Guiyang GYB Financial Leasing Co., Ltd.. Please refer to Note 13b for details. As of March 31, 2018, the lease payment due within 1 year amounted to $2,567, which was included in short-term borrowings. The carrying values of short-term borrowings approximate their fair values due to its short-term maturities.

LONG-TERM BORROWINGS

LONG-TERM BORROWINGS	12 Months Ended
	Mar. 31, 2018
LONG-TERM BORROWINGS
LONG-TERM BORROWINGS	13. LONG-TERM BORROWINGS As of March 31, 2017 2018 Long-term loans $ $ $ $ a. Based on the agreements signed with AVIC Partnership, cash consideration of $65,321 (equivalent to RMB425,000,000) was raised through the financing arrangement related to NCI Health. As of March 31, 2018, the Company received partial amount of $31,886 (equivalent to RMB200,000,000) from AVIC Partnership and recorded it as long-term borrowings. Please refer to Note 9 (2). The effective interest rate for the year ended March 31, 2018 was 10.5%, and the interest expense incurred for the year ended March 31, 2018 was $199. b. In November 2017, two of the Group’s wholly-owned subsidiaries entered into medical equipment sale-leaseback agreements (the “Agreements”) with a third party, Guiyang GYB Financial Leasing Co., Ltd. (the “Lessor”). According to the Agreements: · The Group sold certain medical equipment to the Lessor at cash proceeds of $9,565 (equivalent to RMB60,000,000) on November 27, 2017, and recognized a loss of $908 (equivalent to RMB6,004,400) as the carrying value of these medical equipment was less than the cash proceeds; · The Group agreed to lease back these equipment in 45 months upon signing the Agreements; · The principal amount will be paid semi-annually during the lease period; · Interest expenses are accrued and paid to the Lessor on a quarterly basis, at effective interest rate of 6.65% per annum. The total interest expenses incurred for the year ended March 31, 2018 was $158; · At the end of the lease term, the Group will repurchase this same equipment, at a bargain purchase price. As of March 31, 2018, total amount of $6,998 was recorded as long-term borrowings, and $2,567 for the financing lease payment due within one year was classified as short-term borrowings. The fair value of the long-term loans as of March 31, 2017 and 2018 was $101,697 and 38,884, respectively.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2018
INCOME TAXES
INCOME TAXES	14. INCOME TAXES Cayman Islands The Company is a tax-exempted company incorporated in the Cayman Islands and is not subject to tax on income or capital gains. British Virgin Islands (“BVI”) The iKang Guobin and iKang Zhejiang BVI are exempted from income tax in BVI, where they are incorporated. Hong Kong Bayley & Jackson (Hong Kong), Yuanhua HK, MediFast and WA Health Care are subject to Hong Kong Profits Tax at 16.5% on its activities conducted in Hong Kong. PRC Since January 1, 2008, the Company’s PRC subsidiaries, iKang Holding and its subsidiaries are subject to the 25% standard enterprise income tax (“EIT”). According to “Catalogue of Industries Encouraged to Develop in the Western Region” announced by the State Administration of Taxation, Chengdu iKang Guobin Health Examination Hospital Co., Ltd. (“iKang Chengdu Waishuangnan”), Chengdu Jinjiang iKang General Clinic Co., Ltd., Chengdu Gaoxin iKang West City, Chengdu Ommay, Chongqing Aibin Clinic Co., Ltd. (“iKang Chongqing”), iKang Chongqing Zhuoyue, Chongqing Aibin Xinkang Clinic Co., Ltd., iKang Yinchuan Ciming, Yinchuan Clinic, Guizhou Wishstar, Kaili iKang Guobin Medical Examination Management Co., Ltd., Bijie iKang Guobin Medical Examination Management Co., Ltd., Xi’an iKang Guobin, Xi’an Lianhu Yinglun, Xi’an Qujiang iKang Guobin Clinic Co., Ltd., Xi’an Weiyang iKang Guobin Clinic Co., Ltd., were recognized as “encouraged entities” by relevant PRC government authorities at various dates from calendar years 2014 to 2017, and entitled to a preferential tax rate of 15%. According to the application on preferential tax rate of these entities have been filed with the relevant local tax authorities, the above entities are qualified as encouraged entities and entitled to the preferential tax rate of 15% going forward. Shenzhen iKang Guobin Puji Clinic Co., Ltd., iKang Shenzhen Luohu and Shenzhen iKang Guobin Xinglin Clinic Co., Ltd. are subject to individual income tax rate of 35% due to regulations set by the relevant local tax authorities. Enterprises that qualify as the “newly established software enterprise” (“NESE”) are exempt from EIT for two years beginning the enterprise’s first profitable year followed by a tax rate of 12.5% for the succeeding three years. iKang Health Cloud enjoyed the EIT tax benefit that began from June 2015. Preferential tax rate policy applied by iKang Health Cloud has been filed to the relevant local tax authorities before annual filing. Under the EIT Law and its implementation rules which became effective on January 1, 2008, dividends generated after January 1, 2008 and payable by a foreign-invested enterprise in PRC to its foreign investors who are non-resident enterprises are subject to a 10% withholding tax, unless any such foreign investor’s jurisdiction of incorporation has a tax treaty with PRC that provides for a different withholding arrangement. Under the taxation arrangement between the PRC and Hong Kong, a qualified Hong Kong tax resident which is the “beneficial owner” and directly holds 25% or more of the equity interest in a PRC-resident enterprise is entitled to a reduced withholding tax rate of 5%. The Cayman, where the Company is incorporated, does not have a tax treaty with PRC. Since January 1, 2008, the relevant local tax authorities of the Group’s subsidiaries have not conducted a tax examination on the Group’s PRC entities. In accordance with relevant PRC tax administration laws, tax years from 2013 to 2017 of the Group’s PRC subsidiaries and VIE entities, remain subject to tax audits as of December 31, 2017, at the relevant local tax authorities’ discretion. Aggregate undistributed earnings of the Company’s subsidiaries located in the PRC that are available for distribution to the Company are approximately $54,486 as of March 31, 2018. The undistributed earnings of the Company’s subsidiaries located in the PRC are considered to be indefinitely reinvested, because the Group does not have any present plan to pay any cash dividends on its common shares in the foreseeable future and intends to retain most of its available funds and any future earnings for use in the operation and expansion of its business. Accordingly, no deferred tax liability has been accrued for the Chinese dividend withholding taxes that would be payable upon the distribution of those amounts to the Company as of March 31, 2018. Aggregate undistributed earnings of the Company’s VIEs and its VIEs’ subsidiaries located in the PRC that are available for distribution to the Company were approximately $219,890 as of March 31, 2018. A deferred tax liability should be recorded for taxable temporary differences attributable to the excess of financial reporting amounts over tax basis amount in domestic subsidiaries However, recognition is not required in situations where the tax law provides a means by which the reported amount of that investment can be recovered tax-free and the enterprise expects that it will ultimately use that means. The Company has not recorded any such deferred tax liability attributable to the undistributed earnings of its financial interest in VIEs because it believes such excess earnings can be distributed in a manner that would not be subject to income tax. Uncertainties exist with respect to how the current income tax law in the PRC applies to the Group’s overall operations, and more specifically, with regard to tax residency status. The EIT Law includes a provision specifying that legal entities organized outside of the PRC will be considered residents for Chinese Income tax purposes if the place of effective management or control is within the PRC. The implementation rules to the EIT Law provide that non-resident legal entities will be considered China residents if substantial and overall management and control over the manufacturing and business operations, personnel, accounting, properties, etc., occurs within the PRC. Despite the present uncertainties resulting from the limited PRC tax guidance on the issue, the Group does not believe that the legal entities organized outside of the PRC within the Group should be treated as residents for EIT law purposes. If the PRC tax authorities subsequently determine that the Company and its subsidiaries registered outside the PRC should be deemed resident enterprises, the Company and its subsidiaries registered outside the PRC will be subject to the PRC income taxes, at a rate of 25%. The current and deferred portions of income tax expenses included in the consolidated statements of operations, which were attributable to the Group’s PRC subsidiaries and VIE entities, are as follows: Years ended March 31, 2016 2017 2018 Current tax expenses $ $ $ Deferred tax benefits ) ) ) Income tax expenses $ $ $ The principal components of the deferred income tax assets and liabilities are as follows: The Group adopted ASU 2015-17 in the beginning of the current year, and the Group did not retrospectively apply the changes to prior year. As of March 31, 2017 2018 Current deferred tax assets: Accrued expenses $ $ — Accrued payroll — Allowance for doubtful accounts — Less: Valuation allowance ) — Current deferred tax assets $ $ — Non-current deferred tax assets: Accrued expenses $ $ Accrued payroll — Allowance for doubtful accounts — Depreciation and amortization Impairment of long-lived assets Net operating tax loss carry-forwards Less: Valuation allowance ) ) Non-current deferred tax assets $ $ As of March 31, 2017 2018 Non-current deferred tax liabilities: Intangible assets $ $ Non-current deferred tax liabilities $ $ The Group considers the following factors, among other matters, when determining whether some portion or all of the deferred tax assets will more likely than not be realized: the nature, frequency and severity of recent losses, forecasts of future profitability, the duration of statutory carryforward periods, the Group’s experience with tax attributes expiring unused and tax planning alternatives. The Group’s ability to realize deferred tax assets depends on its ability to generate sufficient taxable income within the carryforward periods provided for in the tax law. As of March 31, 2018, the Group’s PRC subsidiaries, VIEs and VIEs’ subsidiaries had a tax loss carry-forward amounted to $111,189 and would expire on various dates between December 31, 2018 and December 31, 2023. The Group does not file combined or consolidated tax returns, therefore, losses from individual subsidiaries or the VIE entities may not be used to offset other subsidiaries’ or VIE entities’ earnings within the Group. Valuation allowance is considered on each individual subsidiary and legal entity basis. Valuation allowances have been established in respect of certain deferred tax assets as it is considered more likely than not that the relevant deferred tax assets will not be realized in the foreseeable future. Reconciliation between the expense of income taxes computed by applying the PRC tax rate to income before income taxes and the actual provision for income taxes is as follows: For the years ended March 31, 2016 2017 2018 Income before provision for income taxes and income/(loss) from equity method investments $ $ $ ) PRC statutory tax rate % % % Income tax at statutory tax rate ) Change in valuation allowance ) Expenses not deductible for tax purposes Effect of income tax rate difference for entities under individual income tax rate of 35% Effect of income tax rate differences in other jurisdictions Tax holidays and preferential tax rates ) ) ) Income tax expenses $ $ $ The Group did not identify significant unrecognized tax benefits for the years ended March 31, 2016, 2017 and 2018, respectively. The Group did not incur any interest and penalties related to potential underpaid income tax expenses and also believed that uncertainty in income taxes did not have a significant impact on the unrecognized tax benefits within next twelve months.

COMMON SHARE

COMMON SHARE	12 Months Ended
	Mar. 31, 2018
COMMON SHARE
COMMON SHARE	15. COMMON SHARE Before the completion of the IPO in April 2014, the Class A and Class B common shares were owned by Mr. Lee Ligang Zhang, his spouse and other shareholders. Immediately prior to the completion of the IPO, Class B common shares were automatically converted into Class A common shares on a one-for-one basis and 805,100 of the Group’s outstanding Class A common shares held by Time Intelligent Finance Limited were redesignated into Class C common shares. According to the Company’s Amended and Restated Articles of Association which became effective upon the completion of the IPO, the Company currently has two classes of authorized ordinary shares, Class A common shares and Class C common shares. All Class C common shares are held by Time Intelligent Finance Limited and beneficially owned by Mr. Lee Ligang Zhang’s family trust. The rights of the holders of Class A and Class C common shares are identical, except with respect to voting and conversion rights. Each Class A common share is entitled to one vote per share, while each Class C common share is entitled to 15 votes per share and is convertible at any time into one Class A common share. Holders of Class A and Class C common shares shall at all times vote together as one class on all matters subject to a shareholders’ vote. On April 9, 2014, the Company completed its IPO in NASDAQ and a concurrent private placement. The Company issued 5,215,794 Class A ordinary shares, consisting of (i) 3,787,223 Class A common shares offered through IPO, and (ii) 1,428,571 Class A common shares issued in connection with the concurrent private placement. All of the Company’s preferred shares were automatically converted into 20,781,515 Class A common shares. On May 9, 2014, the Company issued an additional 514,556 Class A common shares to the investment bankers for excising the Green Shoe option. On December 2, 2015, the Board of Directors of the Group adopted a rights agreement, commonly referred to as a “poison pill,” and authorized the issuance of one Right for each outstanding Class A Common Share and Class C Common Share (the “Rights Plan”). The Rights Plan is intended to deter hostile or coercive attempts to acquire the Company. The Rights Plan enables shareholders to acquire shares of the Company’s common shares, at a substantial discount to the public market price should any person or group acquire more than 10% of the Company’s common shares. No common shares were issued under the Rights Plan. On November 28, 2016, the Board of Directors of the Company unanimously approved the extension of its Rights Plan, formerly scheduled to expire on December 2, 2016, for another year, which ended on December 2, 2017. 39,648,485 common shares were authorized and 34,721,539 common shares were issued and outstanding as of March 31, 2017 and 2018 respectively.

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE	12 Months Ended
	Mar. 31, 2018
NET INCOME (LOSS) PER SHARE
NET INCOME (LOSS) PER SHARE	16. NET INCOME (LOSS) PER SHARE The calculation of net income (loss) per share is as follows: For the years ended March 31, 2016 2017 2018 Numerator: Net income/(loss) attributable to iKang Guobin Healthcare Group, Inc $ $ ) $ ) Net income/(loss) attributed to common shareholders for computing net income per common share- basic and diluted $ ) $ ) Denominator: Weighted average shares outstanding used in computing diluted net income per common share Basic Diluted Net income/(loss) per common share attributable to common shareholders of iKang Healthcare Group, Inc. Basic $ $ ) $ ) Diluted $ $ ) $ )

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Mar. 31, 2018
SHARE-BASED COMPENSATION.
SHARE-BASED COMPENSATION	17. SHARE-BASED COMPENSATION On February 26, 2013, the BOD made a resolution and approved to set up the 2013 February Plan to grant the maximum of 1,249,000 options to the Grantee. The 2013 February Plan shall be effective as of the date of its approval by the BOD. On February 27, 2017, 1,249,000 options were granted, among which 38,485 options were forfeited subsequently due to employee termination or resignation and back to the option pool. On March 1, 2014, the BOD made a resolution and planned to set up the 2014 Plan to grant the maximum of 1,620,000 options to the management and employees. The 2014 Plan shall be effective as of the date of its approval by the BOD. Amended on June 30, 2014, the directors of the Company passed a resolution that among the 1,620,000 Class A common shares reserved for issuance, 810,000 Class A common shares with an exercise price of US$12.8902 per share may be granted and 810,000 Class A common shares with an exercise price equivalent to the offering price of the Company’s Class A common shares in its initial public offering (“IPO”). Additionally, the exercise price per share under an option granted to an U.S. citizenship shall not be less than the fair market value of a share - $32.92 on the date of grant of such Option. On December, 2016, the Compensation Committee passed a resolution to adjust the exercise price for all the 1,620,000 options under 2014 Plan to US$12.8902 per share. The Group’s Board of Directors has approved the Company to grant various tranches of options to its management and consultants since its inception. Option grants for the years ended March 31, 2016, 2017 and 2018 are as the following: On February 28, 2018, the Company granted 1,658,485 options with exercise price of $12.89 per share to the PRC citizen and $32.92 per share to the US citizen to certain of its management and employees, of which 1,571,884 options were vested and exercisable on the grant date, and the remaining 86,601 options have a vesting period varies from 1 month to 4 years. The following table summarizes information regarding options granted: For the years ended March 31, 2016 2017 2018 Number of Weighted Weighted Number of Weighted Weighted Number of Weighted Weighted Outstanding on April 1 of year Granted — — — — — — Exercised ) ) ) Forfeited ) ) ) Outstanding on March 31 of year The following table summarizes information with respect to share options outstanding as of March 31, 2018: Option outstanding Option exercisable Range of exercise price Number Weighted Weighted Aggregate Number Weighted Aggregate $ $ $ $ $ $ $ $ $ $ $ $ $ $ There were 1,932,124 vested options, and 86,601 options expected to vest as of March 31, 2018. For options expected to vest, the weighted-average exercise price is $12.89 and aggregate intrinsic value is $2,339 as of March 31, 2018. The fair value of each option granted was estimated on the date of grant using the binomial tree pricing model with the following assumptions used for grants during the applicable periods: Risk-free interest Contractual term Volatility Dividend yield Exercise price December 31, 2010 % 10 years % — 5.13 June 8, 2011 % 2.39 years % — 0.01 February 17, 2012 % 10 years % — 5.13 March 18, 2013 % 10 years % — 5.13-6.00 September 12, 2013 % 10 years % — 6.00 February 27, 2014 % 10 years % — 5.13-6.00 August 1, 2014 % 10 years % — 16.18 October 28, 2014 % 10 years % — 5.13-6.00 February 27, 2015 % 10 years % — 5.13 February 28, 2018 % 10 years % — 12.89-32.92 (1) Risk-free interest rate Risk-free interest rate was estimated based on the yield to maturity of China international government bonds with a maturity period close to the expected term of the options for the options granted on and before February 27, 2015. Risk-free interest rate was estimated based on the market yield of US Treasury Active Curves with 10 years maturity as of valuation date plus China country risk premium for the options granted on February 28, 2018. (2) Contractual term The Company used the original contractual term. (3) Volatility The volatility of the underlying common shares during the life of the options was estimated based on the historical stock price volatility of comparable listed companies over a period comparable to the expected term of the options. (4) Dividend yield The dividend yield was estimated by the Group based on its expected dividend policy over the expected term of the options. (5) Exercise price The exercise price of the options was determined by the Group’s Board of Directors. (6) Fair value of underlying common shares The estimated fair value of the common shares underlying the options as of the respective grant dates was determined based on a retrospective valuation, which used management’s best estimate for projected cash flows as of each valuation date. After the closing of the IPO, the fair value of common shares is determined as the closing sales price of the shares as quoted on the principal exchange or system. The Group recorded share-based compensation of $1,949 ,$1,941 and $34,822 during the years ended March 31, 2016, 2017 and 2018, respectively, based on the fair value on the grant dates over the requisite service period of award according to the vesting schedule for employee share option. As of March 31, 2018, total unrecognized compensation expense relating to unvested share options was $1,710, which will be recognized in one year. The weighted-average remaining contractual term of options outstanding is 5.67 years.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Mar. 31, 2018
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	18. FAIR VALUE MEASUREMENTS (1) Measured on a recurring basis The following table summarizes the fair value of the Group’s financial assets and liabilities measured at recurring basis as of March 31, 2017 and 2018: As of March 31, 2017 As of March 31, 2018 Quoted prices in Significant Significant Total Quoted prices in Significant Significant Total Long-term investments Available-for-sale investments — — — — Contingent consideration — — — — Long-term borrowings — — — — Total $ — $ — $ $ $ — $ — $ $ (2) Measured at fair value on a non-recurring basis Goodwill, acquired intangible assets, long-lived assets, equity method investments and cost method investments are measured at fair value on a non-recurring basis or whenever events or changes in circumstances indicate that carrying amount of a reporting unit exceeds its fair value. The fair value for these assets are considered at level 3 because the Group used unobservable inputs to determine their fair values. The Group estimated the fair value of these investee companies, goodwill and acquired intangible assets based on discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. The Group did not recognize any impairment loss related to goodwill, acquired intangible assets, equity method investments and cost method investments for the years ended March 31, 2016, 2017 and 2018.

RELATED PARTY BALANCES AND TRAN

RELATED PARTY BALANCES AND TRANSACTIONS	12 Months Ended
	Mar. 31, 2018
RELATED PARTY BALANCES AND TRANSACTIONS
RELATED PARTY BALANCES AND TRANSACTIONS	19. RELATED PARTY BALANCES AND TRANSACTIONS As of March 31, 2017 2018 Amount due from related parties $ Amount due to related parties-current — Amount due from related parties represents non-interest bearing loans provided by the Group to the non-controlling shareholders of a subsidiary of the Group. In the fiscal year ended March 31, 2018, the Group received repayment of $140 from the related parties. As of March 31, 2018, the balance due from these related parties was $4,831. In December 2017, the Group disposed two subsidiaries - Changchun Jiachang and Changchun Kuancheng District iKang Guobin General Clinic Co., Ltd. (“Changchun Kuancheng”) to a related party, Aiying Xingsheng Fund. The Group had inter-company transactions with these two entities before they were disposed by the Group to Aiying Xingsheng Fund. As of March 31, 2018, the balance due from these two related parties was $2,188, and the balance due to these two related parties was $3,692. Please refer to Note 9 for details.

NONCONTROLLING INTEREST

NONCONTROLLING INTEREST	12 Months Ended
	Mar. 31, 2018
NONCONTROLLING INTEREST
NONCONTROLLING INTEREST	20. NONCONTROLLING INTEREST iKang WA iKang Shenzhen Jianwei China Zhejiang Health Shanghai Fujian Hospital Healthcare Beijing iKang Beijing Yinchuan Shandong Xi’an Physician Guizhou Wuhu Wuxi Zhenjiang Ningbo BVI care Gubei iKang Management Management Jiandatong MediFast Changzhou Tianzhikangjian Ciming Ciming iKang alliance winstar iKang iKang iKang iKang Total Balance at March 31, 2015 $ $ $ $ $ ) $ $ $ $ $ — $ — $ $ — $ — $ — $ — $ — $ Additional purchase of non-controlling interest — — ) — — — — — — ) — — — — — — — — — ) Addition of non-controlling interest in connection with acquisitions — — — — — — — — — — — — — — Addition of non-controlling interest in connection with capital injection — — — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with new establishments — — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holders — — ) — — — — ) — — — — — — — — — — — ) Share of profit (loss) ) ) ) ) ) ) ) ) ) — — — ) Other comprehensive income — ) — ) — ) — ) ) ) ) — — — ) Balance at March 31, 2016 $ $ $ — $ $ ) $ ) $ $ $ $ $ $ $ $ $ $ $ — — — $ Purchase of non-controlling interest of Shenzhen Hospital Management — — — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with establishments of Wuxi iKang — — — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holders of MediFast — — — — — — — ) — — — — — — — — — — — ) Share of profit (loss) ) — ) ) ) ) ) ) ) ) ) ) — — ) Other comprehensive income ) ) — ) ) ) ) ) ) ) ) ) ) ) ) — — — ) Balance at March 31, 2017 $ $ $ — $ $ — $ ) $ $ $ $ $ $ $ $ $ $ $ ) — — $ Capital contribution from non-controlling interest of Zhenjiang iKang — — — — — — — — — — — — — — — — — — Purchase of non-controlling interest of Fujian iKang — — — ) — — — — — — — — — — — — — — — ) Addition of non-controlling interest of IMHealthcare and its subsidiaries (1) — — — — — — — — — — — — — — — — — — Capital contribution through other assets relating to non-controlling interest of Ningbo iKang (2) — — — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holder of iKang Yinchuan Ciming & Yinchuan Clinic — — — — — — — — — — ) — — — — — — — — ) Share of profit (loss) ) ) — ) — ) ) ) ) ) Other comprehensive income — — — ) ) ) Balance at March 31, 2018 $ $ — — — $ ) $ $ $ $ $ $ $ $ $ $ ) $ $ $ (1) On July 31, 2017, the Group acquired 100% equity interest of IMHealthcare and its subsidiaries (“IMHealthcare”) through Shanghai Jianwei Management. As part of the consideration, 35.06% of Shanghai Jianwei Management’s equity interests were exchanged with IMHealthcare’s original shareholders for this transaction, resulting in non-controlling interest in Shanghai Jianwei Management. The non-controlling interest in Shanghai Jianwei Management is amounted at $1,444 as of March 31, 2018. (2) Non-controlling shareholders of Ningbo iKang made a prepayment of capital injection $461 in Ningbo iKang during the year ended March 31, 2016. As the business registration as shareholders for non-controlling interest of Ningbo iKang was only completed in current year, resulting in an increase in non-controlling interest as of March 31, 2018.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Mar. 31, 2018
SEGMENT INFORMATION
SEGMENT INFORMATION	21. SEGMENT INFORMATION The Group’s chief operating decision maker has been identified as the Chief Executive Officer who reviews results of operations by business lines when making decisions about allocating resources and assessing performance of the Group. The Group has two operating segments: medical examinations and other medical services and dental services, and they are also the reporting segments. The Group does not allocate any assets to its operating segments as management does not believe that allocating these assets is useful in evaluating these segments’ performance. Accordingly, the Group has not made disclosure of total assets by reportable segments. For the years ended March 31, 2016 2017 2018 Net revenues: Medical examinations and other medical services $ $ $ Dental services Total net revenues Cost of revenues: Medical examinations and other medical services Dental services Total cost of revenues Gross profit: Medical examinations and other medical services Dental services ) ) Total gross profit Operating expenses: Selling and marketing expenses General and administrative expenses Research and development expenses Total operating expenses Income from operations $ $ $ Components of net revenues are presented in the following table: For the years ended March 31, 2016 2017 2018 Medical examinations $ $ $ Disease screening Other services Medical examinations and other medical services Dental services Total $ $ $ Substantially all of the Group’s revenues for the years ended March 31, 2016, 2017 and 2018 were generated from the PRC entities. Substantially all of the Group’s long-lived assets are located in the PRC as of March 31, 2017 and 2018.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2018
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	22. COMMITMENTS AND CONTINGENCIES Commitments (1) Operating lease as lessee The Group leases its clinics and offices under non-cancelable operating lease agreements. These leases expire through 2036 and are renewable upon negotiation. Rental expenses under the operating leases for the years ended March 31, 2016, 2017 and 2018 were $51,719, $67,250 and $74,695, respectively. Future minimum lease payments under such leases as of March 31, 2018 were as follows: 2019 $ 2020 2021 2022 2023 After 2023 $ (2) Future minimum principal payments related to the Company’s short-term and long-term borrowings as of March 31, 2018 are as follows (see Note 12 and Note 13): 2019 $ 2020 2021 2022 2023 — After 2023 — $ (3) The Group entered into agreements with certain suppliers of reagent and agreed to purchase a minimum level of reagent in order to enjoy volume discounts. Future minimum purchases to such suppliers as of March 31, 2018 are as follows: 2019 $ 7,936 2020 2021 2022 2023 After 2023 $ Contingent liabilities The Group is subject to governmental supervision and regulations by the relevant PRC regulatory authorities including the Ministry of Health, the Ministry of Industry and Information Technology of the PRC, and other relevant government authorities. Each of the Group’s medical centers is required to obtain a business license, a medical institution establishment approval, a medical institution practicing license and a radiation-related diagnosis and treatment license. If the Group fails to obtain such licenses or to amend the medical institution practicing licenses for the forgoing medical centers or other competent PRC regulatory authorities consider that the Group is operating the relevant businesses in an illegal manner, the Group may be ordered to shut down the relevant medical centers or cease the relevant services or suffer fines or penalties. The Group has been named in a number of lawsuits arising in its ordinary course of business. In the case where the management can reasonably estimate the outcome of the lawsuits taking into account of the legal advices, provision would be made for the probable losses. Where the management cannot reasonably estimate the outcome of the lawsuits or believe the probability of loss is remote, no provision is made.

EMPLOYEE BENEFIT PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
	Mar. 31, 2018
EMPLOYEE BENEFIT PLAN
EMPLOYEE BENEFIT PLAN	23. EMPLOYEE BENEFIT PLAN Full time employees of the Group in the PRC participate in a government-mandated defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to employees. The Group accrues for these benefits based on relevant percentages of the employees’ salaries. The total provisions for such employee benefits were $16,342, $21,503 and $25,378 for the years ended March 31, 2016, 2017 and 2018, respectively.

STATUTORY RESERVE AND RESTRICTE

STATUTORY RESERVE AND RESTRICTED NET ASSETS	12 Months Ended
	Mar. 31, 2018
STATUTORY RESERVE AND RESTRICTED NET ASSETS
STATUTORY RESERVE AND RESTRICTED NET ASSETS	24. STATUTORY RESERVE AND RESTRICTED NET ASSETS In accordance with the Regulations on Enterprises with Foreign Investment of China and their articles of association, the Group’s subsidiaries and VIE entities located in the PRC, being foreign invested enterprises established in the PRC, are required to provide for certain statutory reserves. These statutory reserve funds include one or more of the following: (i) a general reserve, (ii) an enterprise expansion fund or discretionary reserve fund, and (iii) a staff bonus and welfare fund. Subject to certain cumulative limits, the general reserve fund requires a minimum annual appropriation of 10% of after-tax profit (as determined under accounting principles generally accepted in China at each year-end); the other fund appropriations are at the subsidiaries’ or the affiliated PRC entities’ discretion. These statutory reserve funds can only be used for specific purposes of enterprise expansion, staff bonus and welfare, and are not distributable as cash dividends except in the event of liquidation of our subsidiaries, our affiliated PRC entities and their respective subsidiaries. The Group’s subsidiaries and VIE entities are required to allocate at least 10% of their after-tax profits to the general reserve until such reserve has reached 50% of their respective registered capital. As of March 31, 2018, the Group’s PRC subsidiaries and VIE entities had a general reserve that reached 50% of their registered capital threshold included Beijing iKang Guobin Jiuxianqiao Clinic Co., Ltd., iKang Beijing Xuanwumen, iKang Beijing Yayun, iKang Health Cloud, iKang Shanghai ikang Road, iKang Shanghai Lujiazui, Yan’an West Road, iKang Guangzhou Huanshi, iKang Chengdu Waishuangnan, iKang Chengdu Hongzhaobi, iKang Chongqing, and iKang Fuzhou Gulou; all others will continue to allocate at least 10% of their after tax profits to the general reserve fund. Appropriations to the enterprise expansion reserve and the staff welfare and bonus reserve are to be made at the discretion of the Board of Directors of each of the Group’s subsidiaries. The appropriation to these reserves by the Group’s PRC subsidiaries was $3,130, $3,232 and $3,635 for the years ended March 31, 2016, 2017 and 2018, respectively. As a result of these PRC laws and regulations and the requirement that distributions by PRC entities can only be paid out of distributable profits computed in accordance with PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Group. Amounts restricted include paid-in capital and the statutory reserves of the Group’s PRC subsidiaries and VIE entities. The aggregate amounts of capital and statutory reserves restricted which represented the amount of net assets of the relevant subsidiaries and VIE entities in the Group not available for distribution was $263,634 as of March 31, 2018. As the restricted net assets of the Group’s subsidiaries and VIE entities were over 25% of the consolidated net assets of the Group as of March 31, 2018, the parent company’s financial statements are presented in Schedule I.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2018
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	25. SUBSEQUENT EVENTS On May 30, 2018, the Company filed the Schedule 13E-3 under Rule 13e-3 for a “going private transaction” in connection with the definitive merger agreement entered into on March 26, 2018 with Yunfeng Capital (“Yunfeng”) and Alibaba Group Holding Limited (“Alibaba”) (collectively, the “Sponsors”). The agreement stipulates the Sponsors will acquire all of the outstanding Class A common shares (“Class A Shares”), Class C common shares (together with Class A Shares, the “Shares”) and American depositary shares (“ADSs,” each representing ½ of a Class A Share) of the Company in an all-cash transaction for $20.00 per ADS or $40.00 per Share. The merger agreement was amended on May 29, 2018 to include Taobao China Holding Limited, Yunfeng Fund III, L.P., Yunfeng Fund III Parallel Fund, L.P. and Boyu Capital Fund III, L.P. as the final sponsors for the transaction. In July 2018, the Group obtained a one-year loan framework agreement for a short-term borrowing facility totalling RMB200,000,000 (equivalent to $31,886) with Shanghai Pudong Development Bank Shanghai Branch to satisfy its daily operation needs , of which RMB48,960,000 (equivalent to $7,805) was drawn down in August 2018. The loan bears interest at a rate of 5% per annum with maturity dates in August 2019.

ADDITIONAL INFORMATION-FINANCIA

ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY	12 Months Ended
	Mar. 31, 2018
ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY
ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY	ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY CONDENSED BALANCE SHEETS (In thousands of US dollars, except share and per share data) As of March 31, 2017 2018 ASSETS Current assets: Cash and cash equivalents $ $ Amounts due from related parties Prepaid expenses and other current assets Total current assets $ $ Investment in subsidiaries and VIE entities Rental deposit and other non-current assets TOTAL ASSETS $ $ LIABILITIES AND EQUITY: Current liabilities: Accrued expenses and other current liabilities $ $ Amount due to related parties — Total current liabilities $ $ Equity: Class A common shares ($0.01 par value; 37,648,485 shares authorized as of March 31, 2017 and 2018, 33,916,439 and issued and outstanding as of March 31, 2017 and 2018, respectively) Class C common shares ($0.01 par value; 2,000,000 shares authorized as of March 31, 2017 and 2018, 805,100 shares issued and outstanding as of March 31, 2017 and 2018) Additional paid-in capital Accumulated deficit ) ) Accumulated other comprehensive loss ) ) Total iKang Healthcare Group, Inc.’s equity TOTAL LIABILITIES AND EQUITY $ $ CONDENSED STATEMENTS OF OPERATIONS (In thousands of US dollars, except share and per share data) For the years ended March 31 2016 2017 2018 Operating expenses: General and administrative expenses Total operating expenses Interest income Interest expense ) — — Investment income — — Exchange gain — — Equity in income/(loss) of subsidiaries and VIE entities ) Income/(loss) before provision for income tax expenses ) ) Net income/(loss) $ $ ) $ ) CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (In thousands of US dollars, except share and per share data) For the years ended March 31, 2016 2017 2018 Net income/(loss) $ $ ) $ ) Other comprehensive income/(loss) Foreign currency translation adjustments ) ) Unrealized gain/(loss) of available-for-sale investments, net of taxes of $47, $40 and $221 for the years ended March 31, 2016, 2017 and 2018, respectively ) Comprehensive income/(loss) attributable to iKang Healthcare Group, Inc. $ $ ) $ CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY (In thousands of US dollars, except share and per share data) Common Accumulated other Total Comprehensive Additional Accumulated comprehensive shareholders’ Shares Amount paid-in capital deficit income(loss) equity Balance at March 31, 2015 $ $ $ ) $ $ Share-based compensation expenses — — — — Exercise of employee share options — — — — Settlement of acquisition payable of Shanghai Huajian Management — — — Additional purchase of non-controlling interest of iKang Shanghai Gubei — — ) — — ) Net income — — — — Foreign currency translation adjustments — — — — ) ) Unrealized gain on available-for-sale investments — — — — Balance at March 31, 2016 $ $ $ ) $ ) $ Share-based compensation expenses — — — — Exercise of employee share options — — — — Issuance of common shares, to option pool, in connection with share-based compensation arrangements — — — Issuance of common shares in connection with exercise of options — — — — — Purchase of non-controlling interest of Shenzhen Hospital Management — — ) — — ) Net loss — — — ) — ) Foreign currency translation adjustments — — — — ) ) Unrealized loss on available-for-sale investments — — — — ) ) Balance at March 31, 2017 $ $ $ ) $ ) $ Share-based compensation expenses Exercise of share based compensation — — — — Purchase of non-controlling interest of Fujian iKang — — ) — — ) Acquisition in connection with IMHealthcare (Beijing) Technology Co., Ltd. — — — — Return of capital of Weihai Ciming Clinic & Weihai Ciming — — ) — — ) Net loss — ) ) Foreign currency translation adjustments — — — — Unrealized loss on available-for-sale investments — Balance at March 31, 2018 $ $ $ ) $ ) $ CONDENSED STATEMENTS OF CASH FLOWS (In thousands of US dollars, except share and per share data) For the years ended March 31, 2016 2017 2018 CASH FLOWS FROM OPERATING ACTIVITIES: Net income/(loss) $ $ ) $ ) Adjustments to reconcile net income to net cash used in operating activities: Investment income/(loss) from subsidiaries ) ) Share based compensation expenses Changes in assets and liabilities: Prepaid expenses and other current assets ) Amount due from related parties ) Accrued expenses and other current liabilities ) ) Net cash used in operating activities ) ) ) CASH FLOW FROM INVESTING ACTIVITIES: Return of prepayment for long-term investment — — Payment for long-term investments ) — — Investment in subsidiaries ) — — Payment for loan receivable ) — — Net cash (used in)/provided by investing activities ) — CASH FLOW FROM FINANCING ACTIVITIES: Proceeds from exercise of share options Net cash provided by financing activities Net increase/(decrease) in cash and cash equivalents ) ) CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR CASH AND CASH EQUIVALENTS AT END OF THE YEAR $ $ $ NOTES TO THE FINANCIAL STATEMENTS 1. BASIS FOR PREPARATION The condensed financial information of the Parent Company has been prepared using the same accounting policies as set out in the Group’s consolidated financial statement except that the Parent Company used the equity method to account for investments in its subsidiaries and VIE entities. The condensed financial information is provided since the restricted net assets of the Group’s subsidiaries and VIE entities were over 25% of the consolidated net assets of the Group as of March 31, 2018. 2. INVESTMENTS IN SUBSIDIARIES The Parent Company, its subsidiaries and VIE entities were included in the consolidated financial statements where inter-company balances and transactions were eliminated upon consolidation. For the purpose of the Parent Company’s stand-alone financial information, its investments in subsidiaries and VIE entities are reported using the equity method of accounting. The Parent Company’s share of income/(loss) from its subsidiaries and VIE entities were reported as share of income/(loss) of subsidiaries and VIE entities in the accompanying Parent Company’s financial information.

SUMMARY OF SIGNIFICANT ACCOUN37

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2018
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation	Basis of presentation The consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Group had negative working capital of approximately $145,150 as of March 31, 2018, which was mainly attributable to the current liability balance associated with the convertible loans issued in December 2015, of which $135,510 will become due during fiscal year 2018. Taking into consideration of the expected positive operating cash flows to be generated from operations by the Group, the undrawn available banking facilities and additional capital commitment from certain privatization investors whom have signed the amended and restated interim investors agreement with the Company and will provide such capital injection to the Company upon the completion of privatization proceeding, the Group is expected to obtain sufficient financial resource prior to the due date of the convertible loans. Therefore, management is of the opinion that the Group will be able to satisfy its liabilities as and when they become due, and accordingly, these consolidated financial statements are prepared on a going concern basis.
Basis of consolidation	Basis of consolidation The consolidated financial statements of the Group include the financial statements of iKang Guobin Healthcare Group Inc., its subsidiaries, its VIEs and its VIEs’ subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation.
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues, costs and expenses in the consolidated financial statements and accompanying notes. Significant accounting estimates reflected in the Group’s consolidated financial statements include allowance for doubtful accounts, the useful lives and impairment of property and equipment, purchase price allocation relating to business acquisitions, the useful lives and impairment of intangible assets, impairment of goodwill, impairment of long-term investments, valuation allowance for deferred tax assets, share-based compensation, interest accrual on long-term borrowings, fair value of long-term available-for-sale investments.
Business Acquisitions	Business Acquisitions Business combinations are recorded using the acquisition method of accounting. The purchase price of the acquisition is allocated to the tangible assets, liabilities, identifiable intangible assets acquired and non-controlling interest, if any, based on their estimated fair values as of the acquisition date. The excess of the purchase price over those fair values is recorded as goodwill. Acquisition-related expenses and restructuring costs are expensed as incurred. Where the consideration in an acquisition includes contingent consideration and the payment of which depends on the achievement of certain specified conditions post-acquisition, the contingent consideration is recognized and measured at its fair value at the acquisition date and if recorded as a liability, it is subsequently carried at fair value with changes in fair value reflected in earnings.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consist of cash on hand and demand deposits, which are unrestricted as to withdrawal and use, and have maturities of three months or less when purchased.
Restricted cash	Restricted cash Restricted cash mainly consists of the cash deposit denominated in U.S. dollar in overseas accounts used to collateralize the local borrowings in China to meet the Group’s RMB funding needs, which is primarily to purchase property and equipment within China. The balance of the restricted cash was $392 and nil as of March 31, 2017 and 2018, respectively.
Term deposits	Term deposits Term deposits consist of deposits placed with financial institutions with original maturity terms of greater than three months but less than one year.
Accounts receivable and allowance for doubtful accounts	Accounts receivable and allowance for doubtful accounts Accounts receivable represents those receivables derived in the ordinary course of business. A general allowance for doubtful accounts is provided based on aging analyses of accounts receivable balances, historical bad debt rates, in addition to specific provisions established based on customers’ repayment patterns and customer credit worthiness. The Group decides to write off a receivable and the corresponding provision when events indicate that there is a remote chance that an account receivable can be collected, such as liquidation of a customer or termination of business cooperation.
Financial instruments	Financial instruments Financial instruments of the Group primarily consist of cash and cash equivalents, restricted cash, term deposits, accounts receivable, available-for-sale investments, amount due from/to related parties, accounts payable, short-term borrowings and long-term borrowings. The carrying values of cash and cash equivalents, restricted cash, term deposits, accounts receivable, accounts payable, amounts due from/to related parties, and short-term borrowings approximate their fair values due to short-term maturities.
Effective interest method	Effective interest method The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Interest expense is recognized on an effective interest basis relating to financing arrangements included in the long-term borrowings.
Fair value measurements	Fair value measurements Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. Authoritative literature provides a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement as follows: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Group also measures certain assets, including long-term investments and intangible assets, at fair value on a nonrecurring basis when they are deemed to be impaired. The fair values of intangible assets are determined based on valuation techniques using the best information available, and may include management judgments, future performance projections, etc. An impairment charge to the intangible assets is recorded when their carrying amounts may not be recoverable. Fair value of financial instruments is discussed in Note 18.
Significant risks and uncertainties	Significant risks and uncertainties The Group operates in an industry with rapid changes in regulations, customer demand and competition and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations, or cash flows: advances and trends in healthcare industry standards, changes in certain strategic relationships or customer relationships, regulatory or other PRC related factors, risks associated with the Group’s ability to keep and increase the customer base, and risks surrounding pending litigations.
Foreign currency risk	Foreign currency risk The Renminbi (“RMB”) is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. Cash and cash equivalents of the Group included aggregate amounts of $57,553 and $56,593 as of March 31, 2017 and 2018, respectively, which were denominated in RMB.
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially expose the Group to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Group places their cash with financial institutions with high-credit ratings and quality. The Group conducts credit evaluations of customers and generally do not require collateral or other security from their customers. No customer accounted for 10% or more of total revenues for the years ended March 31, 2016, 2017 and 2018, respectively. No customer accounted for 10% or more of accounts receivable as of March 31, 2017 and 2018, respectively.
Inventories	Inventories Inventories are medical consumable supplies and are stated at the lower of cost or net realizable value. Inventories are written down for obsolescence to net realizable value based upon estimates of future demand and expiration date of inventories. The Group did not record a write-down of inventories for the years ended March 31, 2016, 2017 and 2018, respectively.
Property and equipment, net	Property and equipment, net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated on a straight-line basis over the following estimated useful lives: Computer equipment and application software 5 years Furniture and fixtures 5 years Medical equipment 10 years Motor vehicles 5 years Leasehold improvement Shorter of useful life of the asset or the lease term Construction in progress represents unfinished leasehold improvement and installment of equipment for new clinics. Construction in progress will be transferred to leasehold improvement or property and equipment when it is finished. Depreciation is recorded starting at the time when assets are ready for the intended use.
Intangible assets, net	Intangible assets, net Intangible assets, other than goodwill, resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by management based on the fair value of assets acquired. Identifiable intangible assets are carried at cost less accumulated amortization. Amortization of customer relationship is computed using the estimated attrition pattern of the acquired customers, and amortization of other finite- lived intangible assets is computed using the straight-line method over the following estimated average useful lives, which are as follows: Weighted average (years) Range (years) Customer relationship 5.7 2.1~10.0 Non-compete agreements 3.0 2.0~3.0 Contract backlog 0.7 0.4~0.9 Operating licenses 3.0 0.3~5.0 Favorable lease contracts 7.1 1.4~9.8 The weighted average estimated average useful life of the intangible assets with determinable lives is 5.5 years.
Intangible assets-indefinite lives	Intangible assets-indefinite lives If an intangible asset is determined to have an indefinite life, it should not be amortized until its useful life is determined to be no longer indefinite. An intangible asset that is not subject to amortization is tested for impairment at least annually or if events or changes in circumstances indicate that the asset might be impaired. Such impairment test consists of the fair values of assets with their carrying value amounts and an impairment loss is recognized if and when the carrying amounts exceed the fair values. The estimates of fair values of intangible assets not subject to amortization are determined using various discounted cash flow valuation methodologies. Significant assumptions are inherent in this process, including estimates of discount rates.
Impairment of long-lived assets and intangible assets with definite life	Impairment of long-lived assets and intangible assets with definite life Long-lived assets, such as property and equipment and definite-lived intangible assets are stated at cost less accumulated depreciation or amortization. Depreciation and amortization is computed using the straight-line method. The Group evaluates the recoverability of long-lived assets, with determinable useful lives whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. The Group measures the carrying amount of long-lived assets against the estimated undiscounted future cash flows associated with it. Impairment exists when the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated. Impairment loss is calculated as the amount by which the carrying value of the asset exceeds its fair value. Fair value is estimated based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Group to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts.
Goodwill	Goodwill Goodwill represents the excess of the fair value of consideration paid over the fair value of identifiable net assets acquired in business combinations. Goodwill and intangible assets deemed to have indefinite useful lives are not amortized, but tested for impairment annually or more frequently if events and circumstances indicate that they might be impaired. Goodwill is tested for impairment at the reporting unit level on an annual basis (March 31 for the Group) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the stock prices, business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. The first step compares the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of each reporting unit exceeds its carrying amount, goodwill is not considered to be impaired and the second step will not be required. If the carrying amount of a reporting unit exceeds its fair value, the second step compares the implied fair value of goodwill to the carrying value of a reporting unit’s goodwill. The implied fair value of goodwill is determined in a manner similar to accounting for a business combination with the allocation of the assessed fair value determined in the first step to the assets and liabilities of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to the assets and liabilities is the implied fair value of goodwill. An impairment loss is recognized for any excess in the carrying value of goodwill over the implied fair value of goodwill. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The estimation of fair value of each reporting unit using a discounted cash flow methodology also requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the Group’s business, estimation of the useful life over which cash flows will occur, and determination of the Group’s weighted average cost of capital. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results and market conditions. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for the reporting unit. The Group did not incur any impairment loss on goodwill for the years ended March 31, 2016, 2017 and 2018, respectively.
Long-term investments	Long-term investments The Group’s long-term investments consist of cost method investments, equity method investments and available-for-sale investments. Cost method investments For equity investments that are not considered to be equity securities that have readily determinable fair values and over which the Group has neither significant influence nor control through investment in common stock or in-substance common stock, the cost method is used. Under the cost method, the Company carries the investment at cost and recognizes income to the extent of dividends received from the distribution of the equity investee’s post-acquisition profits. Equity method investments The Group applies the equity method to account for an equity investment in common stock or in-substance common stock over which it has significant influence but does not own a majority equity interest or otherwise control. Significant influence is generally considered to exist when the Group has an ownership interest in the voting stock of the investee between 20% and 50%, and other factors, such as representation on the investee’s board of directors, voting rights and the impact of commercial arrangements, are considered in determining whether the equity method of accounting is appropriate. Under the equity method, the Group initially records its investment at cost and subsequently adjusts the carrying amount of the investment to recognize the Group’s proportionate share of each equity investee’s net income or loss into earnings after the date of investment. The Group periodically reviews its investments in equity investees to determine whether a decline in fair value below the carrying value is other than temporary. The primary factors the Group considers in its determination are the length of time that the fair value of the investment is below the Group’s carrying value; the financial condition, operating performance and the prospects of the equity investee; and other Group specific information such as recent financing rounds. If the decline in fair value is deemed to be other than temporary, the carrying value of the equity investee is written down to fair value. The Group estimated the fair value of these investee companies based on discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. Available-for-sale investments Available-for-sale investments are carried at their fair values and the unrealized gains or losses from the changes in fair values are included in accumulated other comprehensive income.
Revenue recognition	Revenue recognition The Group recognizes revenues when persuasive evidence of an arrangement exists, service has been provided, the sales price is fixed or determinable, and collectability is reasonably assured. The Group offers medical examination and disease screening services and renders such services at the request of its customers. The Group recognizes revenues when the examination reports are issued and passed to the local couriers if hard copy reports are required by its customers, or when the examination reports are uploaded on-line and can be viewed by the customers on-line if hard copy reports are not required. The Group notifies its customers when their examination reports are delivered to the local couriers or ready to be viewed and downloaded on line. For individual customers, fees are collected before the performance of the services while corporate customers prepay a portion of service fees upon signing of the master contract, which is recorded as deferred revenue by the Group. All fees for services rendered are first charged against the corporate customer’s deferred revenues until it is entirely exhausted before the Group starts to invoice the corporate customers. The Group records accounts receivables from its corporate customers when the examination reports of the employees of corporate customers have been delivered or uploaded on line but the Group has not received remaining payments from the corporate customers. When needed, the Group engages third-party providers to provide medical examination and disease screening services on behalf of the Group. The Group evaluates the services provided by third parties on behalf of the Group to determine whether to recognize the revenues on a gross or net basis. The determination is based upon an assessment as to whether the Group acts as a principal or agent when providing the services. All of the revenues involving third-party providers providing medical examination or disease screening services on behalf of the Group are currently accounted for on a gross basis since the Group is the primary obligor, has the latitude in establishing prices, discretion in third-party provider selection and the credit risks. The Group also provides packages of bundled services principally comprising combinations of medical examination, disease screening, health consultation and medical concierge services to its corporate customers, which normally expire within one year from the date of purchase and does not include right of return. The Group allocates revenues from the sale of bundled services to each component using the relative selling price of each component based on the Group’s best estimate. Revenue recognition criteria for components included in the bundled services is identical to as if the components are sold on a standalone basis. The Group recognizes revenue from dental services when the service is rendered and the service fee is collectable. Before the enforcement of value-added taxes (“VAT”) policy, revenue was stated net of business tax and related surcharges. The Group recorded $2,692 and $910 business tax and related surcharges for the years ended March 31, 2016 and 2017, respectively, and $932 VAT related surcharges for the year ended March 31, 2018.
Value added tax ("VAT")	Value added tax (“VAT”) On March 23, 2016, State Administration of Taxation launched Cai Shui [2016] No.36 (“Circular 36”), which takes effect starting May 1, 2016. In accordance with Circular 36, entities and individuals engaged in sales of services, intangible assets or real property within the territory of the People’s Republic of China are value-added taxpayers, and shall pay VAT rather than business tax (“BT”) according to these Measures. With the effect of Circular 36, Pilot Program is repealed. Pursuant to Circular 36, VAT exemption applies to medical services where all of the following conditions should be satisfied: (1) The medical institutions have obtained the Practice License for Medical Institutions in accordance with the Administrative Regulations on Medical Institutions of the State Council; (2) Medical services include the services which are listed in the Specifications for Pricing Items of National Medical Services; and (3) The price of medical services shall not be higher than the guiding prices for medical services set by competent price departments at or above the prefecture (city) level. Circular 36 becomes effective from May 1, 2016. In accordance with Circular 36, the Group’s medical services is eligible for the aforesaid tax exemption conditions.
Non-monetary exchange	Non-monetary exchange The Group occasionally exchanges medical examination services with advertising agencies for advertising credits. The amount of deferred revenues and prepaid expenses is based on the fair value of the medical examination services to be rendered which approximates the price the Group offers to the individual customers and is more readily determinable. The amounts of revenues recognized for non-monetary transactions were $1,767, $674, and $1,046 for the years ended March 31, 2016, 2017 and 2018, respectively. Direct costs attributable to the revenues have been immaterial.
Cost of revenues	Cost of revenues Cost of revenues consist of expenditures incurred in the generation of the Group’s revenues, includes but not limited to salaries and welfare paid to physicians, nurses, purchase of medical consumables, depreciation and amortization, rental, and fees paid to third-party service providers.
Research and development expenses	Research and development expenses Research and development expenses primarily consist of (i) salaries and benefits for research and development personnel, and (ii) office rental, general expenses and depreciation and amortization expenses associated with the research and development activities. The Group’s research and development activities primarily consist of the research and development of its information technology platform. Research and development expenses are expensed when incurred.
Income taxes	Income taxes Current income taxes are provided for in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Net operating loss carry forwards and credits are applied using enacted statutory tax rates applicable to future years. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that a portion of or all of the deferred tax assets will not be realized. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics up to the period ended March 31, 2017. The Group adopted ASU 2015-17 on April 1, 2017 and classified all deferred tax assets and liabilities as non-current as of March 31, 2018. The Group did not retrospectively apply the changes to prior years. The impact of an uncertain income tax position on the income tax return is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Interest and penalties on income taxes will be classified as a component of the provisions for income taxes. The Group did not recognize any income tax due to uncertain tax position or incur any interest and penalties related to potential underpaid income tax expenses for the years ended March 31, 2016, 2017 or 2018, respectively.
Share-based compensation	Share-based compensation Share-based payment transactions with employees, such as share options are measured based on the grant date fair value of the equity instrument. The Group recognizes the compensation costs net of an estimated forfeiture rate using the graded vesting attribution method over the requisite service period of the award, which is generally the vesting period of the award. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share compensation expense to be recognized in future periods. Share awards issued to non-employees, such as advisors, are measured at fair value at the earlier of the commitment date or the date the service is completed and recognized over the period the service is provided.
Earnings (loss) per share	Earnings (loss) per share Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common share reflect the potential dilution that could occur if securities were exercised or converted into common shares. The Group has stock options, which could potentially dilute basic earnings per share. To calculate the number of shares for diluted income per share, the effect of the stock options is computed using the treasury stock method.
Foreign currency translation	Foreign currency translation The functional and reporting currency of the Company is the United States dollar (“U.S. dollar”). The financial records of the Group’s subsidiaries and VIE entities located in the PRC are maintained in their local currencies, the RMB, which are also the functional currencies of these entities. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange ruling at the balance sheet date. Transactions in currencies other than the functional currency during the year are converted into functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the statement of operations. The Group’s entities with functional currency of RMB translate their operating results and financial positions into the U.S. dollar, the Group’s reporting currency. Assets and liabilities are translated using the exchange rates in effect on the balance sheet date. Revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of other comprehensive income (loss).
Comprehensive income (loss)	Comprehensive income (loss) Comprehensive income (loss) includes net income (loss), cumulative foreign currency translation adjustments, unrealized gain (loss) in available-for-sale investments (net of tax effect), and is reported in the consolidated statement of changes in equity.
Operating leases	Operating leases Leases where the risks and rewards of ownership of assets primarily remain with the lessor are accounted for as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the lease periods.
Newly issued accounting pronouncements adopted and not yet adopted	Newly adopted accounting pronouncements In November 2015, the Financial Accounting Standards Board (“FASB”) issued a new pronouncement Accounting Standard Update (“ASU”) 2015-17 which changes how deferred taxes are classified on organizations’ balance sheets. The ASU eliminates the current requirement for organizations to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, organizations will be required to classify all deferred tax assets and liabilities as noncurrent. The amendments apply to all organizations that present a classified balance sheet. For public companies, the amendments are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. This ASU may be applied prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. At April 1, 2017, the Group adopted ASU 2015-17 on a prospective basis and accordingly, presented all deferred tax assets and liabilities as noncurrent in the accompanying consolidated balance sheet as of March 31, 2018. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new guidance simplifies certain aspects related to income taxes, statement of cash flows, and forfeitures when accounting for share-based payment transactions. Certain of the amendments related to timing of the recognition of tax benefits and tax withholding requirements should be applied using a modified retrospective transition method. Amendments related to the presentation of the statement of cash flows should be applied retrospectively. All other provisions may be applied on a prospective or modified retrospective basis. For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Group adopted this standard on April 1, 2017 and has elected to account for forfeitures by applying an estimated forfeiture rate to share-based compensation expense rather than as they occur. The adoption did not have impact on the Group’s financial position or results of operations. Newly issued accounting pronouncements not yet adopted In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers (Topic 606).”ASU 2014-09 requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration that a company expects to be entitled to in exchange for the goods or services. To achieve this principle, a company must apply five steps including identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when (or as) the company satisfies the performance obligations. Additional quantitative and qualitative disclosure to enhance the understanding about the nature, amount, timing, and uncertainty of revenue and cash flows is also required. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. In April 2016, the FASB issued ASU 2016-10, “Identifying Performance Obligations and Licensing.” ASU 2016-10 clarifies the following two aspects of ASU 2014-09: identifying performance obligations and licensing implementation guidance. The effective date of ASU 2016-10 is the same as the effective date of ASU 2014-09. The Group expects to adopt ASU 2014-09 utilizing the modified retrospective method in the first quarter of fiscal year 2018. The Group has substantially completed an assessment of the impacts of the new standard to its existing portfolio of customer contracts. The Group does not believe the adoption of ASU 2014-09 would have a material effect on its current revenue recognition policies. In January 2016, the FASB issued a new pronouncement ASU 2016-01 Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The ASU also requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. The new guidance is effective for public companies for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The new guidance permits early adoption of the own credit provision. Adoption of the amendment must be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption, except for amendments related to equity instruments that do not have readily determinable fair values, which should be applied prospectively. The Group is in the process of evaluating the impact that this guidance will have on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The guidance supersedes existing guidance on accounting for leases with the main difference being that operating leases are to be recorded in the statement of financial position as right-of-use assets and lease liabilities, initially measured at the present value of the lease payments. For operating leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. For public business entities, the guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application of the guidance is permitted. In transition, entities are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The Group is in the process of evaluating the impact that this guidance will have on its consolidated financial statements. In August 2016, the FASB issued new pronouncements ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The amendments in this ASU provide guidance on the following specific cash flow issues such as: (1) Contingent Consideration Payments Made After a Business Combination; (2) Distributions Received from Equity Method Investees. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. An entity that elect early adoption must adopt all of the amendments in the same period. The Group is in the process of evaluating the impact that this guidance will have on its consolidated financial statements. In November 2016, the FASB issued ASU 2016-18: Statement of Cash Flows (Topic 230): Restricted Cash. The amendments in this ASU require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this AUS do not provide a definition of restricted cash or restricted cash equivalents. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The amendments in this ASU should be applied using a retrospective transition method to each period presented. The Group is in the process of evaluating the impact that this guidance will have on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-01: Business Combinations (Topic 805): Clarifying the Definition of a Business. The ASU requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the amendments in this ASU (1) require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. Public business entities should apply the amendments in this ASU to annual periods beginning after December 15, 2017, including interim periods within those periods. Early application of the amendments in this ASU is allowed. The amendments in this ASU should be applied prospectively on or after the effective date. No disclosures are required at transition. The Group is in the process of evaluating the impact that this guidance will have on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-04: Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. To simplify the subsequent measurement of goodwill, the Board eliminated Step 2 from the goodwill impairment test. Under the amendments in this ASU, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity should apply the amendments in this ASU on a prospective basis. An entity is required to disclose the nature of and reason for the change in accounting principle upon transition. A public business entity that is a SEC filer should adopt the amendments in this ASU for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Group is in the process of evaluating the impact that this guidance will have on its consolidated financial statements.

ORGANIZATION AND PRINCIPAL AC38

ORGANIZATION AND PRINCIPAL ACTIVITIES (Tables)	12 Months Ended
	Mar. 31, 2018
ORGANIZATION AND PRINCIPAL ACTIVITIES
Schedule of list of the Group's subsidiaries, VIEs and the VIEs' subsidiaries	Percentage of beneficial interest by iKang Names Place of Healthcare Principal activities Subsidiaries: iKang Guobin Healthcare Group, Inc.(“iKang Guobin”) BVI 100% Holding company ShanghaiMed iKang, Inc. (“Beijing iKang”) PRC 100% On-demand healthcare services Shanghai iKang Co., Ltd. (“Shanghai iKang”) PRC 100% On-demand healthcare services iKang Zhejiang, Inc. (“iKang Zhejiang BVI”) BVI 73% Holding company iKang Health Management (Zhejiang) Co., Ltd. (“Zhejiang iKang”) PRC 73% On-demand healthcare services Bayley & Jackson (China) Medical Services Limited (“Bayley & Jackson (Hong Kong)”) Hong Kong 100% Holding company Beijing Bayley & Jackson Clinic Co., Ltd. (“iKang Beijing Ritan”) PRC 100% Medical examinations & clinical services Yuanhua Healthcare Limited (“Yuanhua HK”) Hong Kong 100% Holding company Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. (“Yuanhua WFOE”) PRC 100% On-demand healthcare services MediFast (Hong Kong) Limited (“MediFast”) Hong Kong 80% Medical examinations & clinical services WA Centers HK Limited (“WA Health Care”) Hong Kong 70% Holding company iKang(Shanghai) Financing Lease Co., Ltd. (“iKang(Shanghai) Financing Lease”) PRC 100% Lease services iKang MRI Center, Inc. BVI 70% Medical service iKang MRI Center, Limited Hong Kong 100% Medical service iKang mHealth, Inc. BVI 70% Medical service iKang Health Cloud Technology Limited Hong Kong 100% Medical service iKang Health Cloud (Beijing) Software Co., Ltd. (“iKang Health Cloud”) PRC 100% Research & development VIEs: iKang Healthcare Technology Group Co., Ltd.(formerly named as “Shanghai iKang Guobin Holding Co., Ltd.”)(“iKang Holding”) PRC 100% Holding company Hangzhou iKang Guobin Clinic Co., Ltd. (“iKang Hangzhou Xixi”) PRC 73% Medical examinations Shanghai Yuanhua Information Technology Co., Ltd. (“Yuanhua Information”) PRC 100% Holding company Jiandatong Health Technology (Beijing) Co., Ltd. (“Beijing Jiandatong”) PRC 80% On-demand healthcare services Percentage of Names Place of Principal activities VIEs’ major subsidiaries (Note): iKang Guobin Healthcare Group Co., Ltd.(formerly named as “Beijing iKang Online Technology PRC 100% On-demand healthcare services Guangzhou iKang Guobin Health Examination Co., Ltd. (“iKang Guangzhou Huanshi”) PRC 100% Medical examinations Shanghai Guobin Medical Center Co., Ltd. (“iKang Shanghai Xikang Road”) PRC 100% Medical examinations & clinical services Shanghai iKang Guobin Mingmen Clinic Co., Ltd. (“iKang Shanghai Pudong Avenue”) PRC 100% Medical examinations Shanghai iKang Jianwei Healthcare Management Co., Ltd. (“Jianwei Healthcare Management”) PRC 54.4% On-demand healthcare services Shanghai Yalong Daoyi Services Co., Ltd. (“Yalong Daoyi”) PRC 70% On-demand healthcare services Beijing iKang Jun’an Clinic Co., Ltd. (“iKang Beijing Jun’an”) PRC 100% Medical examinations & clinical services Beijing iKang Guobin Yayun Clinic Co., Ltd. (“iKang Beijing Yayun”) PRC 100% Medical examinations Beijing iKang Guobin Wanzhishou Clinic Co., Ltd. (“iKang Beijing Wanzhishou”) PRC 100% Medical examinations Beiijng iKang Medical Examination Application Technology Co., Ltd. (“Medical Examination Application”) PRC 70% On-demand healthcare services Beijing Daoyitong Health Management Co., Ltd. (“Beijing Daoyitong”) PRC 70% On-demand healthcare services Shanghai Jinxiu Huajian Clinic Co., Ltd. (“Shanghai Jinxiu Huajian”) PRC 100% Medical examinations Chengdu Gaoxin iKang Dental Clinic Co., Ltd. (“iKang Chengdu Gaoxin”) PRC 100% Dental services Shenzhen iKang Guobin Clinic Co., Ltd. PRC 100% Medical examinations Beijing iKang Guobin Zhongguan Clinic Co., Ltd. (“iKang Beijing Zhongguancun”) PRC 100% Medical examinations Shanghai iKang Guobin Renren Clinic Co., Ltd. (“iKang Shanghai Yangpu”) PRC 100% Medical examinations Shanghai iKang Guobin Blue Cross Clinic Co., Ltd. (“iKang Shanghai Lujiazui”) PRC 100% Medical examinations Beijing iKang Guobin Clinic Co., Ltd. (“iKang Beijing Xuanwumen”) PRC 100% Medical examinations Nanjing iKang Guobin Clinic Co., Ltd. (“iKang Nanjing Gulou”) PRC 100% Medical examinations Beijing iKang Guobin Xinei Clinic Co., Ltd. (“iKang Beijing Xinei”) PRC 100% Medical examinations Shanghai iKang Guobin Fukang Clinic Co., Ltd. (“Yan’an West Road”) PRC 100% Medical examinations Hangzhou iKang Guobin Wenhui Clinic Co., Ltd. (“iKang Hangzhou Wenhui”) PRC 100% Medical examinations Chengdu Jinjiang iKang Guobin Hongzhaobi Health Examination General Clinic Co., Ltd. (“iKang Chengdu Hongzhaobi”) PRC 100% Medical examinations iKang Dental Hospital Management Co., Ltd. (“iKang Dental Hospital Management”) PRC 100% Management of dental services Beijing iKang Guobin Lidu Clinic Co., Ltd. (“iKang Beijing Lidu”) PRC 100% Medical examinations Beijing iKang Guobin Jianwai Clinic Co., Ltd. (“iKang Beijing Jianguomen”) PRC 100% Medical examinations Fuzhou iKang Guobin Clinic Co., Ltd. (“iKang Fuzhou Gulou”) PRC 100% Medical examinations Shanghai iKang Guobin Zhonghuan Yipin Clinic Co., Ltd. (formerly named as “Shanghai Zhonghuan Yipin Clinic Co., Ltd.”) (“iKang Shanghai Zhonghuan”) PRC 100% Medical examinations Shanghai iKang Guobin Yipin Clinic Co., Ltd. PRC 100% Medical examinations Shanghai iKang Guobin Waizhitan Clinic Co., Ltd. PRC 100% Medical examinations Shanghai iKang Guobin Jianzhiwei Clinic Co., Ltd. PRC 100% Medical examinations Tianjin Heping Aibin Clinic Co., Ltd. (“iKang Tianjin Heping”) PRC 100% Medical examinations Suzhou iKang Guobin Clinic Co., Ltd. PRC 100% Medical examinations Suzhou Zhuoyue Clinic Co., Ltd. (“Suzhou Zhuoyue”) PRC 100% Medical examinations Guangzhou iKang Guobin Huacheng Clinic (LLP) (“iKang Guangzhou Wokang”) PRC 100% Medical examinations Shanghai Yuanhua Clinic Co., Ltd. (“Yuanhua Clinic”) PRC 100% Medical examinations Shanghai Wangzu Guobin Medical Center Co., Ltd. (“iKang Shanghai Gubei”) PRC 100% Medical examinations Changzhou iKang Guobin Clinic Co., Ltd. (“iKang Changzhou”) PRC 62.5% Medical examinations Chengdu Gaoxin iKang Guobin Chengnan Clinic Co., Ltd. (“Chengdu Gaoxin iKang West City”) PRC 100% Medical examinations Shanghai Huajian Clinic Co., Ltd. (“Shanghai Huajian”) PRC 100% Medical examinations Shanghai Huajian Health Examination Management Co., Ltd. (“Shanghai Huajian Management”) PRC 100% On-demand healthcare services Shanghai Zhenjing Clinic Co., Ltd. (“Shanghai Zhenjing”) PRC 70% Medical examinations Beijing iKang Guobin Shunping Clinic Co., Ltd. (“iKang Beijing Shunping”) PRC 100% Medical examinations Chongqing iKang Zhuoyue Clinic Co., Ltd. (“iKang Chongqing Zhuoyue”) PRC 100% Medical examinations Xi’an Lianhu iKang Guobin Zhuoyue Hospital Co., Ltd. (“Xi’an Lianhu Yinglun”) PRC 70% Medical examinations Guizhou Wishstar Health Examination Clinic Co., Ltd. (“Guizhou Wishstar”) PRC 60% Medical examinations Beijing iKang Guobin Sunny Jingchao Clinic Co., Ltd. (“iKang Beijing Jingchao”) PRC 83% Medical examinations Yantai iKang Guobin Ciming Medical Examination Management Co., Ltd. (“Yantai Ciming”) PRC 70% On-demand healthcare services Beijing Bohui Clinic Co., Ltd. (“Beijing Bohui”) PRC 100% Medical examinations Wuhan iKang Zhuoyue Clinic Co., Ltd. (“Wuhan Zhuoyue”) PRC 100% Medical examinations Shanghai iKang Jun’an Clinic Co., Ltd. (“Shanghai Jun’an”) PRC 100% Medical examinations Yinchuan iKang Guobin Clinic Co., Ltd. (“Yinchuan Clinic”) PRC 100% Medical examinations Note: Net revenues generated from these VIEs’ major subsidiaries accounted for approximately 80% of the Group’s net revenues as of March 31, 2018.
Schedule of financial statements amounts and balances of the VIE entities were included in the accompanying consolidated financial statements (after inter-company elimination)	As of March 31, 2017 2018 Cash and cash equivalents $ $ Accounts receivable and other current assets Amount due from related parties — Total current assets Property and equipment, net Acquired intangible assets, net Other noncurrent assets Total non-current assets Total assets Deferred revenues Accounts payable and other current liabilities Amount due to related parties — Total current liabilities Total non-current liabilities Total liabilities For the years ended March 31, 2016 2017 2018 Net revenues $ $ $ Net income/(loss) $ $ ) $ For the years ended March 31, 2016 2017 2018 Net cash provided by operating activities $ $ $ Net cash used in investing activities $ ) $ ) $ ) Net cash provided by (used in) financing activities $ $ ) $ )

SUMMARY OF SIGNIFICANT ACCOUN39

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2018
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of estimated useful lives of property and equipment	Computer equipment and application software 5 years Furniture and fixtures 5 years Medical equipment 10 years Motor vehicles 5 years Leasehold improvement Shorter of useful life of the asset or the lease term
Schedule of estimated average useful lives of finite-lived intangible assets	Weighted average (years) Range (years) Customer relationship 5.7 2.1~10.0 Non-compete agreements 3.0 2.0~3.0 Contract backlog 0.7 0.4~0.9 Operating licenses 3.0 0.3~5.0 Favorable lease contracts 7.1 1.4~9.8

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	12 Months Ended
	Mar. 31, 2018
Beijing Bohui
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 4.6 years Operating license 2.6 years Goodwill Deferred tax liability )
Summary of the unaudited pro forma information	Years ended March 31, 2016 2017 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income/(loss) attributable to common shareholders of iKang Healthcare Group, Inc. $ $ )
IMHealthcare and its subsidiaries
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 6.7 years Trademark Indefinite Favorable Lease 1.4 years Operating license 3.6 years Goodwill Deferred tax liability )
Summary of the unaudited pro forma information	Years ended March 31, 2017 2018 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net loss attributable to common shareholders of iKang Healthcare Group, Inc. $ ) $ )

ACCOUNTS RECEIVABLE, NET (Table

ACCOUNTS RECEIVABLE, NET (Tables)	12 Months Ended
	Mar. 31, 2018
ACCOUNTS RECEIVABLE, NET
Schedule of accounts receivable	As of March 31, 2017 2018 Accounts receivable $ $ Less: allowance for doubtful accounts Accounts receivable, net $ $
Schedule of movement of allowance for doubtful accounts	As of March 31, 2016 2017 2018 Balance at beginning of year $ $ $ Charge to expenses Write off ) ) — Exchange difference ) ) Balance at end of year $ $ $

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Mar. 31, 2018
INVENTORIES
Schedule of inventories	As of March 31, 2017 2018 Medical consumable supplies $ $

PREPAID EXPENSES AND OTHER CU43

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Mar. 31, 2018
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Schedule of prepaid expenses and other current assets	As of March 31, 2017 2018 Advance to suppliers $ $ Other receivable (1) Staff advance Prepaid rental expenses Advance payments to acquisitions Prepaid expenses (2) Interest income receivable $ $ (1) Other receivable mainly consist of VAT receivable and amounts receivable from independent third parties. (2) Prepaid expenses mainly consist of amounts paid for professional fees and advertisement fees for which the related services have not been provided.

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Mar. 31, 2018
PROPERTY AND EQUIPMENT, NET
Schedule of property and equipment, net	As of March 31, 2017 2018 Medical equipment $ $ Leasehold improvement Computer equipment and application software Furniture and fixtures Motor vehicles Construction in progress Total cost Less: accumulated depreciation and amortization Property and equipment, net $ $

ACQUIRED INTANGIBLE ASSETS, N45

ACQUIRED INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
	Mar. 31, 2018
ACQUIRED INTANGIBLE ASSETS, NET
Schedule of gross carrying amount, accumulated amortization, impairment and net carrying amount of the intangible assets	As of March 31, 2017 2018 Acquired intangible assets not subject to amortization Trade-name $ $ Acquired intangible assets subject to amortization Customer relationship Operating licenses Favorable lease contracts Contract backlog Non-compete agreements Less: accumulated amortization Customer relationship Operating licenses Favorable lease contracts Contract backlog Non-compete agreements Less: impairment Intangible assets, net $ $

LONG-TERM INVESTMENTS (Tables)

LONG-TERM INVESTMENTS (Tables)	12 Months Ended
	Mar. 31, 2018
LONG-TERM INVESTMENTS
Schedule of long-term investments	As of March 31, 2017 2018 Cost method investments (1) $ $ Equity method investments (2) Available-for-sale investments (3) $ $ (1) Cost method investments Pursuant to a co-operation agreement with shareholder of Xi’an Puhui Physical Examination Co., Ltd. (“Xi’an Puhui”) in November 2015, the Group invested 23.1% equity interest of Xi’an Puhui, which operates fifteen medical clinics in Xi’an, Zhengzhou and other six cities, with a cash consideration of approximately $32,090. The transaction was closed in December 2015. The Group has no representative on Xi’an Puhui’s board of directors and does not have the ability to exercise significant influence over the operating and financial policies of Xi’an Puhui. The Group used cost method to account for this investment. In May 2015, the Group invested 1.8% equity interests of American Well Corporation (“AW”), a Delaware company with a cash consideration of approximately $13,500. The Group used cost-method to account for the investment as the Group has no representative on AW’s board of directors and does not have the ability to exercise significant influence over the operating and financial policies of AW. In September 2015, March 2016, and October 2016, the Group acquired minority equity interests in several third-party private companies through investments in their common shares or in-substance common shares with cash consideration of $2,000, $993, $232 respectively. The Group accounts for these investments under the cost method as the Group has no ability to exercise significant influence over the investees. In December 2017, the Group sold and disposed two early-stage subsidiaries to a related party, Ningbo Meishan Bonded Port Area Aiying Xingsheng Investment LLP (“Aiying Xingsheng Fund”). After the transaction, the Group held 1% equity interest of each of these two entities, which was accounted for using cost method and the carrying value was at $66 as of March 31, 2018. (2) Equity method investments In September 2015, the Group invested $10, 372 cash to acquire 21.8% equity interest of Shenzhen Topsky Jianxin Technology Co., Ltd. (“Topsky”). The transaction was closed in October 2015. The Group has two out of five representations on Topsky’s board of directors and has the ability to exercise significant influence over the operating and financial policies of Topsky. The Group accounted for this investment as equity method investment and recognized its share of loss of $931 and $315 for the years ended March 31, 2017 and 2018, respectively. In December 2015, a share purchase agreement was signed by the Group and Worldcare International Inc., a worldwide medical institution providing innovative advisory services for various hospitals and medical organizations, pursuant to which the Group agreed to invest $4,032 cash to acquire 20% equity interest. The transaction was closed in January 2016. The Group accounted for this investment as equity method investment because the Group has one out of five representations on the investee’s board of directors and has the ability to exercise significant influence but does not have control over the investees. The Group accounted for this investment as equity method investment and recognized its share of loss of $246 and $142 for the years ended March 31, 2017 and 2018, respectively. In February 2016, the Group completed a strategic investment in New China Life Insurance Health Investment Management Co., Ltd. (“NCI Health”), which was established by New China Life Insurance Co., Ltd. on December 13, 2012 and operates sixteen medical centers in 16 cities in China, with a total cash consideration of $119,363. After the investment, the Group holds 45% equity interest in NCI Health. The Group has two out of five representations on NCI Health’s board of directors and has the ability to exercise significant influence but does not have control over NCI Health and used the equity method to account for the investment. The Group recognized its share of loss of $7,985 and $1,536 for the years ended March 31, 2017 and 2018, respectively. NCI Health’s audited financial statements for the year ended December 31, 2017 are included in this annual report in accordance with Regulation S-X Rule 3-09. In December 2017, the Group, together with three other parties, entered into partnership agreement to establish AVIC Partnership, a limited partnership, to invest in the healthcare section, with total registered capital amounted to $80,031 (equivalent to RMB502,000,000). Ligang Capital Investment (Shenzhen) Co. Ltd.(“Ligang Capital”), an entity owned by the Group’s founder, also invested in the partnership as one of the general partners. The Group subscribed $11,160 (equivalent to RMB70,000,000) as a junior limited partner and as of March 31, 2018, but had not made the capital contribution. The Group signed agreements with AVIC Partnership in December 2017 to sell 25% of its equity interest in NCI Health to AVIC Partnership for a total consideration of $ 65,321 (equivalent to RMB 425,000,000). The Company will purchase back the 25% equity interest in NCI Health in three years at the above purchase price plus interest at an annual rate of 10%. The above transaction did not have any impact over the Company’s voting right on NCI Health, and the Company still had the ability to exercise significant influence of NCI Health. The transaction was a financing arrangement and the Company continued to account for its investment in NCI Health as equity investment with 45% equity interest holdings in NCI Health for the year ended March 31, 2018. (Please refer to Note 13.a). The Group purchased 40% equity interest of Beijing Minzhong Clinic Co., Ltd. (“Beijing MZ”) with a total cash consideration of $12,407. The transaction was closed in March 2016. The Group has one out of three representations on Beijing MZ’s board of directors and has the ability to exercise significant influence but does not have control over Beijing MZ and used the equity method to account for the investment. The Group recognized its share of loss of $385 and $455 for the years ended March 31, 2017 and 2018. In August 2016, the Group invested 49% equity interest of Shanghai Changqingshu Health Management Co., Ltd. (“Changqingshu”) with a total cash consideration of $712. The transaction was closed in November 2016. The Group has two out of five representations on Changqingshu’s board of directors and has the ability to exercise significant influence over the operating and financial policies of Changqingshu but does not have control over Changqingshu and used the equity method to account for the investment. The Group did not recognize its share of income or loss for the years ended March 31, 2017 and 2018 as they were immaterial. In December 2017, the Group invested $768 cash to acquire 9.96% equity interest of Aiying Xingsheng Fund, as a junior limited partner. Ligang Capital, an entity owned by the Group’s founder serves as one of the general partners of Aiying Xingsheng Fund. The other general partner of Aiying Xingsheng Fund is a related party of the preferred limited partner to Aiying Xingsheng Fund whom holds veto power on investment decisions made by the Investment Committee of Aiying Xingsheng Fund. The Group does not have control over Aiying Xingsheng Fund and used equity method to account for the investment. The Group did not recognize its share of loss for the year ended March 31, 2018 as it was immaterial. In part of the investment on Aiying Xingsheng Fund, medical centers owned and operated by Aiying Xingsheng Fund will be transferred to the Group firstly or other third parties at tentative agreed price equals to its original costs plus an annual rate of 15% or the price then agreed by partners of Aiying Xingsheng Fund during the exit period. The Group summarizes the condensed financial information below for the Group’s equity method investments as a group in accordance with Rule 4-08 of Regulation S-X. The summarized financial information of the equity method investments were as follows: As of March 31, 2017 2018 Current assets $ $ Non-current assets Current liabilities Non-current liabilities For the years ended March 31, 2016 2017 2018 Total revenues $ $ $ Gross profit Loss from operations ) ) ) Net loss ) ) ) (3) Available-for-sale investments In June 2015, the Group acquired 20% equity interest in Shanghai Shenmin Medical Technology Company Limited, with a cash consideration of $1,897, which is a medical technology company incorporated under the laws of the PRC. The investment was classified as available-for-sale investments since it can be redeemed at the option of the Group once the redeemable events occurred and measured subsequently at fair value. The change in fair value are recorded in other comprehensive income. There was no unrealized gain or loss recognized for the years ended March 31, 2017 and 2018. In June 2015, the Group invested $5,000 in China Medonline Inc. (“HDF”), a company engaged in providing on-line medical services, for 1% equity ownership interests on an as-converted basis. The investment was classified as available-for-sale investments since it can be redeemed at the option of the Group once the redeemable events occurred, and measured subsequently at fair value. $161 unrealized loss and $885 unrealized gain, net of tax, were recorded in other comprehensive income for the years ended March 31, 2017 and 2018, respectively.
Summarized condensed financial information of the equity method investments	As of March 31, 2017 2018 Current assets $ $ Non-current assets Current liabilities Non-current liabilities For the years ended March 31, 2016 2017 2018 Total revenues $ $ $ Gross profit Loss from operations ) ) ) Net loss ) ) )

GOODWILL (Tables)

GOODWILL (Tables)	12 Months Ended
	Mar. 31, 2018
GOODWILL
Schedule of changes in carrying amounts of goodwill	As of March 31, 2017 2018 Beginning balance $ $ Additions for the year by acquisitions of Beijing Bohui — IMHealthcare and its subsidiaries — Disposal for the year Changchun iKang Guobin Jiachang General Clinic Co., Ltd. (“Changchun Jiachang”) — ) Impairment loss: ) ) Exchange difference ) Goodwill $ $

ACCRUED EXPENSES AND OTHER CU48

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Mar. 31, 2018
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Schedule of accrued expenses and other current liabilities	As of March 31, 2017 2018 Accrued payroll and welfare $ $ Acquisitions consideration payable (1) Interest expense payable Other taxes payable Accrued rental expense Accrued social insurance Accrued professional fee Accrued outsourcing cost Dividend payable (2) — Other payables $ $ (1) A acquisitions consideration payable consists of remaining payables to sellers of the acquired business for the years ended March 31, 2017 and 2018, which were as follows: As of March 31, 2017 2018 Beijing Tianzhikangjian Xi’an iKang Guobin Yantai Hongkang Fujian iKang — Others (i) $ $ (i) Others consist of a number of individually insignificant acquisitions made in prior years. (2) As of March 31, 2017, the balance represents the dividend payable for the non-controlling interest shareholder of MediFast which is paid in fiscal year ended March 31, 2018.
Schedule of acquisitions consideration payable	As of March 31, 2017 2018 Beijing Tianzhikangjian Xi’an iKang Guobin Yantai Hongkang Fujian iKang — Others (i) $ $ (i) Others consist of a number of individually insignificant acquisitions made in prior years.

SHORT-TERM BORROWINGS (Tables)

SHORT-TERM BORROWINGS (Tables)	12 Months Ended
	Mar. 31, 2018
SHORT-TERM BORROWINGS
Schedule of short-term borrowings	As of March 31, 2017 2018 Bank borrowings (1) $ $ Long-term loans due within one year (2) $ $ (1) Bank borrowings a. In December 2015, iKang Holding entered into multiple two-year loan framework agreements with China Merchants Bank totaling RMB104,600,000 (equivalent to $15,198) to satisfy its daily operation needs. Each of the loans bear interest at a rate of 4.75% per annum. During fiscal years ended March 31, 2017 and 2018, the Group repaid RMB43,500,000 (equivalent to $6,249) and RMB61,100,000 (equivalent to $9,602). As of March 31, 2017 and 2018, the Group has RMB61,100,000 (equivalent to $8,877) and nil bank borrowings outstanding, respectively. b. In June 2016, iKang Holding entered into multiple two-year loan framework agreements with Industrial and Commercial Bank of China totaling RMB40,000,000 (equivalent to $5,811) to satisfy the daily operation needs. Each of the loan bears interest at a rate of 4.35%. During fiscal year ended March 31, 2018, the Group repaid RMB40,000,000 (equivalent to $6,377). As of March 31, 2017 and 2018, the Group has RMB40,000,000 (equivalent to $5,811) and nil bank borrowings outstanding, respectively. c. In September 2016, iKang Holding entered into a two-year loan framework agreements with China Merchants Bank totaling RMB15,000 ,000 (equivalent to $2,179) to satisfy the daily operation needs. The annual interest rate is 4.75%. During fiscal year ended March 31, 2018, the Group repaid RMB15,000,000 (equivalent to $2,391). The balance of this short-term borrowing were RMB15,000,000 (equivalent to $2,179) and nil as of March 31, 2017 and 2018, respectively. d. In December 2016, iKang Holding entered into a two-year loan framework agreements with Industrial Bank Co., Ltd. totaling RMB100,000,000 (equivalent to $14,528) to satisfy the daily operation needs. The annual interest rate is 4.35%. During fiscal year ended March 31, 2018, the Group repaid RMB100,000,000 (equivalent to $15,942). As of March 31, 2017 and 2018, the Group has RMB100,000,000 (equivalent to $14,528) and nil bank borrowings outstanding, respectively. e. In December 2016, iKang Holding entered into a two-year loan framework agreements with Hongkong and Shanghai Banking Corporation Limited RMB50,000,000 (equivalent to $7,264) to satisfy the daily operation needs. The annual interest rate is 4.35%. During fiscal years ended March 31, 2017 and 2018, the Group repaid RMB20,00,000 (equivalent to $2,906) and RMB30,000,000 (equivalent to $4,783). As of March 31, 2017 and 2018, the Group has RMB30,000,000 (equivalent to $4,358) and nil bank borrowings outstanding, respectively. f. In March 2017, iKang Holding entered into a two-year loan framework agreements with Bank of China RMB20,000,000 (equivalent to $2,906) to satisfy the daily operation needs. The annual interest rate is 4.35%. During fiscal year ended March 31, 2018, the Group repaid RMB20,000,000 (equivalent to $3,188). As of March 31, 2017 and 2018, the Group has RMB20,000,000 (equivalent to $2,906) and nil bank borrowings outstanding, respectively. g. In June 2017, iKang Holding entered into a one-year loan framework agreement to obtain a short-term borrowing facility totaling RMB20,000,000 (equivalent to $3,188) with Industrial and Commercial Bank of China to satisfy the daily operation needs, of which RMB20,000,000 (equivalent to $3,188) was drawn down in June 2017. The loan bears interest at a rate of 4.35% per annum with a maturity date of June 15, 2018. As of March 31, 2018, the outstanding balance of this short-term borrowing was RMB20,000,000 (equivalent to $3,188). h. In April 2017, iKang Holding entered into a one-year loan framework agreement to obtain a short-term borrowing facility totaling RMB100,000,000 (equivalent to $15,942) with China Minsheng Bank to satisfy the daily operation needs, of which RMB47,055,000 (equivalent to $7,502) was drawn down in August 2017. The loan bears interest at a rate of 5.00% per annum with a maturity date on August 7, 2018. As of March 31, 2018, the outstanding balance of this short-term borrowing was RMB47,055,000 (equivalent to $7,502). i. In November 2017, iKang Holding entered into a one-year loan framework agreement of RMB100,000,000 (equivalent to $15,942) with Industrial Bank Co., Ltd. to satisfy the daily operation needs. The loan bears interest at a rate of 4.83% per annum with a maturity date on November 28, 2018. As of March 31, 2018, the balance of this short-term borrowing was RMB100,000,000 (equivalent to $15,942). j. In December 2017, iKang Holding entered into a one-year loan framework agreement to obtain a short-term borrowing facility totaling RMB30,000,000 (equivalent to $4,783) with the Hongkong and Shanghai Banking Corporation Limited to satisfy the daily operation needs, of which RMB29,100,000 (equivalent to $4,639) was drawn down in December 2017. The loan bears interest at a rate of 4.79% per annum with a maturity date on December 6, 2018. As of March 31, 2018, the outstanding balance of this short-term borrowing was RMB29,100,000 (equivalent to $4,639). k. In December 2017, iKang Holding entered into a one-year loan framework agreement to obtain a short-term borrowing facility totaling RMB200,000,000 (equivalent to $31,884) with China Merchants Bank to satisfy the daily operation needs, of which RMB100,000,000 (equivalent to $15,942) and RMB50,000,000 (equivalent to $7,972) were drawn down in December 2017 and January 2018, respectively. Both of the two loans bear interest at a rate of 4.57% per annum with a maturity date on June 5, 2018 and January 8, 2019, respectively. As of March 31, 2018, the outstanding balance of these short-term borrowings were RMB150,000,000 (equivalent to $23,914). l. In March 2018, iKang Holding entered into a one-year loan framework agreement of RMB20,000,000 (equivalent to $3,188) with Industrial Bank Co., Ltd. to satisfy the daily operation needs. The loan bears interest at a rate of 5.00% per annum with a maturity date on March 29, 2019. As of March 31, 2018, the balance of this short-term borrowing was RMB20,000,000 (equivalent to $3,188). The above amount of short-term borrowing remained outstanding, which amounted to $38,659 and $58,373 as of March 31, 2017 and 2018, respectively. Interest expense incurred for the years ended March 31, 2016, 2017 and 2018 was $1,734 and $1,725 and $2,517, respectively. The weighted average effective interest rate for the years ended March 31, 2016, 2017 and 2018 was 3.3%, 4.2% and 4.54%, respectively. (2) Long-term loans due within one year a. In December 2015, iKang Holding entered into a series of agreements to issue long-term loans with principal amount totaling $203,393 (equivalent to RMB1,400,000,000) to four third-party investors (“bond holders”) with terms varying from eighteen months to thirty-six months. The agreement stipulate that if the Group successfully completes the privatization before the maturity date of the long-term loans, and the bond holders decide to convert the loans into the future listing vehicle’s shares, no interest will be charged; however, if the bond holders decide not to convert, the interest rate will be at 5% or 8% (was originally 20%, amended to 8% subsequently in January 2017). Furthermore, if the privatization is not completed before the maturity date of the long-term loans, or the Group fails to put their best effort to facilitate the bond holder conversion of the loan into the future listing vehicle’s shares, the interest rate will be at 8% or 10% (was originally 5%, amended to 10% subsequently in December 2017). Interest rates of 8% and 10% were applied to accrue the interest expenses for above long-term loans for the year ended March 31, 2018, respectively. Interest expense incurred for the years ended March 31, 2016, 2017 and 2018 was $2,869, $11,768 and $17,317, respectively. The effective interest rate for the year ended March 31, 2018 was 11.1%. Loan amount of $29,056 (equivalent to RMB200, 000,000) was repaid in the year ended March 31, 2017, and $52,808 (equivalent to RMB350,000,000) was repaid during the year ended March 31, 2018. As of March 31, 2018, all the remaining outstanding loan amount of $135,510 (equivalent to RMB 850,000,000) was classified to short-term borrowings as the loans become due in three tranches in December 2018, January 2019 and March 2019, respectively. b. In November 2017, two of the Group’s wholly-owned subsidiaries entered into medical equipment sale-leaseback agreements as financial lease arrangement with Guiyang GYB Financial Leasing Co., Ltd.. Please refer to Note 13b for details. As of March 31, 2018, the lease payment due within 1 year amounted to $2,567, which was included in short-term borrowings.

LONG-TERM BORROWINGS (Tables)

LONG-TERM BORROWINGS (Tables)	12 Months Ended
	Mar. 31, 2018
LONG-TERM BORROWINGS
Schedule of long-term borrowings	As of March 31, 2017 2018 Long-term loans $ $ $ $

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2018
INCOME TAXES
Schedule of current and deferred portions of income tax expenses included in the consolidated statements of operations, which were all attributable to the Group's PRC subsidiaries and VIE entities	Years ended March 31, 2016 2017 2018 Current tax expenses $ $ $ Deferred tax benefits ) ) ) Income tax expenses $ $ $
Schedule of principal components of the deferred income tax assets and liabilities	As of March 31, 2017 2018 Current deferred tax assets: Accrued expenses $ $ — Accrued payroll — Allowance for doubtful accounts — Less: Valuation allowance ) — Current deferred tax assets $ $ — Non-current deferred tax assets: Accrued expenses $ $ Accrued payroll — Allowance for doubtful accounts — Depreciation and amortization Impairment of long-lived assets Net operating tax loss carry-forwards Less: Valuation allowance ) ) Non-current deferred tax assets $ $ As of March 31, 2017 2018 Non-current deferred tax liabilities: Intangible assets $ $ Non-current deferred tax liabilities $ $
Schedule of reconciliation between the expense of income taxes computed by applying the PRC tax rate to income before income taxes and the actual provision for income taxes	For the years ended March 31, 2016 2017 2018 Income before provision for income taxes and income/(loss) from equity method investments $ $ $ ) PRC statutory tax rate % % % Income tax at statutory tax rate ) Change in valuation allowance ) Expenses not deductible for tax purposes Effect of income tax rate difference for entities under individual income tax rate of 35% Effect of income tax rate differences in other jurisdictions Tax holidays and preferential tax rates ) ) ) Income tax expenses $ $ $

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
	Mar. 31, 2018
NET INCOME (LOSS) PER SHARE
Schedule of calculation of net income (loss) per share	For the years ended March 31, 2016 2017 2018 Numerator: Net income/(loss) attributable to iKang Guobin Healthcare Group, Inc $ $ ) $ ) Net income/(loss) attributed to common shareholders for computing net income per common share- basic and diluted $ ) $ ) Denominator: Weighted average shares outstanding used in computing diluted net income per common share Basic Diluted Net income/(loss) per common share attributable to common shareholders of iKang Healthcare Group, Inc. Basic $ $ ) $ ) Diluted $ $ ) $ )

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Mar. 31, 2018
SHARE-BASED COMPENSATION.
Summary of information regarding options granted	For the years ended March 31, 2016 2017 2018 Number of Weighted Weighted Number of Weighted Weighted Number of Weighted Weighted Outstanding on April 1 of year Granted — — — — — — Exercised ) ) ) Forfeited ) ) ) Outstanding on March 31 of year
Summary of information with respect to share options outstanding	Option outstanding Option exercisable Range of exercise price Number Weighted Weighted Aggregate Number Weighted Aggregate $ $ $ $ $ $ $ $ $ $ $ $ $ $
Schedule of assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods	Risk-free interest Contractual term Volatility Dividend yield Exercise price December 31, 2010 % 10 years % — 5.13 June 8, 2011 % 2.39 years % — 0.01 February 17, 2012 % 10 years % — 5.13 March 18, 2013 % 10 years % — 5.13-6.00 September 12, 2013 % 10 years % — 6.00 February 27, 2014 % 10 years % — 5.13-6.00 August 1, 2014 % 10 years % — 16.18 October 28, 2014 % 10 years % — 5.13-6.00 February 27, 2015 % 10 years % — 5.13 February 28, 2018 % 10 years % — 12.89-32.92

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Mar. 31, 2018
FAIR VALUE MEASUREMENTS
Schedule of fair value of the Group's financial assets and liabilities measured at recurring basis	As of March 31, 2017 As of March 31, 2018 Quoted prices in Significant Significant Total Quoted prices in Significant Significant Total Long-term investments Available-for-sale investments — — — — Contingent consideration — — — — Long-term borrowings — — — — Total $ — $ — $ $ $ — $ — $ $

RELATED PARTY BALANCES AND TR55

RELATED PARTY BALANCES AND TRANSACTIONS (Tables)	12 Months Ended
	Mar. 31, 2018
RELATED PARTY BALANCES AND TRANSACTIONS
Schedule of amounts due from related parties of the Group	As of March 31, 2017 2018 Amount due from related parties $ Amount due to related parties-current —

NONCONTROLLING INTEREST (Tables

NONCONTROLLING INTEREST (Tables)	12 Months Ended
	Mar. 31, 2018
NONCONTROLLING INTEREST
Schedule of noncontrolling interest	iKang WA iKang Shenzhen Jianwei China Zhejiang Health Shanghai Fujian Hospital Healthcare Beijing iKang Beijing Yinchuan Shandong Xi’an Physician Guizhou Wuhu Wuxi Zhenjiang Ningbo BVI care Gubei iKang Management Management Jiandatong MediFast Changzhou Tianzhikangjian Ciming Ciming iKang alliance winstar iKang iKang iKang iKang Total Balance at March 31, 2015 $ $ $ $ $ ) $ $ $ $ $ — $ — $ $ — $ — $ — $ — $ — $ Additional purchase of non-controlling interest — — ) — — — — — — ) — — — — — — — — — ) Addition of non-controlling interest in connection with acquisitions — — — — — — — — — — — — — — Addition of non-controlling interest in connection with capital injection — — — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with new establishments — — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holders — — ) — — — — ) — — — — — — — — — — — ) Share of profit (loss) ) ) ) ) ) ) ) ) ) — — — ) Other comprehensive income — ) — ) — ) — ) ) ) ) — — — ) Balance at March 31, 2016 $ $ $ — $ $ ) $ ) $ $ $ $ $ $ $ $ $ $ $ — — — $ Purchase of non-controlling interest of Shenzhen Hospital Management — — — — — — — — — — — — — — — — — — Addition of non-controlling interest in connection with establishments of Wuxi iKang — — — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holders of MediFast — — — — — — — ) — — — — — — — — — — — ) Share of profit (loss) ) — ) ) ) ) ) ) ) ) ) ) — — ) Other comprehensive income ) ) — ) ) ) ) ) ) ) ) ) ) ) ) — — — ) Balance at March 31, 2017 $ $ $ — $ $ — $ ) $ $ $ $ $ $ $ $ $ $ $ ) — — $ Capital contribution from non-controlling interest of Zhenjiang iKang — — — — — — — — — — — — — — — — — — Purchase of non-controlling interest of Fujian iKang — — — ) — — — — — — — — — — — — — — — ) Addition of non-controlling interest of IMHealthcare and its subsidiaries (1) — — — — — — — — — — — — — — — — — — Capital contribution through other assets relating to non-controlling interest of Ningbo iKang (2) — — — — — — — — — — — — — — — — — — Dividend distribution to non-controlling interest holder of iKang Yinchuan Ciming & Yinchuan Clinic — — — — — — — — — — ) — — — — — — — — ) Share of profit (loss) ) ) — ) — ) ) ) ) ) Other comprehensive income — — — ) ) ) Balance at March 31, 2018 $ $ — — — $ ) $ $ $ $ $ $ $ $ $ $ ) $ $ $ (1) On July 31, 2017, the Group acquired 100% equity interest of IMHealthcare and its subsidiaries (“IMHealthcare”) through Shanghai Jianwei Management. As part of the consideration, 35.06% of Shanghai Jianwei Management’s equity interests were exchanged with IMHealthcare’s original shareholders for this transaction, resulting in non-controlling interest in Shanghai Jianwei Management. The non-controlling interest in Shanghai Jianwei Management is amounted at $1,444 as of March 31, 2018. (2) Non-controlling shareholders of Ningbo iKang made a prepayment of capital injection $461 in Ningbo iKang during the year ended March 31, 2016. As the business registration as shareholders for non-controlling interest of Ningbo iKang was only completed in current year, resulting in an increase in non-controlling interest as of March 31, 2018.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Mar. 31, 2018
SEGMENT INFORMATION
Schedule of reconciliation of gross profit by segment to consolidated income from operations	For the years ended March 31, 2016 2017 2018 Net revenues: Medical examinations and other medical services $ $ $ Dental services Total net revenues Cost of revenues: Medical examinations and other medical services Dental services Total cost of revenues Gross profit: Medical examinations and other medical services Dental services ) ) Total gross profit Operating expenses: Selling and marketing expenses General and administrative expenses Research and development expenses Total operating expenses Income from operations $ $ $
Schedule of components of net revenues	For the years ended March 31, 2016 2017 2018 Medical examinations $ $ $ Disease screening Other services Medical examinations and other medical services Dental services Total $ $ $

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Mar. 31, 2018
COMMITMENTS AND CONTINGENCIES
Schedule of future minimum lease payments	Future minimum lease payments under such leases as of March 31, 2018 were as follows: 2019 $ 2020 2021 2022 2023 After 2023 $
Schedule of future minimum principal payments related to short-term and long-term borrowings	Future minimum principal payments related to the Company’s short-term and long-term borrowings as of March 31, 2018 are as follows (see Note 12 and Note 13): 2019 $ 2020 2021 2022 2023 — After 2023 — $
Schedule of future minimum purchases to such suppliers	Future minimum purchases to such suppliers as of March 31, 2018 are as follows: 2019 $ 7,936 2020 2021 2022 2023 After 2023 $

ORGANIZATION AND PRINCIPAL AC59

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details)	Mar. 01, 2014	Jan. 31, 2012	Mar. 31, 2018item	Jul. 31, 2013
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Ratio of shares swap with existing shareholders of iKang Guobin Healthcare Group, Inc.	1
Percentage of net revenues from VIEs' major subsidiaries			80.00%
Maximum percentage of direct foreign ownership allowed in business entities providing healthcare services in the PRC		70.00%
Yuanhua
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Interest acquired (as a percent)				100.00%
iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Number of shareholders who are directors and shareholders of the Company			2
Mr. Lee Ligang Zhang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			34.80%
Mr. Lee Ligang Zhang | iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			50.00%
Mr. Boquan He
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			9.74%
iKang Holding | iKang Hangzhou Xixi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			80.00%
Total equity interest held, including indirect ownership			100.00%
Yalong Daoyi | iKang Hangzhou Xixi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			20.00%
Mr. Haiqing Hu | Beijing Jiandatong
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			80.00%
Mr. Haiqing Hu | Yuanhua Information
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			80.00%
Ms. Jaun Tan | Yuanhua Information
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			20.00%
Exclusive Equity Option Agreement
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Term of agreement			10 years
Exclusive Services Agreement
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Term of agreement			10 years
iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Hangzhou Xixi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			73.00%
Yuanhua Information
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Beijing Jiandatong
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			80.00%
iKang Online
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Guangzhou Huanshi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Xikang Road
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Pudong Avenue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Jianwei Healthcare Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			54.40%
Yalong Daoyi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Beijing Jun'an
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Yayun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Wanzhishou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Medical Examination Application
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Beijing Daoyitong
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Shanghai Jinxiu Huajian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chengdu Gaoxin
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenzhen Luohu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Zhongguancun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Yangpu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Lujiazui
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Xuanwumen
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Nanjing Gulou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Xinei
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Yan'an West Road
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Hangzhou Wenhui
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chengdu Hongzhaobi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Dental Hospital Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Lidu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Jianguomen
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Fuzhou Gulou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Zhonghuan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Jing'an
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Yan'an East Road
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Jianwei
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Tianjin Heping
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Suzhou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Suzhou Zhuoyue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Guangzhou Wokang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Yuanhua Clinic
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Gubei
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Changzhou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			62.50%
Chengdu Gaoxin iKang West City
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Huajian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Huajian Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Zhenjing
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Beijing Shunping
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chongqing Zhuoyue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Xi'an Lianhu Yinglun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Guizhou Wishstar
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			60.00%
iKang Beijing Jingchao
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			83.00%
Yantai Ciming
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Beijing Bohui
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Wuhan Zhuoyue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Jun'an
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Yinchuan Clinic
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Guobin
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Beijing iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Shanghai iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
iKang Zhejiang BVI
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			73.00%
Zhejiang iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			73.00%
Bayley & Jackson (Hong Kong)
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
iKang Beijing Ritan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Yuanhua HK
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Yuanhua WFOE
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
MediFast
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			80.00%
WA Health Care
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			70.00%
iKang (Shanghai) Financing Lease
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
IKang MRI Center, Inc.
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang MRI Center, Limited
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang mHealth, Inc.
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Health Cloud Technology Limited
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Health Cloud
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%

ORGANIZATION AND PRINCIPAL AC60

ORGANIZATION AND PRINCIPAL ACTIVITIES - VIE (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Financial statements amounts and balances of the VIE entities included in the accompanying consolidated financial statements
Cash and cash equivalents	$ 62,901	$ 64,898	$ 108,111	$ 97,336
Amounts due from a related party	7,019	4,538
Total current assets	295,379	219,915
Property and equipment, net	173,283	163,081
Acquired intangible assets, net	21,993	25,852
TOTAL ASSETS	865,155	728,491
Deferred revenues	95,422	64,740
Amount due to related parties	3,692
Total current liabilities	440,529	287,160
TOTAL LIABILITIES	485,330	396,086
Net revenues	563,932	435,713	370,812
Net income/(loss)	(16,676)	(12,544)	16,488
Net cash provided by operating activities	23,005	50,043	43,602
Net cash used in investing activities	(34,783)	(32,011)	(261,533)
Net cash provided by (used in) financing activities	$ 4,504	$ (52,421)	$ 237,465
Net revenues from VIE entities as a percentage of consolidated net revenues	91.20%	87.10%	89.10%
Assets from VIE entities as a percentage of consolidated total assets	86.50%	85.20%
Liabilities from VIE entities as a percentage of consolidated total liabilities	92.50%	92.70%
VIE entities
Financial statements amounts and balances of the VIE entities included in the accompanying consolidated financial statements
Cash and cash equivalents	$ 52,868	$ 49,222
Accounts receivable and other current assets	206,082	131,780
Amounts due from a related party	6,794
Total current assets	265,744	181,002
Property and equipment, net	169,114	158,662
Acquired intangible assets, net	15,347	24,337
Other noncurrent assets	298,210	256,522
Total non-current assets	482,671	439,521
TOTAL ASSETS	748,415	620,523
Deferred revenues	87,388	57,361
Accounts payable and other current liabilities	314,094	201,260
Amount due to related parties	3,480
Total current liabilities	404,962	258,621
Total non-current liabilities	43,828	108,706
TOTAL LIABILITIES	448,790	367,327
Net revenues	514,141	379,606	$ 330,391
Net income/(loss)	3,508	(12,012)	12,614
Net cash provided by operating activities	63,646	54,439	92,294
Net cash used in investing activities	(22,276)	(44,407)	(239,274)
Net cash provided by (used in) financing activities	(37,724)	(53,041)	216,341
Service fees charged to VIEs	$ 3,326	$ 2,245	$ 3,354

SUMMARY OF SIGNIFICANT ACCOUN61

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Statement
Working capital	$ (145,150)
Convertible loans	$ 135,510
Restricted cash		$ 392
Term deposits
Maturity terms of term deposits- minimum	3 months
Maturity terms of term deposits- maximum	1 year
Foreign currency risk
Aggregate amounts of cash and cash equivalent denominated in RMB	$ 62,901	64,898	$ 108,111	$ 97,336
Foreign currency risk | China, Yuan Renminbi
Foreign currency risk
Aggregate amounts of cash and cash equivalent denominated in RMB	$ 56,593	$ 57,553

SUMMARY OF SIGNIFICANT ACCOUN62

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and equipment, net (Details)	12 Months Ended
	Mar. 31, 2018
Computer equipment and application software
Property and equipment, net
Estimated useful life	5 years
Furniture and fixtures
Property and equipment, net
Estimated useful life	5 years
Medical equipment
Property and equipment, net
Estimated useful life	10 years
Motor vehicles
Property and equipment, net
Estimated useful life	5 years

SUMMARY OF SIGNIFICANT ACCOUN63

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible assets, net (Details)	12 Months Ended
	Mar. 31, 2018
Weighted average
Intangible assets, net
Estimated useful lives	5 years 6 months
Customer relationship | Weighted average
Intangible assets, net
Estimated useful lives	5 years 8 months 12 days
Customer relationship | Minimum
Intangible assets, net
Estimated useful lives	2 years 1 month 6 days
Customer relationship | Maximum
Intangible assets, net
Estimated useful lives	10 years
Non-compete agreements | Weighted average
Intangible assets, net
Estimated useful lives	3 years
Non-compete agreements | Minimum
Intangible assets, net
Estimated useful lives	2 years
Non-compete agreements | Maximum
Intangible assets, net
Estimated useful lives	3 years
Contract backlog | Weighted average
Intangible assets, net
Estimated useful lives	8 months 12 days
Contract backlog | Minimum
Intangible assets, net
Estimated useful lives	4 months 24 days
Contract backlog | Maximum
Intangible assets, net
Estimated useful lives	10 months 24 days
Operating licenses | Weighted average
Intangible assets, net
Estimated useful lives	3 years
Operating licenses | Minimum
Intangible assets, net
Estimated useful lives	3 months 18 days
Operating licenses | Maximum
Intangible assets, net
Estimated useful lives	5 years
Favorable lease contracts | Weighted average
Intangible assets, net
Estimated useful lives	7 years 1 month 6 days
Favorable lease contracts | Minimum
Intangible assets, net
Estimated useful lives	1 year 4 months 24 days
Favorable lease contracts | Maximum
Intangible assets, net
Estimated useful lives	9 years 9 months 18 days

SUMMARY OF SIGNIFICANT ACCOUN64

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue recognition and Value added tax ("VAT") (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Revenue recognition
Business tax and related surcharges		$ 910	$ 2,692
VAT related surcharges	$ 932
Maximum
Revenue recognition
Expiry period of components from date of purchase	1 year

SUMMARY OF SIGNIFICANT ACCOUN65

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Non-monetary exchange (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Non-monetary exchange
Revenues recognized for non-monetary transactions	$ 1,046	$ 674	$ 1,767

ACQUISITIONS - Purchase Price A

ACQUISITIONS - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Jul. 31, 2017	May 20, 2016	Mar. 31, 2018	Mar. 31, 2017
Net tangible assets:
Goodwill			$ 117,995	$ 107,237
Beijing Bohui
Acquisitions
Equity interest acquired (as a percent)		100.00%
Cash consideration		$ 5,371
Acquisition-related costs		0
Net tangible assets:
Current assets		770
Non-current assets		1,611
Current liabilities		(2,135)
Total		246
Goodwill		4,777
Deferred tax liability		(217)
Net revenue			5,448	3,795
Net income (loss)			1,810	$ 1,382
IMHealthcare and its subsidiaries
Acquisitions
Equity interest acquired (as a percent)	100.00%
Consideration for acquisition	$ 2,930
Net tangible assets:
Current assets	508
Non-current assets	1,028
Current liabilities	(1,385)
Total	151
Goodwill	1,806
Deferred tax liability	$ (325)
Net revenue			2,024
Net income (loss)			$ 101
Shanghai Jianwei Management | IMHealthcare and its subsidiaries
Acquisitions
Percentage of equity interest exchanged for acquisition	35.06%
Customer relationship | Beijing Bohui
Net tangible assets:
Intangible assets acquired, finite		$ 504
Estimated useful lives		4 years 7 months 6 days
Customer relationship | IMHealthcare and its subsidiaries
Net tangible assets:
Intangible assets acquired, finite	$ 967
Estimated useful lives	6 years 8 months 12 days
Favorable lease contracts | IMHealthcare and its subsidiaries
Net tangible assets:
Intangible assets acquired, finite	$ 4
Estimated useful lives	1 year 4 months 24 days
Operating licenses | Beijing Bohui
Net tangible assets:
Intangible assets acquired, finite		$ 61
Estimated useful lives		2 years 7 months 6 days
Operating licenses | IMHealthcare and its subsidiaries
Net tangible assets:
Intangible assets acquired, finite	$ 89
Estimated useful lives	3 years 7 months 6 days
Trademark | IMHealthcare and its subsidiaries
Net tangible assets:
Intangible assets acquired, indefinite	$ 238

ACQUISITIONS - Pro Forma Inform

ACQUISITIONS - Pro Forma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Beijing Bohui
Pro forma financial information
Pro forma net revenue		$ 435,550	$ 372,374
Pro forma net income/(loss) attributable to common shareholders of iKang Healthcare Group, Inc.		(11,417)	$ 16,456
IMHealthcare and its subsidiaries
Pro forma financial information
Pro forma net revenue	$ 564,313	435,318
Pro forma net income/(loss) attributable to common shareholders of iKang Healthcare Group, Inc.	$ (17,296)	$ (11,646)

ACCOUNTS RECEIVABLE, NET (Detai

ACCOUNTS RECEIVABLE, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2018	Mar. 31, 2017
Accounts receivable
Accounts receivable				$ 172,401	$ 93,837
Less: allowance for doubtful accounts	$ 14,261	$ 14,329	$ 8,055	23,142	14,261
Accounts receivable, net				$ 149,259	$ 79,576
Movement of allowance for doubtful accounts
Balance at beginning of year	14,261	14,329	8,055
Charge to expenses	7,317	6,136	8,509
Write off		(5,170)	(1,822)
Exchange difference	(1,564)	1,034	413
Balance at end of year	$ 23,142	$ 14,261	$ 14,329

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
INVENTORIES
Medical consumable supplies	$ 9,261	$ 6,781
Medical consumable
INVENTORIES
Medical consumable supplies	$ 9,261	$ 6,781

PREPAID EXPENSES AND OTHER CU70

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Advance to suppliers	$ 28,366	$ 19,433
Other receivable	14,257	9,400
Staff advance	8,103	6,630
Prepaid rental expenses	8,454	8,744
Advance payments to acquisitions	4,524	3,322
Prepaid expenses	2,974	2,067
Interest income receivable	261	140
Total	$ 66,939	$ 49,736

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Property and equipment, net
Total cost	$ 308,010	$ 254,206
Less: accumulated depreciation and amortization	134,727	91,125
Property and equipment, net	173,283	163,081
Depreciation expenses	34,972	27,560	$ 19,625
Medical equipment
Property and equipment, net
Total cost	144,685	119,654
Leasehold improvement
Property and equipment, net
Total cost	123,570	101,355
Computer equipment and application software
Property and equipment, net
Total cost	18,861	14,743
Furniture and fixtures
Property and equipment, net
Total cost	19,273	17,004
Motor vehicles
Property and equipment, net
Total cost	1,379	1,255
Construction in progress
Property and equipment, net
Total cost	$ 242	$ 195

ACQUIRED INTANGIBLE ASSETS, N72

ACQUIRED INTANGIBLE ASSETS, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Acquired intangible assets, net
Intangible assets, gross	$ 61,159	$ 55,033
Less: impairment	422	385
Intangible assets, net	21,993	25,852
Amortization expenses	7,210	9,853	$ 10,769
Future amortization expenses
2,019	4,784
2,020	2,785
2,021	1,024
2,022	209
2,023	142
thereafter	839
Impairment loss recognized on acquired intangible assets	0	0	$ 0
Customer relationship
Acquired intangible assets, net
Acquired intangible assets subject to amortization	41,077	36,913
Less: accumulated amortization	32,873	23,946
Operating licenses
Acquired intangible assets, net
Acquired intangible assets subject to amortization	5,942	5,371
Less: accumulated amortization	3,988	3,277
Favorable lease contracts
Acquired intangible assets, net
Acquired intangible assets subject to amortization	1,886	1,733
Less: accumulated amortization	1,350	1,043
Contract backlog
Acquired intangible assets, net
Acquired intangible assets subject to amortization	87	79
Less: accumulated amortization	87	79
Non-compete agreements
Acquired intangible assets, net
Acquired intangible assets subject to amortization	446	451
Less: accumulated amortization	446	451
Trade name
Acquired intangible assets, net
Acquired intangible assets not subject to amortization	$ 11,721	$ 10,486

LONG-TERM INVESTMENTS (Details)

LONG-TERM INVESTMENTS (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
LONG-TERM INVESTMENTS
Cost method investments	$ 50,626	$ 46,724
Equity method investments	138,330	127,233
Available-for-sale investments	7,860	6,801
Total	$ 196,816	$ 180,758

LONG-TERM INVESTMENTS - Cost me

LONG-TERM INVESTMENTS - Cost method investments (Details) $ in Thousands	1 Months Ended
	Dec. 31, 2017subsidiary	Nov. 30, 2015USD ($)cityclinic	Mar. 31, 2018USD ($)	Jan. 01, 2018	Mar. 31, 2017USD ($)	Oct. 31, 2016USD ($)	Mar. 31, 2016USD ($)	Sep. 30, 2015USD ($)	May 31, 2015USD ($)
LONG-TERM INVESTMENTS
Cash consideration- cost method						$ 232	$ 993	$ 2,000
Carrying value of cost method investments			$ 50,626		$ 46,724
Xi'an Puhui
LONG-TERM INVESTMENTS
Percentage of equity interest owned- cost method		23.10%
Number of medical centers in Xi'an, Zhengzhou and other six cities | clinic		15
Number of medical centers in the cities outside of Xi'an and Zhengzhou | city		6
Cash consideration- cost method		$ 32,090
American Well Corporation
LONG-TERM INVESTMENTS
Percentage of equity interest owned- cost method									1.80%
Cash consideration- cost method									$ 13,500
Two early-stage subsidiaries
LONG-TERM INVESTMENTS
Number of subsidiaries sold and disposed | subsidiary	2
Carrying value of cost method investments			$ 66
Early-stage subsidiary A
LONG-TERM INVESTMENTS
Percentage of equity interest owned- cost method				1.00%
Early-stage subsidiary B
LONG-TERM INVESTMENTS
Percentage of equity interest owned- cost method				1.00%

LONG-TERM INVESTMENTS - Equity

LONG-TERM INVESTMENTS - Equity method investments (Details) $ in Thousands	1 Months Ended							12 Months Ended
	Dec. 31, 2017CNY (¥)item	Dec. 31, 2017USD ($)item	Aug. 31, 2016USD ($)director	Mar. 31, 2016USD ($)director	Feb. 29, 2016USD ($)clinicdirector	Dec. 31, 2015USD ($)director	Sep. 30, 2015USD ($)director	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2017USD ($)item
LONG-TERM INVESTMENTS
Percentage of annual interest rate								10.50%
Summary of the condensed financial information
Current assets								$ 179,377	$ 166,991
Non-current assets								30,562	32,205
Current liabilities								39,094	35,167
Non-current liabilities								64	135
Total revenues								65,771	56,253	$ 52,185
Gross profit								21,803	17,503	16,580
Loss from operations								(19,794)	(23,070)	(23,094)
Net loss								(5,399)	(22,657)	(23,181)
Topsky
LONG-TERM INVESTMENTS
Cash consideration- equity method							$ 10,372
Percentage of equity interest owned- equity method							21.80%
Number of representatives to the board of directors | director							2
Number of board of directors | director							5
Income (loss) from equity method investment								(315)	(931)
Worldcare International Inc.
LONG-TERM INVESTMENTS
Cash consideration- equity method						$ 4,032
Percentage of equity interest owned- equity method						20.00%
Number of representatives to the board of directors | director						1
Number of board of directors | director						5
Income (loss) from equity method investment								(142)	(246)
NCI Health
LONG-TERM INVESTMENTS
Cash consideration- equity method					$ 119,363
Percentage of equity interest owned- equity method					45.00%
Number of representatives to the board of directors | director					2
Number of board of directors | director					5
Income (loss) from equity method investment								(1,536)	(7,985)
Number of medical centers in Xi'an, Zhengzhou and other six cities | clinic					16
Number of cities in which acquiree's medical centers/clinics are located | clinic					16
NCI Health | AVIC Partnership
LONG-TERM INVESTMENTS
Percentage of sale of equity interest	25.00%	25.00%
Consideration for sale of equity interest	¥ 425,000,000	$ 65,321
Percentage of purchase back of equity interest	25.00%	25.00%
Period of purchase back of equity interest	3 years	3 years
Percentage of annual interest rate	10.00%	10.00%
AVIC Partnership
LONG-TERM INVESTMENTS
Number of parties | item	3	3
Limited partnership, registered capital	¥ 502,000,000										$ 80,031
Limited partnership, subscribed capital	¥ 70,000,000										11,160
Beijing MZ
LONG-TERM INVESTMENTS
Cash consideration- equity method				$ 12,407						$ 12,407
Percentage of equity interest owned- equity method				40.00%						40.00%
Number of representatives to the board of directors | director				1
Number of board of directors | director				3
Income (loss) from equity method investment								$ (455)	$ (385)
Changqingshu
LONG-TERM INVESTMENTS
Cash consideration- equity method			$ 712
Percentage of equity interest owned- equity method			49.00%
Number of representatives to the board of directors | director			2
Number of board of directors | director			5
Aiying Xingsheng Fund
LONG-TERM INVESTMENTS
Cash consideration- equity method											$ 768
Percentage of equity interest owned- equity method	9.96%										9.96%
Number of general partners | item	1										1
Percentage of annual rate	15.00%	15.00%

LONG-TERM INVESTMENTS - Availab

LONG-TERM INVESTMENTS - Available-for-sale investments (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2015	Mar. 31, 2018	Mar. 31, 2017
Shanghai Shenmin Medical Technology Company Limited
Available-for-sale investments
Percentage of equity interest acquired	20.00%
Cash consideration to acquire available-for-sale security	$ 1,897
Unrealized gain recognized		$ 0	$ 0
Unrealized loss recognized		0	0
HDF
Available-for-sale investments
Percentage of equity interest acquired	1.00%
Cash consideration to acquire available-for-sale security	$ 5,000
Unrealized gain (loss), net of tax		$ 885	$ (161)

GOODWILL (Details)

GOODWILL (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	May 20, 2016
Changes in carrying amounts of goodwill
Beginning balance	$ 132,637	$ 134,239
Impairment loss:	(25,400)	(25,400)
Exchange difference	9,351	(6,379)
Goodwill	117,995	107,237
Beijing Bohui
Changes in carrying amounts of goodwill
Additions for the year by acquisitions of		$ 4,777
Goodwill			$ 4,777
IMHealthcare and its subsidiaries
Changes in carrying amounts of goodwill
Additions for the year by acquisitions of	1,806
Changchun Jiachang
Changes in carrying amounts of goodwill
Disposal for the year	$ (399)

ACCRUED EXPENSES AND OTHER CU78

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Accrued expenses and other current liabilities
Accrued payroll and welfare	$ 22,537	$ 13,391
Acquisitions consideration payable	5,719	6,436
Interest expense payable	8,633	13,116
Other taxes payable	7,378	4,209
Accrued rental expense	7,330	6,640
Accrued social insurance	4,018	3,650
Accrued professional fee	4,556	3,196
Accrued outsourcing cost	3,465	1,892
Dividend payable		279
Other payables	12,950	6,469
Total	76,586	59,278
Beijing Tianzhikangjian
Accrued expenses and other current liabilities
Acquisitions consideration payable	1,881	1,714
Xi'an iKang Guobin
Accrued expenses and other current liabilities
Acquisitions consideration payable	1,196	2,626
Yantai Hongkang
Accrued expenses and other current liabilities
Acquisitions consideration payable	748	718
Fujian iKang
Accrued expenses and other current liabilities
Acquisitions consideration payable	461
Others
Accrued expenses and other current liabilities
Acquisitions consideration payable	$ 1,433	$ 1,378

SHORT TERM BORROWINGS (Details)

SHORT TERM BORROWINGS (Details) $ in Thousands	1 Months Ended																							12 Months Ended
	Mar. 31, 2018CNY (¥)	Mar. 31, 2018USD ($)	Jan. 31, 2018CNY (¥)	Jan. 31, 2018USD ($)	Dec. 31, 2017CNY (¥)	Dec. 31, 2017USD ($)	Nov. 30, 2017CNY (¥)	Nov. 30, 2017USD ($)	Aug. 31, 2017CNY (¥)	Aug. 31, 2017USD ($)	Jun. 30, 2017CNY (¥)	Jun. 30, 2017USD ($)	Apr. 30, 2017CNY (¥)	Mar. 31, 2017CNY (¥)	Mar. 31, 2017USD ($)	Dec. 31, 2016CNY (¥)	Dec. 31, 2016USD ($)	Sep. 30, 2016CNY (¥)	Sep. 30, 2016USD ($)	Jun. 30, 2016CNY (¥)	Jun. 30, 2016USD ($)	Dec. 31, 2015CNY (¥)item	Dec. 31, 2015USD ($)item	Mar. 31, 2018CNY (¥)tranche	Mar. 31, 2018USD ($)tranche	Mar. 31, 2017CNY (¥)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Apr. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Jan. 31, 2017	Dec. 31, 2015USD ($)
Short term borrowings
Bank borrowings																													$ 58,373			$ 38,659
Long-term loans due within one year																													138,077			72,640
Short-term borrowings, Total																													196,450			111,299
Short-term borrowing facility drawn down																									$ 65,679		$ 37,176	$ 54,126
Amount repaid																									$ 103,403		60,610	55,359
Weighted average effective interest rate (as a percent)																								10.50%	10.50%
Long-term loans
Short term borrowings
Face amount																						¥ 1,400,000,000												$ 203,393
Interest expense																									$ 17,317		11,768	2,869
Weighted average effective interest rate (as a percent)																								11.10%	11.10%
Number of third-party investors | item																						4	4
Repayment long-term borrowing																								¥ 350,000,000	$ 52,808	¥ 200,000,000	29,056
Borrowings reclassified from long-term loan to short-term borrowing	¥ 850,000,000																							¥ 850,000,000					135,510
Number of tranches in loan repayable | tranche																								3	3
Long-term loans | Minimum
Short term borrowings
Term of loan																						18 months	18 months
Weighted average effective interest rate (as a percent)																								8.00%	8.00%
Long-term loans | Maximum
Short term borrowings
Term of loan																						36 months	36 months
Weighted average effective interest rate (as a percent)																								10.00%	10.00%
Long-term loans | Guiyang GYB Financial Leasing Co., Ltd
Short term borrowings
Long-term loans due within one year																													6,998
Interest expense																									$ 158
Weighted average effective interest rate (as a percent)																								6.65%	6.65%
Long-term loans | Privatization and convert before maturity date of the long-term loans
Short term borrowings
Interest expense																							$ 0
Long-term loans | Privatization but not convert before maturity date of the long-term loans | Minimum
Short term borrowings
Interest rate (as a percent)																						5.00%												5.00%
Long-term loans | Privatization but not convert before maturity date of the long-term loans | Maximum
Short term borrowings
Interest rate (as a percent)																						20.00%											8.00%	20.00%
Long-term loans | Privatization not completed or failed to convert the loan before maturity date of convertible bonds | Minimum
Short term borrowings
Interest rate (as a percent)																						8.00%												8.00%
Long-term loans | Privatization not completed or failed to convert the loan before maturity date of convertible bonds | Maximum
Short term borrowings
Interest rate (as a percent)					10.00%																	5.00%								10.00%				5.00%
Bank borrowings
Short term borrowings
Short-term borrowings, Total																													58,373			38,659
Interest expense																									$ 2,517		$ 1,725	$ 1,734
Weighted average effective interest rate (as a percent)																								4.54%	4.54%	4.20%	4.20%	3.30%
Short-term borrowings | Guiyang GYB Financial Leasing Co., Ltd
Short term borrowings
Finance lease payment due within one year																													2,567
iKang Holding | Bank borrowings | Industrial and Commercial bank of China
Short term borrowings
Short-term borrowings, Total																													3,188
iKang Holding | Two year loan framework agreement with China Merchants bank signed in December 2015 | Bank borrowings | China Merchants Bank
Short term borrowings
Short-term borrowings, Total														¥ 61,100,000												¥ 61,100,000			0			8,877
Term of loan																						2 years	2 years
Short-term borrowing facility drawn down																						¥ 104,600,000	$ 15,198
Interest rate (as a percent)																						4.75%												4.75%
Amount repaid																								¥ 61,100,000	$ 9,602	43,500,000	$ 6,249
iKang Holding | Two year loan framework agreement with Industrial and Commercial Bank of China Signed in June 2016 | Bank borrowings | China Merchants Bank
Short term borrowings
Interest rate (as a percent)																						4.35%												4.35%
iKang Holding | Two year loan framework agreement with Industrial and Commercial Bank of China Signed in June 2016 | Bank borrowings | Industrial and Commercial bank of China
Short term borrowings
Short-term borrowings, Total														40,000,000												40,000,000			0			5,811
Term of loan																				2 years	2 years
Short-term borrowing facility drawn down																				¥ 40,000,000	$ 5,811
Interest rate (as a percent)																				4.35%	4.35%
Amount repaid																								40,000,000	6,377
iKang Holding | Two year loan framework agreement with China Merchants Bank Signed in September 2016 | Bank borrowings | China Merchants Bank
Short term borrowings
Short-term borrowings, Total														15,000,000												15,000,000			0			2,179
Term of loan																		2 years	2 years
Short-term borrowing facility drawn down																		¥ 15,000,000	$ 2,179
Interest rate (as a percent)																		4.75%	4.75%
Amount repaid																								15,000,000	2,391
iKang Holding | Two year loan framework agreement with Industrial Bank Co.Ltd Signed in December 2016 | Bank borrowings | Industrial Bank Co. Ltd
Short term borrowings
Short-term borrowings, Total														100,000,000												100,000,000			0			14,528
Term of loan																2 years	2 years
Short-term borrowing facility drawn down																¥ 100,000,000	$ 14,528
Interest rate (as a percent)																4.35%	4.35%
Amount repaid																	$ 15,942									100,000,000
iKang Holding | Two year loan framework agreement with Hongkong and Shanghai Banking Corporation Limited Signed in December 2016 | Bank borrowings | Hongkong and Shanghai Banking Corporation Limited
Short term borrowings
Short-term borrowings, Total														30,000,000												30,000,000			0			4,358
Term of loan																2 years	2 years
Short-term borrowing facility drawn down																¥ 50,000,000	$ 7,264
Interest rate (as a percent)																4.35%	4.35%
Amount repaid																								30,000,000	4,783	2,000,000	$ 2,906
iKang Holding | Two year loan framework agreement with Bank of China Signed in March 2017 | Bank borrowings | Bank of China
Short term borrowings
Short-term borrowings, Total														¥ 20,000,000												¥ 20,000,000			0			$ 2,906
Term of loan														2 years	2 years
Short-term borrowing facility drawn down														¥ 20,000,000	$ 2,906
Interest rate (as a percent)														4.35%												4.35%						4.35%
Amount repaid																								20,000,000	$ 3,188
iKang Holding | One-year loan framework agreement with Commercial Bank of China signed in June 2017 | Bank borrowings | Industrial and Commercial bank of China
Short term borrowings
Short-term borrowings, Total	20,000,000																							20,000,000					3,188
Term of loan											1 year	1 year
Short-term borrowing facility drawn down											¥ 20,000,000	$ 7,191
Interest rate (as a percent)											4.35%	4.35%
iKang Holding | One-year loan framework agreement with China Minsheng Bank signed in April 2017 | Bank borrowings | China Minsheng Bank
Short term borrowings
Short-term borrowings, Total	47,055,000																							47,055,000					7,502
Term of loan													1 year
Face amount													¥ 100,000,000																		$ 15,942
Short-term borrowing facility drawn down									¥ 47,055,000	$ 7,502
Interest rate (as a percent)									5.00%	5.00%
iKang Holding | One-year loan framework agreement with Industrial Bank Co., Ltd signed in November 2017 | Bank borrowings | Industrial Bank Co. Ltd
Short term borrowings
Short-term borrowings, Total	100,000,000																							100,000,000					15,942
Term of loan							1 year	1 year
Short-term borrowing facility drawn down							¥ 100,000,000	$ 15,942
Interest rate (as a percent)							4.83%	4.83%
iKang Holding | One-year loan framework agreement with Hongkong and Shanghai Banking Corporation Limited signed in December 2017 | Bank borrowings | Hongkong and Shanghai Banking Corporation Limited
Short term borrowings
Short-term borrowings, Total	29,100,000																							29,100,000					4,639
Term of loan					1 year	1 year
Face amount					¥ 30,000,000																									$ 4,783
Short-term borrowing facility drawn down					¥ 29,100,000	$ 4,639
Interest rate (as a percent)					4.79%																									4.79%
iKang Holding | One-year loan framework agreement with China Merchants Bank signed in December 2017 | Bank borrowings | China Merchants Bank
Short term borrowings
Short-term borrowings, Total	150,000,000																							150,000,000					23,914
Term of loan					1 year	1 year
Face amount					¥ 200,000,000																									$ 31,884
Short-term borrowing facility drawn down			¥ 50,000,000	$ 7,972	¥ 100,000,000	$ 15,942
Interest rate (as a percent)					4.57%																									4.57%
iKang Holding | One-year loan framework agreement with Industrial Bank Co., Ltd signed in March 2018 | Bank borrowings | Industrial Bank Co. Ltd
Short term borrowings
Short-term borrowings, Total	¥ 20,000,000																							¥ 20,000,000					$ 3,188
Term of loan	1 year	1 year
Short-term borrowing facility drawn down	¥ 20,000,000	$ 3,188
Interest rate (as a percent)	5.00%																							5.00%					5.00%

LONG-TERM BORROWINGS (Details)

LONG-TERM BORROWINGS (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2018CNY (¥)	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2017CNY (¥)	Dec. 31, 2017USD ($)	Feb. 29, 2016USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2015USD ($)
Long-term borrowings
Long-term loans			$ 101,697		$ 38,884
Total long-term borrowings			101,697		38,884
Weighted average effective interest rate (as a percent)	10.50%	10.50%
Long-term loans due within one year			72,640		138,077
NCI Health
Long-term borrowings
Cash consideration- equity method								$ 119,363
iKang Online | NCI Health
Long-term borrowings
Cash consideration- equity method						¥ 425,000,000	$ 65,321
Short-term borrowings | Guiyang GYB Financial Leasing Co., Ltd
Long-term borrowings
Finance lease payment due within one year					2,567
Long-term loans
Long-term borrowings
Amount borrowed									¥ 1,400,000,000	$ 203,393
Interest expense		$ 17,317	11,768	$ 2,869
Weighted average effective interest rate (as a percent)	11.10%	11.10%
Fair value of long-term borrowing			$ 101,697		38,884
Long-term loans | Guiyang GYB Financial Leasing Co., Ltd
Long-term borrowings
Interest expense		$ 158
Weighted average effective interest rate (as a percent)	6.65%	6.65%
Proceeds from sale of medical equipment	¥ 60,000,000	$ 9,565
Loss on sale of medical equipment	¥ 6,004,400,000	$ 908
Lease term	45 months	45 months
Long-term loans due within one year					6,998
Long-term loans | iKang Online
Long-term borrowings
Amount borrowed	¥ 200,000,000				$ 31,886
Interest expense		$ 199
Weighted average effective interest rate (as a percent)	10.50%	10.50%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2015	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Income Taxes
Income tax rate (as a percent)		25.00%	25.00%	25.00%
Individual income tax rate (as a percent)		35.00%	35.00%	35.00%
Hong Kong | Bayley & Jackson (Hong Kong), Yuanhua HK, MediFast and WA Health Care
Income Taxes
Income tax rate (as a percent)		16.50%
PRC
Income Taxes
Income tax rate (as a percent)		25.00%
Preferential tax rate according to "Catalogue of Industries Encouraged to Develop in the Western Region" (as a percent)		15.00%	15.00%	15.00%	15.00%	15.00%
Withholding tax rate (as a percent)		10.00%
Minimum percentage of equity interest in a PRC-resident enterprise to be held by a qualified Hong Kong tax resident for reduced withholding tax rate		25.00%
Reduced withholding tax rate, if 25% or more equity interest in a PRC-resident enterprise is held by a qualified Hong Kong tax resident (as a percent)		5.00%
Aggregate undistributed earnings of Company's subsidiaries		$ 54,486
Accrued deferred tax liability		0
Aggregate undistributed earnings of the Company's VIEs and its VIEs' subsidiaries		$ 219,890
PRC | Shenzhen Ikang Guobin Puji Clinic, Ikang Shenzhen Luohu and Shenzhen Ikang Guobin Xinglin Clinic
Income Taxes
Individual income tax rate (as a percent)		35.00%
PRC | iKang Health Cloud
Income Taxes
Period exempt from EIT under the "newly established software enterprise" ("NESE")	2 years
Preferential tax rate under NESE (as a percent)	12.50%
Period for preferential tax rate under NESE, after tax exempt period	3 years

INCOME TAXES - Current and defe

INCOME TAXES - Current and deferred portions (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Current and deferred portions of income tax expenses included in the consolidated statements of operations, which were all attributable to the Group's PRC subsidiaries and VIE entities
Current tax expenses	$ 21,150	$ 16,057	$ 13,778
Deferred tax benefits	(14,359)	(12,703)	(7,940)
Income tax expenses	6,791	3,354	$ 5,838
Current deferred tax assets:
Accrued expenses		3,218
Accrued payroll		3,302
Allowance for doubtful accounts		3,278
Less: Valuation allowance		(163)
Current deferred tax assets		9,635
Non-current deferred tax assets:
Accrued expenses	3,584
Accrued payroll	4,177
Allowance for doubtful accounts	5,885
Depreciation and amortization	53	322
Impairment of long-lived assets	36	44
Net operating tax loss carry-forwards	30,438	19,571
Less: Valuation allowance	(4,793)	(3,239)
Non-current deferred tax assets	39,380	16,698
Non-current deferred tax liabilities:
Intangible assets	5,917	7,229
Non-current deferred tax liabilities	$ 5,917	$ 7,229

INCOME TAXES - Tax loss carry-f

INCOME TAXES - Tax loss carry-forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
INCOME TAXES
Tax loss carry-forward	$ 111,189
Reconciliation between the expense (benefit) of income taxes computed by applying the PRC tax rate to income (loss) before income taxes and the actual provision for income taxes
Income before provision for income taxes and income/(loss) from equity method investments	$ (7,437)	$ 357	$ 24,058
PRC statutory tax rate (as a percent)	25.00%	25.00%	25.00%
Income tax at statutory tax rate	$ (1,859)	$ 89	$ 6,015
Change in valuation allowance	1,391	1,500	(726)
Expenses not deductible for tax purposes	2,298	3,162	1,565
Effect of income tax rate difference for entities under individual income tax rate of 35%	496	295	714
Effect of income tax rate differences in other jurisdictions	10,685	2,072	968
Tax holidays and preferential tax rates	(6,220)	(3,764)	(2,698)
Income tax expenses	$ 6,791	$ 3,354	$ 5,838
Individual income tax rate (as a percent)	35.00%	35.00%	35.00%

COMMON SHARE (Details)

COMMON SHARE (Details)	Dec. 02, 2015shares	May 09, 2014shares	Apr. 09, 2014shares	Apr. 30, 2014shares	Mar. 31, 2018Voteclassshares	Mar. 31, 2017shares
Common share
Class B to Class A common share conversion ratio				1
Class A redesignated to Class C common shares (in shares)				805,100
Number of classes of authorized ordinary shares | class					2
Common shares, authorized					39,648,485	39,648,485
Common shares, issued					34,721,539	34,721,539
Common shares, outstanding					34,721,539	34,721,539
Rights Plan
Common share
Common shares issued (in shares)	0
Minimum percentage of common shares required to exercise right	10.00%
Class A common shares
Common share
Number of vote each share entitled to | Vote					1
Common shares issued (in shares)			5,215,794
Conversion of convertible preferred shares to common shares (in shares)			20,781,515
Common shares, authorized					37,648,485	37,648,485
Common shares, issued					33,916,439	33,916,439
Common shares, outstanding					33,916,439	33,916,439
Class A common shares | IPO
Common share
Common shares issued (in shares)			3,787,223
Class A common shares | Private placement
Common share
Common shares issued (in shares)			1,428,571
Class A common shares | Green Shoe
Common share
Common shares issued (in shares)		514,556
Class C common shares
Common share
Number of vote each share entitled to | Vote					15
Common shares, authorized					2,000,000	2,000,000
Common shares, issued					805,100	805,100
Common shares, outstanding					805,100	805,100

NET INCOME (LOSS) PER SHARE (De

NET INCOME (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net income/(loss) attributable to iKang Guobin Healthcare Group, Inc.	$ (17,309)	$ (11,251)	$ 18,325
Net income/(loss) attributed to common shareholders for computing net income per common share- basic and diluted	$ (17,309)	$ (11,251)	$ 18,325
Denominator: Weighted average shares outstanding used in computing diluted net income per common share
Basic (in shares)	34,295,160	34,060,579	33,583,005
Diluted (in shares)	34,295,160	34,060,579	34,235,542
Net income/(loss) per common share attributable to common shareholders of iKang Healthcare Group, Inc.
Basic (in dollars per share)	$ (0.50)	$ (0.33)	$ 0.55
Diluted (in dollars per share)	$ (0.50)	$ (0.33)	$ 0.54

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - $ / shares	Feb. 28, 2018	Feb. 27, 2017	Jun. 30, 2013	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Mar. 31, 2015	Mar. 01, 2014	Feb. 26, 2013
Share-based compensation
Share options granted (in shares)	1,658,485			1,658,485
Forfeited (in shares)				9,650	1,885	16,050
Exercise price (in dollars per share)				$ 13.01
Grant date fair value of option (in dollars per share)				$ 21.30
Vested and exercisable ( in shares)	1,571,884
Options outstanding (in shares)	86,601			2,018,725	612,724	889,174		1,900,479
Minimum
Share-based compensation
Vesting period	1 month
Maximum
Share-based compensation
Vesting period	4 years
2013 February Plan
Share-based compensation
Maximum number of shares available for grant (in shares)										1,249,000
Share options granted (in shares)		1,249,000
Forfeited (in shares)		38,485
2014 Plan
Share-based compensation
Maximum number of shares available for grant (in shares)									1,620,000
Grant date fair value of option (in dollars per share)			$ 32.92
2014 Plan | $12.89
Share-based compensation
Maximum number of shares available for grant (in shares)							1,620,000
Exercisable exercise price (in dollars per share)							$ 12.8902
2014 Plan | Class A common shares
Share-based compensation
Maximum number of shares available for grant (in shares)			810,000
2014 Plan | Class A common shares | $12.89
Share-based compensation
Maximum number of shares available for grant (in shares)			810,000
Exercisable exercise price (in dollars per share)			$ 12.8902
PRC Citizen
Share-based compensation
Exercise price (in dollars per share)	$ 12.89
US Citizen
Share-based compensation
Exercise price (in dollars per share)	$ 32.92

SHARE-BASED COMPENSATION - Opti

SHARE-BASED COMPENSATION - Options granted (Details) - $ / shares	Feb. 28, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Number of options
Outstanding at the beginning of the period (in shares)		612,724	889,174	1,900,479
Granted (in shares)	1,658,485	1,658,485
Exercised (in shares)		(242,834)	(274,565)	(995,255)
Forfeited (in shares)		(9,650)	(1,885)	(16,050)
Outstanding at the end of the period (in shares)	86,601	2,018,725	612,724	889,174
Weighted average exercise price per option
Outstanding at the beginning of the period (in dollars per share)		$ 5.29	$ 5.15	$ 6.63
Granted (in dollars per share)		13.01
Exercised (in dollars per share)		5.46	4.83	7.97
Forfeited (in dollars per share)		5.51	5.19	5.38
Outstanding at the end of the period (in dollars per share)		11.61	5.29	5.15
Weighted average fair value per option at grant date
Outstanding at the beginning of the period (in dollars per share)		10.93	10.02	12.36
Granted (in dollars per share)		21.30
Exercised (in dollars per share)		10.44	7.89	14.29
Forfeited (in dollars per share)		20.50	23.93	22.25
Outstanding at the end of the period (in dollars per share)		$ 19.46	$ 10.93	$ 10.02

SHARE-BASED COMPENSATION - Shar

SHARE-BASED COMPENSATION - Share options outstanding (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Option outstanding
Number outstanding (in shares) | shares	2,018,725
Aggregate intrinsic value | $	$ 57,107
Option exercisable
Number exercisable (in shares) | shares	1,932,124
Aggregate intrinsic value | $	$ 54,768
Additional information
Vested options (in shares) | shares	1,932,124
Options expected to vest (in shares) | shares	86,601
Weighted-average exercise price of options expected to vest (in dollars per share)	$ 12.89
Aggregate intrinsic value of options expected to vest | $	$ 2,339
$ 5.13
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 5.13
Option outstanding
Number outstanding (in shares) | shares	343,990
Weighted average remaining contractual life in years	4 years 11 months 23 days
Weighted average Exercise price per option (in dollars per share)	$ 5.13
Aggregate intrinsic value | $	$ 11,968
Option exercisable
Number exercisable (in shares) | shares	343,990
Weighted average Exercise price per option (in dollars per share)	$ 5.13
Aggregate intrinsic value | $	$ 11,968
$ 6
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 6
Option outstanding
Number outstanding (in shares) | shares	16,250
Weighted average remaining contractual life in years	6 years 4 days
Weighted average Exercise price per option (in dollars per share)	$ 6
Aggregate intrinsic value | $	$ 544
Option exercisable
Number exercisable (in shares) | shares	16,250
Weighted average Exercise price per option (in dollars per share)	$ 6
Aggregate intrinsic value | $	$ 544
$ 12.89
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 12.89
Option outstanding
Number outstanding (in shares) | shares	1,648,485
Weighted average remaining contractual life in years	9 years 11 months 1 day
Weighted average Exercise price per option (in dollars per share)	$ 12.89
Aggregate intrinsic value | $	$ 44,525
Option exercisable
Number exercisable (in shares) | shares	1,561,884
Weighted average Exercise price per option (in dollars per share)	$ 12.89
Aggregate intrinsic value | $	$ 42,186
$ 32.92
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 32.92
Option outstanding
Number outstanding (in shares) | shares	10,000
Weighted average remaining contractual life in years	9 years 11 months 1 day
Weighted average Exercise price per option (in dollars per share)	$ 32.92
Aggregate intrinsic value | $	$ 70
Option exercisable
Number exercisable (in shares) | shares	10,000
Weighted average Exercise price per option (in dollars per share)	$ 32.92
Aggregate intrinsic value | $	$ 70

SHARE-BASED COMPENSATION - Assu

SHARE-BASED COMPENSATION - Assumptions (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 28, 2018	Feb. 27, 2015	Oct. 28, 2014	Aug. 01, 2014	Feb. 27, 2014	Sep. 12, 2013	Mar. 18, 2013	Feb. 17, 2012	Jun. 08, 2011	Dec. 31, 2010	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods
Risk-free interest rate of return (as a percent)	3.61%	3.33%	3.09%	3.09%	3.24%	3.22%	2.15%	2.99%	1.11%	4.67%
Contractual term	10 years	10 years	10 years	10 years	10 years	10 years	10 years	10 years	2 years 4 months 21 days	10 years
Volatility (as a percent)	38.00%	58.87%	45.38%	40.00%	38.09%	38.20%	40.00%	41.00%	42.00%	40.90%
Exercise price (in dollars per share)		$ 5.13		$ 16.18		$ 6		$ 5.13	$ 0.01	$ 5.13
US Treasury Active Curves maturity term for estimation of risk-free interest rate	10 years
Additional disclosure
Share-based compensation											$ 34,822	$ 1,941	$ 1,949
Unrecognized compensation expense											$ 1,710
Period over which total unrecognized compensation expense relating to unvested share options will be recognized											1 year
Weighted-average remaining contractual term of options outstanding											5 years 8 months 1 day
Minimum
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods
Exercise price (in dollars per share)	$ 12.89		$ 5.13		$ 5.13		$ 5.13
Maximum
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods
Exercise price (in dollars per share)	$ 32.92		$ 6		$ 6		$ 6

FAIR VALUE MEASUREMENTS - Finan

FAIR VALUE MEASUREMENTS - Financial assets and liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Fair value measurements
Available-for-sale Investments	$ 7,860	$ 6,801
Recurring basis
Fair value measurements
Available-for-sale Investments	7,860	6,801
Contingent consideration	1,196	2,626
Long-term borrowings	38,884	101,697
Outstanding on March 31 year	47,940	111,124
Recurring basis | Level 3
Fair value measurements
Available-for-sale Investments	7,860	6,801
Contingent consideration	1,196	2,626
Long-term borrowings	38,884	101,697
Outstanding on March 31 year	$ 47,940	$ 111,124

RELATED PARTY BALANCES AND TR91

RELATED PARTY BALANCES AND TRANSACTIONS (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Related party balances and transactions
Amount due from related parties	$ 7,019	$ 4,538
Amount due to related parties	3,692
Repayment of loan by related parties	140	$ 2,324
Non-interest bearing loans due from related parties	4,831
Two early-stage subsidiaries
Related party balances and transactions
Amount due from related parties	2,188
Amount due to related parties	$ 3,692

NONCONTROLLING INTEREST (Detail

NONCONTROLLING INTEREST (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Jul. 31, 2017
Noncontrolling interest
Balance at the beginning of the period	$ 19,968	$ 22,576	$ 9,218
Addition of non-controlling interest in connection with acquisition			16,767
Purchase of non-controlling interest	(630)	906	(1,664)
Addition of non-controlling interest in connection with capital injection			457
Addition of non-controlling interest in connection with new establishments		130	733
Dividend distribution to non-controlling interest holder		(983)	(614)
Share of profit (loss)	633	(1,293)	(1,837)
Other comprehensive income	1,938	(1,368)	(484)
Balance at the end of the period	24,118	19,968	22,576
Shanghai Jianwei Management
Noncontrolling interest
Balance at the end of the period	1,444
iKang Zhejiang BVI
Noncontrolling interest
Balance at the beginning of the period	584	418	260
Share of profit (loss)	(4)	176	158
Other comprehensive income		(10)
Balance at the end of the period	580	584	418
WA Health Care
Noncontrolling interest
Balance at the beginning of the period	3,428	4,678	5,330
Share of profit (loss)	(516)	(957)	(453)
Other comprehensive income	255	(293)	(199)
Balance at the end of the period	3,167	3,428	4,678
iKang Shanghai Gubei
Noncontrolling interest
Balance at the beginning of the period			1,034
Purchase of non-controlling interest			(486)
Dividend distribution to non-controlling interest holder			(557)
Share of profit (loss)			9
Fujian iKang
Noncontrolling interest
Balance at the beginning of the period	669	650	617
Purchase of non-controlling interest	(630)
Share of profit (loss)	(59)	62	61
Other comprehensive income	20	(43)	(28)
Balance at the end of the period		669	650
Shenzhen Hospital Management
Noncontrolling interest
Balance at the beginning of the period		(828)	(52)
Purchase of non-controlling interest		906
Share of profit (loss)		(69)	(789)
Other comprehensive income		(9)	13
Balance at the end of the period			(828)
Jianwei Healthcare Management
Noncontrolling interest
Balance at the beginning of the period	(261)	(94)	68
Addition of non-controlling interest in connection with acquisition	1,444
Share of profit (loss)	43	(177)	(162)
Other comprehensive income	69	10
Balance at the end of the period	1,295	(261)	(94)
Beijing Jiandatong
Noncontrolling interest
Balance at the beginning of the period	33	64	94
Share of profit (loss)	(49)	(28)	(27)
Other comprehensive income	(1)	(3)	(3)
Balance at the end of the period	(17)	33	64
MediFast
Noncontrolling interest
Balance at the beginning of the period	1,186	1,753	1,553
Dividend distribution to non-controlling interest holder		(983)	(57)
Share of profit (loss)	354	419	257
Other comprehensive income	(13)	(3)
Balance at the end of the period	1,527	1,186	1,753
iKang Changzhou
Noncontrolling interest
Balance at the beginning of the period	555	350	314
Share of profit (loss)	165	236	52
Other comprehensive income	70	(31)	(16)
Balance at the end of the period	790	555	350
Beijing Tianzhikangjian
Noncontrolling interest
Balance at the beginning of the period	2,866	3,166
Addition of non-controlling interest in connection with acquisition			5,050
Purchase of non-controlling interest			(1,178)
Share of profit (loss)	654	(97)	(495)
Other comprehensive income	328	(203)	(211)
Balance at the end of the period	3,848	2,866	3,166
iKang Yinchuan Ciming
Noncontrolling interest
Balance at the beginning of the period	1,821	1,785
Addition of non-controlling interest in connection with acquisition			1,613
Share of profit (loss)	543	154	241
Other comprehensive income	208	(118)	(69)
Balance at the end of the period	1,967	1,821	1,785
Shandong Ciming Clinics
Noncontrolling interest
Balance at the beginning of the period	1,511	1,926
Addition of non-controlling interest in connection with acquisition			2,416
Share of profit (loss)	(543)	(295)	(399)
Other comprehensive income	131	(120)	(91)
Balance at the end of the period	1,099	1,511	1,926
Xi'an iKang
Noncontrolling interest
Balance at the beginning of the period	3,216	3,520
Addition of non-controlling interest in connection with acquisition			3,242
Addition of non-controlling interest in connection with capital injection			457
Share of profit (loss)	55	(85)	(199)
Other comprehensive income	312	(219)	20
Balance at the end of the period	3,583	3,216	3,520
China Physician Alliance
Noncontrolling interest
Balance at the beginning of the period	421	519
Addition of non-controlling interest in connection with new establishments			551
Share of profit (loss)	(43)	(67)	(39)
Other comprehensive income	39	(31)	7
Balance at the end of the period	417	421	519
Guizhou Winstar Medical Center
Noncontrolling interest
Balance at the beginning of the period	3,886	4,540
Addition of non-controlling interest in connection with acquisition			4,446
Share of profit (loss)	389	(366)	4
Other comprehensive income	451	(288)	90
Balance at the end of the period	4,726	3,886	4,540
Wuhu iKang
Noncontrolling interest
Balance at the beginning of the period	66	129
Addition of non-controlling interest in connection with new establishments			182
Share of profit (loss)	23	(56)	(56)
Other comprehensive income	15	(7)	3
Balance at the end of the period	104	66	129
Wuxi iKang
Noncontrolling interest
Balance at the beginning of the period	(13)
Addition of non-controlling interest in connection with new establishments		130
Share of profit (loss)	(169)	(143)
Other comprehensive income	(6)
Balance at the end of the period	(188)	$ (13)
Zhenjiang iKang
Noncontrolling interest
Capital contribution from non-controlling interest	909
Share of profit (loss)	(263)
Other comprehensive income	38
Balance at the end of the period	684
IMHealthcare and its subsidiaries
Noncontrolling interest
Addition of non-controlling interest in connection with acquisition	1,444
IMHealthcare and its subsidiaries | Shanghai Jianwei Management
Noncontrolling interest
Equity interest acquired (as a percent)				100.00%
Percentage of equity interest exchanged for acquisition				35.06%
Ningbo iKang
Noncontrolling interest
Capital contribution from non-controlling interest	461
Share of profit (loss)	53
Other comprehensive income	22
Balance at the end of the period	536
Prepayment capital contribution from non-controlling interest			$ 461
iKang Yinchuan Ciming & Yinchuan Clinic
Noncontrolling interest
Dividend distribution to non-controlling interest holder	$ (605)

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2018USD ($)segment	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)
Segment information
Number of operating segments | segment	2
Number of reporting segments | segment	2
Net revenues:
Net revenues	$ 563,932	$ 435,713	$ 370,812
Cost of revenues:
Cost of revenues	325,656	262,134	210,909
Gross profit:
Gross profit	238,276	173,579	159,903
Operating expenses:
Selling and marketing expenses	96,594	74,304	64,763
General and administrative expenses	126,255	82,783	65,422
Research and development expenses	3,055	3,194	3,716
Total operating expenses	225,904	160,281	133,901
Income from operations	12,372	13,298	26,002
Medical examinations and other medical services
Net revenues:
Net revenues	546,610	427,065	364,635
Cost of revenues:
Cost of revenues	308,064	253,147	206,034
Gross profit:
Gross profit	238,546	173,918	158,601
Medical examinations and other medical services | Medical examinations
Net revenues:
Net revenues	451,005	360,365	308,053
Medical examinations and other medical services | Disease screening
Net revenues:
Net revenues	55,233	34,951	27,092
Medical examinations and other medical services | Other services
Net revenues:
Net revenues	40,372	31,749	29,490
Dental services
Net revenues:
Net revenues	17,322	8,648	6,177
Cost of revenues:
Cost of revenues	17,592	8,987	4,875
Gross profit:
Gross profit	$ (270)	$ (339)	$ 1,302

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Operating lease as lessee (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
COMMITMENTS AND CONTINGENCIES
Rental expenses under operating leases	$ 74,695	$ 67,250	$ 51,719
Future minimum lease payments
2,019	75,466
2,020	68,424
2,021	60,701
2,022	52,628
2,023	46,853
After 2,023	112,752
Total	$ 416,824

COMMITMENTS AND CONTINGENCIES95

COMMITMENTS AND CONTINGENCIES - Long-term borrowings (Details) $ in Thousands	Mar. 31, 2018USD ($)
Future minimum principal payments related to long-term borrowings
2,019	$ 196,450
2,020	2,567
2,021	34,453
2,022	1,864
Total	235,334
2,019	7,936
2,020	5,944
2,021	4,406
2,022	1,941
2,023	345
After 2,023	15
Total	$ 20,587

EMPLOYEE BENEFIT PLAN (Details)

EMPLOYEE BENEFIT PLAN (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
EMPLOYEE BENEFIT PLAN
Total provision under government-mandated defined contribution plan	$ 25,378	$ 21,503	$ 16,342

STATUTORY RESERVE AND RESTRIC97

STATUTORY RESERVE AND RESTRICTED NET ASSETS (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
STATUTORY RESERVE AND RESTRICTED NET ASSETS
Percentage of after-tax profits required to be appropriated to general reserve	10.00%
General reserve as a percentage of registered capital up to which after-tax profit of PRC subsidiaries and VIEs shall be transferred	50.00%
Amount appropriated to statutory reserve	$ 3,635	$ 3,232	$ 3,130
Aggregate amounts of capital and statutory reserves restricted	$ 263,634
Restricted net assets of subsidiaries and VIE entities as a percentage of consolidated net assets of the Group	25.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) $ / shares in Units, $ in Thousands	1 Months Ended			12 Months Ended
	Aug. 31, 2018CNY (¥)	Aug. 31, 2018USD ($)	Jul. 31, 2018CNY (¥)	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Jul. 31, 2018USD ($)	May 30, 2018$ / shares
Subsequent events
Short-term borrowing facility drawn down | $				$ 65,679	$ 37,176	$ 54,126
Subsequent event | Shanghai Pudong Development Bank | One year loan framework agreement with Shanghai Pudong Development Bank In July 2018 | Bank borrowings
Subsequent events
Term of loan			1 year
Face amount			¥ 200,000,000				$ 31,886
Short-term borrowing facility drawn down	¥ 48,960,000	$ 7,805
Interest rate (as a percent)	5.00%	5.00%
Sponsors | Company | Subsequent event
Subsequent events
All-cash acquisition (in dollars per share)								$ 40
Sponsors | Company | Subsequent event | ADS
Subsequent events
All-cash acquisition (in dollars per share)								$ 20

FINANCIAL STATEMENT SCHEDULE I

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Current assets:
Cash and cash equivalents	$ 62,901	$ 64,898	$ 108,111	$ 97,336
Amount due from related parties	7,019	4,538
Prepaid expenses and other current assets	66,939	49,736
Total current assets	295,379	219,915
Rental deposit and other non-current assets	20,309	14,950
TOTAL ASSETS	865,155	728,491
Current liabilities:
Accrued expenses and other current liabilities	76,586	59,278
Amount due to related parties	3,692
Total current liabilities	440,529	287,160
Equity:
Additional paid-in capital	472,677	436,649
Accumulated deficit	(133,642)	(112,698)
Accumulated other comprehensive loss	(2,071)	(26,622)
Total iKang Healthcare Group, Inc. shareholders' equity	355,707	312,437
TOTAL LIABILITIES AND EQUITY	865,155	728,491
Class A common shares
Equity:
Common shares	339	339
Class C common shares
Equity:
Common shares	8	8
PARENT COMPANY
Current assets:
Cash and cash equivalents	1,910	2,041	1,995		$ 55,883
Amount due from related parties	152,627	154,046
Prepaid expenses and other current assets	591	643
Total current assets	155,128	156,730
Investment in subsidiaries and VIE entities	199,954	156,123
Rental deposit and other non-current assets	2,282	1,740
TOTAL ASSETS	357,364	314,593
Current liabilities:
Accrued expenses and other current liabilities	1,657	1,769
Amount due to related parties		387
Total current liabilities	1,657	2,156
Equity:
Additional paid-in capital	472,677	436,649
Accumulated deficit	(115,246)	(97,937)
Accumulated other comprehensive loss	(2,071)	(26,622)
Total iKang Healthcare Group, Inc. shareholders' equity	355,707	312,437	$ 342,826	$ 319,130
TOTAL LIABILITIES AND EQUITY	357,364	314,593
PARENT COMPANY | Class A common shares
Equity:
Common shares	339	339
PARENT COMPANY | Class C common shares
Equity:
Common shares	$ 8	$ 8

FINANCIAL STATEMENT SCHEDULE100

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Parenthetical) (Details) - $ / shares	Mar. 31, 2018	Mar. 31, 2017
CONDENSED BALANCE SHEETS
Common shares, authorized	39,648,485	39,648,485
Common shares, issued	34,721,539	34,721,539
Common shares, outstanding	34,721,539	34,721,539
Class A common shares
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	37,648,485	37,648,485
Common shares, issued	33,916,439	33,916,439
Common shares, outstanding	33,916,439	33,916,439
Class C common shares
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	2,000,000	2,000,000
Common shares, issued	805,100	805,100
Common shares, outstanding	805,100	805,100

FINANCIAL STATEMENT SCHEDULE101

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY - CONDENSED STATEMENTS OF OPERATIONS (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Operating expenses:
General and administrative expenses	$ 126,255	$ 82,783	$ 65,422
Total operating expenses	225,904	160,281	133,901
Interest income	382	939	785
Interest expense	(20,191)	(13,880)	(4,603)
Net income/(loss) attributable to iKang Healthcare Group, Inc.	(17,309)	(11,251)	18,325
PARENT COMPANY
Operating expenses:
General and administrative expenses	38,620	8,015	5,000
Total operating expenses	38,620	8,015	5,000
Interest income	121	89	24
Interest expense			(2)
Investment income	1,800
Exchange gain	878
Equity in income/(loss) of subsidiaries and VIE entities	18,512	(3,325)	23,303
Income/(loss) before provision for income tax expenses	(17,309)	(11,251)	18,325
Net income/(loss) attributable to iKang Healthcare Group, Inc.	$ (17,309)	$ (11,251)	$ 18,325

FINANCIAL STATEMENT SCHEDULE102

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY - CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Condensed Statement of Income Captions [Line Items]
Net income/(loss)	$ (16,676)	$ (12,544)	$ 16,488
Other comprehensive income/(loss)
Unrealized gain/(loss) of available-for-sale investments, net of taxes of $47, $40 and $221 for the years ended March 31, 2016, 2017 and 2018, respectively	885	(161)	186
Unrealized gain (loss) available-for-sale investments, tax	221	40	47
Comprehensive income/(loss) attributable iKang Healthcare Group, Inc.	7,242	(30,296)	6,808
PARENT COMPANY
Condensed Statement of Income Captions [Line Items]
Net income/(loss)	(17,309)	(11,251)	18,325
Other comprehensive income/(loss)
Foreign currency translation adjustments	23,666	(18,884)	(11,703)
Unrealized gain/(loss) of available-for-sale investments, net of taxes of $47, $40 and $221 for the years ended March 31, 2016, 2017 and 2018, respectively	885	(161)	186
Unrealized gain (loss) available-for-sale investments, tax	221	40	47
Comprehensive income/(loss) attributable iKang Healthcare Group, Inc.	$ 7,242	$ (30,296)	$ 6,808

FINANCIAL STATEMENT SCHEDULE103

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY - CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017		Mar. 31, 2016
Increase (Decrease) in Stockholders' Equity
Balance	$ 312,437
Balance (in shares)	34,721,539
Share-based compensation expenses	$ 34,822	$ 1,941		$ 1,949
Exercise of employee share options	$ 1,324	1,324	[1]	8,035	[1]
Settlement of acquisition payable of Shanghai Huajian Health Examination Management Co., Ltd.				$ 7,206
Issuance of common shares, to option pool, in connection with share-based compensation arrangements		$ 4
Issuance of common shares in connection with exercise of options (in shares)	242,834	274,565		995,255
Purchase of non-controlling interest	$ (630)	$ 906		$ (1,664)
Acquisition in connection				16,767
Net loss	(17,309)	(11,251)		18,325
Unrealized gain (loss) on available-for-sale investments	885	(161)		186
Balance	$ 355,707	$ 312,437
Balance (in shares)	34,721,539	34,721,539
Shenzhen Hospital Management
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		$ (2,456)
iKang Shanghai Gubei
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest				$ (788)
Fujian iKang
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest	$ (2,502)
Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd. Clinic & Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd
Increase (Decrease) in Stockholders' Equity
Return of capital	$ (572)
Common
Increase (Decrease) in Stockholders' Equity
Balance (in shares)	34,721,539	34,361,539		34,361,539
Issuance of common shares, to option pool, in connection with share-based compensation arrangements		$ 4
Issuance of common shares, to option pool, in connection with share-based compensation arrangements (in shares)		350,000
Issuance of common shares in connection with exercise of options (in shares)		10,000
Balance (in shares)	34,721,539	34,721,539		34,361,539
Additional paid-in capital
Increase (Decrease) in Stockholders' Equity
Share-based compensation expenses	$ 34,822	$ 1,941		$ 1,949
Exercise of employee share options	1,324	1,324	[1]	8,035	[1]
Settlement of acquisition payable of Shanghai Huajian Health Examination Management Co., Ltd.				7,202
Additional paid-in capital | Shenzhen Hospital Management
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		(3,362)
Additional paid-in capital | iKang Shanghai Gubei
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest				(302)
Additional paid-in capital | Fujian iKang
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest	(1,872)
Additional paid-in capital | Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd. Clinic & Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd
Increase (Decrease) in Stockholders' Equity
Return of capital	(572)
Accumulated other comprehensive income/(loss)
Increase (Decrease) in Stockholders' Equity
Settlement of acquisition payable of Shanghai Huajian Health Examination Management Co., Ltd.				4
Unrealized gain (loss) on available-for-sale investments	885	(161)		186
PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance	312,437	342,826		319,130
Share-based compensation expenses	34,822	1,941		1,949
Exercise of employee share options	1,324	1,324		8,035
Settlement of acquisition payable of Shanghai Huajian Health Examination Management Co., Ltd.				7,206
Issuance of common shares, to option pool, in connection with share-based compensation arrangements		4
Net loss	(17,309)	(11,251)		18,325
Foreign currency translation adjustments	23,666	(18,884)		(11,703)
Unrealized gain (loss) on available-for-sale investments	885	(161)		186
Balance	355,707	312,437		342,826
PARENT COMPANY | Shenzhen Hospital Management
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		(3,362)
PARENT COMPANY | iKang Shanghai Gubei
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest				(302)
PARENT COMPANY | Fujian iKang
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest	(1,872)
PARENT COMPANY | IMHealthcare (Beijing) Technology Co., Ltd
Increase (Decrease) in Stockholders' Equity
Acquisition in connection	2,326
PARENT COMPANY | Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd. Clinic & Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd
Increase (Decrease) in Stockholders' Equity
Return of capital	(572)
PARENT COMPANY | Common
Increase (Decrease) in Stockholders' Equity
Balance	$ 347	$ 343		$ 343
Balance (in shares)	34,721,539	34,361,539		34,361,539
Issuance of common shares, to option pool, in connection with share-based compensation arrangements		$ 4
Issuance of common shares, to option pool, in connection with share-based compensation arrangements (in shares)		350,000
Issuance of common shares in connection with exercise of options (in shares)		10,000
Balance	$ 347	$ 347		$ 343
Balance (in shares)	34,721,539	34,721,539		34,361,539
PARENT COMPANY | Additional paid-in capital
Increase (Decrease) in Stockholders' Equity
Balance	$ 436,649	$ 436,746		$ 419,862
Share-based compensation expenses	34,822	1,941		1,949
Exercise of employee share options	1,324	1,324		8,035
Settlement of acquisition payable of Shanghai Huajian Health Examination Management Co., Ltd.				7,202
Balance	472,677	436,649		436,746
PARENT COMPANY | Additional paid-in capital | Shenzhen Hospital Management
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		(3,362)
PARENT COMPANY | Additional paid-in capital | iKang Shanghai Gubei
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest				(302)
PARENT COMPANY | Additional paid-in capital | Fujian iKang
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest	(1,872)
PARENT COMPANY | Additional paid-in capital | IMHealthcare (Beijing) Technology Co., Ltd
Increase (Decrease) in Stockholders' Equity
Acquisition in connection	2,326
PARENT COMPANY | Additional paid-in capital | Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd. Clinic & Weihai iKang Guobin Ciming Medical Examination Management Co., Ltd
Increase (Decrease) in Stockholders' Equity
Return of capital	(572)
PARENT COMPANY | Accumulated deficit
Increase (Decrease) in Stockholders' Equity
Balance	(97,937)	(86,686)		(105,011)
Net loss	(17,309)	(11,251)		18,325
Balance	(115,246)	(97,937)		(86,686)
PARENT COMPANY | Accumulated other comprehensive income/(loss)
Increase (Decrease) in Stockholders' Equity
Balance	(26,622)	(7,577)		3,936
Settlement of acquisition payable of Shanghai Huajian Health Examination Management Co., Ltd.				4
Foreign currency translation adjustments	23,666	(18,884)		(11,703)
Unrealized gain (loss) on available-for-sale investments	885	(161)		186
Balance	$ (2,071)	$ (26,622)		$ (7,577)
[1]	Shares were previously issued to the option pool.

FINANCIAL STATEMENT SCHEDULE104

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY - CONDENSED STATEMENTS OF CASH FLOWS (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income/(loss)	$ (16,676)	$ (12,544)	$ 16,488
Adjustments to reconcile net income to net cash used in operating activities:
Share-based compensation expenses	34,822	1,941	1,949	$ 1,949
Changes in assets and liabilities:
Prepaid expenses and other current assets	(6,344)	3,165	(10,069)
Accrued expenses and other current liabilities	7,453	18,741	3,979
Net cash provided by generated from operating activities	23,005	50,043	43,602
CASH FLOWS FROM INVESTING ACTIVITIES:
Return of prepayment for long-term investment		4,000
Payment for long-term investments	(3,149)	(5,473)	(204,414)
Payment for loan receivable			(1,000)
Payments for business acquisitions	(1,307)	(2,371)	(37,249)
Net cash used in investing activities	(34,783)	(32,011)	(261,533)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from exercise of share options	1,324	1,324	8,035
Net cash provided by (used in) financing activities	4,504	(52,421)	237,465
Net increase (decrease) in cash and cash equivalents	(1,997)	(43,213)	10,775
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	64,898	108,111	97,336
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	62,901	64,898	108,111
PARENT COMPANY
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income/(loss)	(17,309)	(11,251)	18,325
Adjustments to reconcile net income to net cash used in operating activities:
Investment income/(loss) from subsidiaries	(18,512)	3,325	(23,303)
Share-based compensation expenses	34,822	1,941	1,949
Changes in assets and liabilities:
Prepaid expenses and other current assets	(490)	71	775
Amount due from related parties	148	522	(27,675)
Accrued expenses and other current liabilities	(114)	114	(494)
Net cash provided by generated from operating activities	(1,455)	(5,278)	(30,423)
CASH FLOWS FROM INVESTING ACTIVITIES:
Return of prepayment for long-term investment		4,000
Payment for long-term investments			(24,500)
Investment in subsidiaries			(6,000)
Payment for loan receivable			(1,000)
Net cash used in investing activities		4,000	(31,500)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from exercise of share options	1,324	1,324	8,035
Net cash provided by (used in) financing activities	1,324	1,324	8,035
Net increase (decrease) in cash and cash equivalents	(131)	46	(53,888)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	2,041	1,995
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	$ 1,910	$ 2,041	$ 1,995	$ 55,883